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Abstract 
After the introduction of clean water, vaccination is thought to be the most effective public health tool 
ever introduced, responsible for preventing millions of cases of disease, disability and death each year. 
Unfortunately there remain a number of important human diseases for which we have no vaccine, 
particularly parasitic diseases, such as leishmaniasis, which primarily affect poor communities in tropical 
regions. There are many complex reasons why we have failed to develop effective vaccines for parasitic 
diseases, but there is hope that with our improved understanding of the immune system alongside the 
development of a new generation of vaccines, we will soon develop new vaccines which are effective 
enough to prevent such diseases. Toll-like receptors (TLRs) are major targets for adjuvants and have been 
shown to be crucial for defence against a number of infections. TLR2 recognises bacterial lipopeptides in 
a heterodimer with either TLR1 or TLR6, and its function has been linked to protection against various 
bacterial infections and to the efficacy of the BCG vaccine. TLR2 has been shown to recognise surface 
glycoconjugates of Leishmania parasites in vitro, particularly lipophosphoglycan (LPG). In this study, in vivo 
experimental infections show that TLR2 has a protective role in controlling cutaneous leishmaniasis (CL), 
as shown by increased lesion sizes and parasite burdens in TLR2-/- mice infected with L. major and L. 
mexicana. Furthermore, it appears that LPG is not the major mediator of TLR2 activation during infection 
with L. mexicana, as parasites lacking LPG also resulted in exacerbated disease in TLR2-/- mice. Mice 
lacking TLR2 co-receptors TLR1 and TLR6 did not show increased susceptibility to infection, suggesting 
either mono-TLR2 function or alternative co-receptor involvement. Infected TLR2-/- mice show a 
skewed Th2 immune response to Leishmania, as demonstrated by elevated IL-4, IL-13 and IL-10 
production by draining lymph node (DLN) cells in response to antigen. These results suggest that TLR2 
is involved in promoting protective immune responses to Leishmania parasites during primary infection in 
vivo, and is a potential target for protective and therapeutic vaccine adjuvants. Paradoxically, however, 
TLR2-targeting lipopeptides Pam2 and Pam3 were ineffective adjuvants for use in a whole-cell vaccine to 
protect against CL, as whole-cell autoclaved L. major (ALM) vaccines containing lipopeptides resulted in 
exacerbated disease upon challenge when compared to unvaccinated controls and in contrast to effective 
vaccination when CpG adjuvants were used. The ratio of antigen specific IgG1:IgG2c antibody isotypes, 
which is a marker of the type of adaptive immune response (Th1 or Th2), was elevated in mice that 
received vaccines containing lipopeptide adjuvants, suggesting that these adjuvants drive non-protective 
Th2 responses to Leishmania. In a Th2-dependent vaccine model using Brugia malayi, the use of Pam2 as 
an adjuvant resulted in an enhanced protective phenotype with similar efficacy to the Th2-driving 
adjuvant Alum. Thus, in the context of CL infection TLR2 has a protective role in late-stage primary 
infections with L. major and L. mexicana, yet when targeted with lipopeptide adjuvants in whole-cell 
vaccines promotes exacerbated disease in challenge infections, through driving Th2 immune responses. 
Lipopeptides that target TLR2, such as Pam2, are therefore more appropriate for use as adjuvants in 
vaccines where Th2 protective immunity is required. 
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Chapter 1. Introduction 
Leishmaniasis 
Leishmaniasis is a neglected tropical disease (NTD), currently affecting at least 12 million people, with 
350 million at risk in 98 countries across the globe (1, 2). Protozoan parasites from the genus Leishmania 
are the causative agents for leishmaniasis, which encompasses a spectrum of disease types which can 
affect humans and other animal species. Species of the Leishmania (Sauroleishmania) subgenus infect lizards, 
whilst the Leishmania (Leishmania) and Leishmania (Viannia) parasites infect mammals (3). Leishmania 
parasites are transmitted to mammal hosts via the bite of an infected female sandfly. Manifestations of the 
disease range from minor self-healing lesions to the fatal visceral disease. The main disease types are: 
cutaneous leishmaniasis (CL) where lesions form on the skin tissue and are usually self-contained and 
heal; diffuse cutaneous leishmaniasis (DCL) where cutaneous lesions spread across the cutaneous skin 
tissue; mucocutaneous leishmaniasis (MCL) where parasites preferentially replicate in the mucosal tissue 
causing severe tissue destruction; and finally visceral leishmaniasis (VL, also known as Kala-azar) where 
parasites migrate to the liver and spleen and replicate in macrophages (MΦs) within these organs, and 
which can be fatal if untreated (4, 5). A rare form of leishmaniasis that can manifest several years after 
successful treatment of VL is post Kala-azar dermal leishmaniasis (PKDL), which occurs in a varying 
proportion of VL patients. The outcome upon infection is largely dependent upon the species of 
Leishmania, although other factors also have important roles in disease outcome such as immunity and 
nutritional status (4). There are 20 identified species which can infect humans, and they can be classified 
according to their geographical location, their vector species, the sub genus of Leishmania, the clade and 
the disease they are associated with (1, 5). The characteristics of the 12 most important human Leishmania 
pathogens are given in Table 1; note that L. infantum and L. chagasi are the same species, but they are 
named differently depending on the geographical location. 
Epidemiology and global burden of leishmaniasis 
Leishmaniasis is primarily a disease which affects poor communities in developing countries, and as there 
are very limited resources available for the diagnosis and treatment of the disease, it is considered by some 
to be one of the most neglected of NTDs (6). Although VL accounts for almost 100% of all deaths 
attributed to leishmaniasis, CL accounts for the majority of cases. Whilst 98 countries have recently been 
identified as having endemic transmission of human leishmaniasis, the burden of disease is largely 
confined to major foci in a smaller number of countries (2). For VL, 90% of cases are found in six 
countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia; CL is more widely distributed, 
with up to 75% cases occurring in Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North 
Sudan, Costa Rica and Peru (2). The species responsible for causing the majority of cases of MCL are 
confined to South American countries, particularly Bolivia, Peru and Brazil (1). It is likely that the real 
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global burden of leishmaniasis is far greater than the estimated 12 million infected worldwide, as 
underreporting and a lack of surveillance are major problems in many endemic areas (6). Furthermore, 
there is diversity in the disease manifestations, transmission sites, vector hosts, animal reservoirs and 
levels of asymptomatic infection within the field of leishmaniasis, making predicting the burden extremely 
difficult (6).  
Sub-genus Clade Species Associated 
disease/s 
Geographical 
location 
Leishmania 
(Leishmania) 
L. major L. major 
L. tropica 
L aethiopica 
CL 
CL 
CL 
 
 
Old world 
L. donovani L. donovani 
L. infantum * 
VL, PKDL 
VL 
L. chagasi * VL  
 
 
New world 
L. mexicana L. mexicana 
L. amazonensis 
L. venezuelensis 
CL, DCL 
CL, DCL 
CL 
Leishmania 
(Viannia) 
 L. braziliensis 
L. peruviana 
L. panamensis 
L guyanensis 
CL, MCL 
CL 
CL, MCL 
CL 
Life cycle 
The life cycle of Leishmania parasites is shown in Figure 1, and consists of two developmentally distinct 
stages: the promastigote stage which exists within the sandfly and is extracellular, and the amastigote stage 
which exists intracellularly within phagocytic cells in the mammalian host. Leishmania parasites are 
transmitted to mammalian hosts by an infected female sandfly when it takes a blood meal. During the 
feeding process infective metacyclic promastigotes are transmitted to the site of the sandfly bite and are 
readily engulfed by phagocytic cells such as neutrophils and MΦs. Once inside host MΦs, Leishmania 
parasites transform into the small, non-flagellated amastigote stage and are able to survive and replicate 
asexually within the phagolysosome compartment. After several rounds of replication, infected cells 
rupture and release amastigotes, which then infect other surrounding MΦs and cause tissue pathology at 
the site of parasite replication. Infected MΦs can be taken up into an uninfected female sandfly during 
feeding on mammalian blood. Within the midgut of the sandfly, amastigotes are released from MΦs and 
will transform to the extracellular procyclic promastigote stage (7). 
Table 1. The 12 major Leishmania spp to infect humans, classified according to subgenus, clade, 
associated disease manifestations and geographical location. * N.B. L. infantum and L. chagasi are the 
same species, but are named differently depending on the geographical location.     
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 Life cycle of Leishmania parasites. Figure taken from (8) with permission. Figure 1.
The first promastigote development stage is a procyclic promastigote, with short flagella, which are able 
to attach to the midgut wall and divide asexually. As the parasites migrate towards the mouthparts, they 
divide and mature through distinct morphological forms, until finally transforming into the infective 
metacyclic promastigote form, which are very motile with long flagella and do not divide (3, 7). These 
metacyclics are able to infect a new mammal host and continue the life cycle when the sandfly takes the 
next blood meal. 
Overview of Leishmania cell biology with a focus on the biochemistry of the 
parasite surface 
The surface of the Leishmania parasite plays an important role in the interaction with host cells in both the 
sandfly and the mammalian host (9, 10). The promastigote and the amastigote have varying quantities and 
modifications of surface glycoconjugate molecules (see Figure 2), and these differences influence the 
events after exposure to specific cell types and other immune components. Promastigotes possess a thick 
outer surface called the glycocalyx, which is almost entirely absent on the amastigote parasite. During 
metacyclogenesis, modifications are made to the composition of molecules that comprise the glycocalyx, 
which relate to increased infectivity of the metacyclics to the mammalian host (11, 12). The major surface 
components are anchored to the parasite membrane by a glycosylinositolphospholipid (GPI) anchor.  
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 The major surface molecules of Leishmania promastigotes and amastigote parasites. Figure 2.
This figure is a schematic representation, taken from (9) with permission. 
Lipophosphoglycan 
Lipophosphoglycan (LPG) is the major macromolecular component of the glycocalyx of the flagellated 
promastigote form of Leishmania, but it is not detectable on the glycocalyx of amastigotes (13). Analysis of 
purified LPG from L. major has shown that the molecule has an unusual lyso-1-0-alkylphosphatidylinositol 
lipid anchor (14), which unlike other GPI-anchored molecules, contains only one alkyl chain. The alkyl 
chain is an unsaturated hydrocarbon of either C24 or C26 in length (12). The GPI anchor is linked via the 
inositol to heptasaccharide glycan core, which is attached to the large phosphoglycan (PG) domain 
containing 15-30 Gal-Man-P repeating units. The Gal-Man-P repeats can have additional substitutions, 
which differ between strains and species of Leishmania (12). At the end of the PG backbone is a mannose-
containing cap. The lpg1 gene encodes a putative galactofuranosyltransferase (Galf transferase), which is 
involved in the biosynthesis of LPG. Studies with Leishmania parasites that specifically lack lpg1 have shed 
light on the roles of LPG in different Leishmania species. An L. major lpg1-/- mutant was generated by 
Späth et al which was shown to lack LPG expression, but retain GPI anchored proteins, secreted 
phosphoglycans (PGs) and GIPLs (15). The lpg1-/- parasites had lost the Galf –mannose (Galf-Man) 
linkage in the LPG molecule, whereas the same linkage was present in the GIPLs. Indeed, biochemical 
characterisation of the lpg1-/- parasites showed that they had normal levels of secreted phosphoglycans 
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and GIPLs, suggesting only LPG is affected.  Thus, the Galf transferase encoded by the lpg1 is important 
for biosynthesis of LPG, but not the other major groups of glycoconjugates (15). 
It is established that LPG plays an important role in parasite viability within the sandfly vector. L. major 
and L. donovani parasites lacking LPG show reduced survival in the sandfly midgut. Whilst the LPG 
deficient (lpg1-/-) parasites were able to survive and replicate initially (albeit at reduced levels), they were 
unable to persist past midgut meal excretion (16). This effect is linked to the ability of LPG to mediate 
binding to midgut epithelial cells (16).  
Several roles have been attributed to LPG within the mammal host, including protection against 
complement mediated lysis, prevention of phagolysosomal fusion and attachment and uptake to MΦs (12, 
15, 17-19). Many species of Leishmania drastically modify their LPG structure during metacyclogenesis, 
and the increased resistance of metacyclic (and log-phase) L. major was linked to increased branching of 
LPG on the surface, and the release of the C5b-9 complex (membrane attack complex, MAC) into culture 
by the resistant parasites was speculated to be associated with LPG shedding (20). Furthermore, L. major 
lpg1-/- parasites were found to be more susceptible to human serum (i.e. complement mediated lysis) than 
wildtype (WT) parasites (19). The L. major lpg1-/-  promastigotes were found to enter mammalian MΦs  
normally, but unlike the wild type parasites they were destroyed within 2 days (21). Furthermore, although 
L. major lpg1-/- parasites were found to produce lesions in susceptible BALB/c mice, formation of these 
lesions was delayed (15). However, when the size of inoculum was increased to 5 x 107 parasites, there 
was little difference between L. major WT and lpg1-/- mutants on onset of lesion formation in susceptible 
BALB/c mice. Despite the reduction in virulence displayed in the experiments, the mutants were still able 
to establish lesions, which grew, and mutant amastigotes that were isolated from such lesions are as 
infectious as the WT, which is perhaps to be expected as LPG is not expressed in this life stage. L. major 
lpg1-/- parasites are more susceptible to complement mediated lysis than WT parasites (19), and were able 
to infect phox-deficient MΦs as well as WT, suggesting LPG protects L. major promastigotes against 
oxidative burst during phagocytosis by MΦs (19). However, it appears that unlike previous suggestions 
(11), L. major LPG plays no role in complement mediated uptake to macrophages (19).  
In contrast to L. major, L. mexicana lpg1-/- promastigotes are as able as WT parasites to infect and replicate 
in macrophages in vitro, and to infect and replicate in mice as effectively as the WT (22). Consistent with 
the finding that LPG is not crucial for L. mexicana virulence, is the fact that LPG is not altered during 
metacyclogenesis of L. mexicana, whereas it is substantially modified  in L. major and L. donovani (23). In 
fact, expression of LPG is down-regulated on the surface of infective L. mexicana promastigotes (24).  
It is unclear why LPG is down-regulated in the mammalian amastigote stage, but as LPG displays 
stimulatory activities (25-27), it is hypothesised that this is a mechanism of avoiding immune activation in 
the mammalian host. 
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GIPLs 
GPI anchored glycolipids (GIPLs), are smaller than LPG and are expressed by both promastigote and 
amastigote forms of Leishmania, and are the predominant glycolipid on both the promastigote and 
amastigote surface. GIPLs are also variable in both their glycan and lipid structures, as with LPG, and 
differences in abundance and modification exist between the different Leishmania species (28). However, a 
conserved core structure is present, which is a Manα1-4GlcN core linked to an alkyl-acylglycerol or a lyso-
alkylglycerol through a phosphatidylinositol (28). GIPLs are usually subdivided into three groups (Type I, 
II and hybrid) based on the location of the R-Manα1-substitution on the proximal mannose. There has 
been no precise function assigned to GIPLs, although they are likely to be important for the parasite as 
GIPLs of some form are found on all trypanosomatids (29). It has not been possible to generate mutants 
that lack all GIPLs specifically, which has hampered our understanding of their functional significance, so 
the conclusions that can be made about LPG functions are not as easily made for GIPLs.  
Gp63 
Gp63 is a GPI anchored surface metalloproteinase, which is highly conserved amongst all Leishmania 
species and plays an important role in resistance against the mammalian immune response, particularly in 
the initial stages after infection. Gp63 binds serum complement components, and is able to convert 
complement protein C3b to the inactive iC3b form, which acts to both opsonise the parasite for 
phagocytosis as well as avoid the mechanisms of complement mediated lysis (discussed further below) 
(30). This is demonstrated partly by the observation that gp63 is down-regulated in the intracellular 
amastigote stage (9). However, isoforms of gp63 are expressed at low levels in the amastigote stage (31). 
In addition to its roles in interacting with complement, gp63 has also been reported to cleave host cell 
surface proteins, such as MHC class I and cluster of differentiation (CD)4 (which suggests a mechanism 
of host immune response modulation), as well as components of the extracellular matrix (9, 32). 
However, as the parasite does not exist as a promastigote in the host for long, it is unlikely that gp63 plays 
a major role in immune modulation during chronic stages of infection. In support of this speculation, L. 
major parasites with the gp63 gene cluster deleted showed more susceptibility to complement mediated 
lysis in the promastigotes form, but amastigotes were as virulent as WT (33). 
Multiple mechanisms of immune subversion 
Leishmania parasites possess many other ‘virulence factors’ which promote their survival in the host, many 
of which have properties relating to immune subversion, as reviewed in (9, 32, 34). Examples include the 
cysteine peptidase enzymes, which modulate MΦ activation by interfering with cell signalling pathways 
(35-37). Importantly, different species rely on individual components to differing extents, and some 
possess unique virulence factors which relate to the pathology of the disease they cause (21, 32, 38).  
22 
 
 
Immunology of leishmaniasis 
Mouse models of Leishmania spp. infection  
As Leishmania parasites are often able to infect several mammal hosts, it is possible to carry out 
experimental infections of mice with Leishmania species that cause disease in humans, and many of these 
models closely resemble human clinical disease. In particular, models of CL using L. major have been 
widely exploited as tools for immunological research and have greatly increased out understanding of the 
immunopathology of leishmaniasis, as well as the adaptive immune responses to intracellular pathogens in 
general (39). The finding that non-healing BALB/c mice develop a CD4+ T helper 2 (Th2) cell type of 
immune response to infection, whilst C57BL/6 mice, which heal their lesions, develop a Th1-type 
response, was instrumental in our understanding of how the adaptive immune response can be tailored 
towards different types of pathogen. It is now a fundamental understanding in immunology that a Th1 
cell-mediated type of response is appropriate for combating infection by intercellular pathogens (e.g. 
Leishmania parasites), whilst Th2 responses are required for protection against extracellular pathogens 
(39). It is interesting that the understanding of the adaptive immune response involved in Leishmania 
infection preceded our understanding of the innate immune responses in different cell types, which has 
been a major focus of Leishmania immunological research in recent years (40, 41). It is now clear that the 
mechanisms involved in the immunopathological processes of Leishmania infections are extremely 
complex, involving a number of different host cell types as well as parasite and sandfly factors, and can 
vary dramatically depending on the parasite species and host genetic background. In this review of 
Leishmania immunology, I will focus on the studies exploring immune responses in CL infection. While 
some mouse strains (such as the C57BL/6 or CBA mice) develop lesions upon infection with the old-
world species L. major, which heal within a period of a few weeks (so are called ‘healing’ mice), they 
develop non-healing but contained lesions upon infection with new-world species which cause CL, such 
as L. mexicana and L. amazonensis (42-44). Contrastingly, BALB/c mice are more susceptible to most 
species which cause CL, and develop uncontrolled lesion development which leads eventually to the 
death of the mouse (i.e they are ‘non-healing’ (42, 44).   
The protective Th1 response 
As introduced above, the adaptive immune response and CD4 T cells in particular, play a major role in 
the outcome to infection with Leishmania parasites. The early events after infection with L. major and how 
this can lead to a protective Th1 response are summarised in Figure 3 below. At the time of infection, 
Leishmania parasites are first exposed to cells of the innate immune system, such as phagocytic cells and 
antigen presenting cells (APCs) which play an important role in shaping the adaptive immune response. 
The roles of different innate immune components are discussed in more detail later, but their role in 
terms of promoting a protective Th1 response is to drive the expansion of naïve T cells to a Th1 
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phenotype. CD4 Th1 cells are characterised by their production of the cytokines interleukin 12 (IL-12), 
interferon-γ (IFNγ) and tumour necrosis factor alpha (TNFα). 
 
 The protective immune response in Leishmania infection. Upon infection with Figure 3.
Leishmania, parasites are taken up by phagocytic cells such as neutrophils, MΦs or monocyte-derived 
dendritic cells (DCs) (1a, b, c. respectively). Within the phagolysosome of infected MΦs, amastigote 
parasites can replicate. mDCs and NK cells are activated by Leishmania parasites to produce IL-12 and 
IFNγ (respectively), which promotes the expansion naïve T cells (Th0) to antigen specific Th1 cells (2). 
Th1 cells produce cytokines such as IFNγ, TNFα which promote the classical activation of infected MΦs 
(3). Classically activated MΦs produce inducible nitric oxide synthase (iNOS), which breaks down L-
arginine to form nitric oxide (NO), which is required for parasite killing (4).  
IL-12 is particularly important for development of cellular immunity and a robust Th1 response to L. 
major infection, and indeed to infection with other intracellular pathogens (45). Production of IL-12 by 
immune cells drives the development of an adaptive Th1 response, and is also important for the 
maintenance of an effective Th1 response during the course of L.major infection (46). IL-12 receptor 
depleted mice on a resistant/healing background are unable to control L. major infection (47), and 
administration of IL-12 to susceptible BALB/c mice confers resistance (48, 49). In more natural low-dose 
infections, it is likely that IL-12 acts to redirect early Th2 responses to L. major, as IL-12 production does 
not occur at high levels in the initial stages of L. major infection even in healing mice, and growth of L. 
major is the same for the first 4-5 weeks of infection, in the presence or absence of IL-12 (50). The role of 
IL-12 in protection against new world CL is not as clear as for L. major. Administration of IL-12 cannot 
cure infection of C57BL/6 mice with L. amazonensis as it can with BALB/c mice infected with L. major 
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(51). Furthermore, mice lacking IL-12p40 showed progression of lesions to the same extent as WT mice 
when infected with L. mexicana.  The lack of IL-12 did not affect the production of IFNγ by draining 
lymph node (DLN) cells collected 7 weeks after infection, whereas production of IFNγ is substantially 
diminished in IL12p40-/- mice infected with L. major  when compared to WT mice at the same time point 
(52). The production of IL-4, a non-protective Th2 cytokine, was slightly increased in response to parasite 
antigen in L. mexicana infected mice which lacked IL-12p40 compared to WT mice (52). A vaccination 
study in a mouse model of L. amazonensis infection showed that mice lacking IL-12 were just as protected 
as WT mice when vaccinated with the killed Leishmania vaccine ‘Leishvacin ®’ in association with 
Corynebacterium parvum  as an  adjuvant (53). Therefore, IL-12 does not appear to be as crucial for the 
control of L. mexicana complex parasites as it is for L. major (54).  
Key effector cytokines in the Th1 response that leads to parasite clearance are IFNγ and TNFα. Both of 
these cytokines are important in activating infected MΦs for intracellular killing (classical activation), by 
causing an upregulation of inducible nitric oxide synthase (iNOS) production, which breaks down L-
arginine to producing nitric oxide (NO) (55) (Figure 3). Healing mice with the TNFα gene deleted are 
very susceptible to even low numbers of L. major. Furthermore, these mice develop a disease in which the 
parasite disseminates as in VL, and the infection is eventually fatal (56). The importance of NO in 
controlling Leishmania has long been known, as mice lacking iNOS are extremely susceptible to infection 
with L. major (55). In models of leishmaniasis where lesions heal, a robust Th1 response is found, 
characterised by increased production of IFNγ, TNFα and iNOS (57). Early IFNγ production is also 
important for the development of a robust Th1 response. Natural killer (NK) cells are known to be an 
important source of IFNγ during infection with L. major, and of particular importance in the early innate 
immune response to infection (58, 59). In addition to its role in enabling parasite killing by NO, 
production of IFNγ plays an important role in down regulation of Th2 and regulatory immune responses, 
which are detrimental to controlling infection. This is demonstrated in mouse models where anti-IFNγ 
antibodies administered to genetically susceptible mice prior to infection with L. major resulted in a Th2 
response to infection and more severe disease (44). Similarly, a protective role for TNFα was 
demonstrated when administration of anti-TNFα antibodies caused exacerbated infection in C3H and 
BALB/c mice infected with L. major, whilst recombinant TNFα reduced disease severity in both strains 
(60). 
In general, levels of IFNγ are much lower in resistant/healing mice infected with L. mexicana parasites 
compared to those found in L. major infection of resistant/healing mice (52). As with L. major infection, 
iNOS is an important factor for control of L. mexicana, as iNOS-/- mice develop lesions which grow 
uncontrollably and are progressive, and parasite numbers continue to increase throughout the infection, 
as opposed to being contained at a steady state (52). STAT4 is a transcription factor, which is important 
for development of Th1 responses. As with iNOS and IFNγ, a lack of STAT4 leads to uncontrolled 
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parasite growth and lesion progression in L. mexicana infected mice on a C57BL/6 background (52). 
Thus, a Th1 response, which occurs independently of IL-12, appears to be responsible for control of L. 
mexicana and other new world species. It therefore appears that whilst effector cytokine responses are 
relatively low during L. mexicana and L. amazonensis infection compared to L. major, these low levels are 
required to control the slow growing L. mexicana parasites, and limit lesion progression to controllable 
levels.  
Immune responses that promote parasite survival 
The production of IL-4 early on in infection is key to the development of an inappropriate Th2 response 
to L. major infection in BALB/c mice, as IL-4-/- BALB/c mice heal infection, as do BALB/c mice treated 
with anti-IL-4 monoclonal antibody at the time of infection (61, 62). The source of this early IL-4 in this 
model has been identified as an oligoclonal population of T cells possessing a Vβ4Vα8 T cell receptor, 
which are responsive to the Leishmania homolog of receptors for activated kinase (LACK) antigen (63). 
IL-13 is also important for maintenance of a Th2 response to L. major infection, and acts in much the 
same way as IL-4 to potentiate Th2 development (64), and can compensate for IL-4 in experiments where 
IL-4 is depleted.  Resistant/healing mouse strains, however, also show production of IL-4 in the initial 
phase of L. major infection from the same T cell population, but are able to redirect an early Th2 response 
by production of IL-12. Thus, it is the inability of BALB/c mice to redirect an initial Th2 response to a 
Th1 response, which is key to their susceptibility to L. major. A number of factors have been implicated in 
the sustained Th2 responses in BALB/c mice, including a down-regulation of IL-12 receptor (IL-12R), an 
increased inflammatory cell infiltrate, intrinsic defects in Th1 differentiation by CD4 T cells and innate 
immune cells, and an inability to prevent parasite dissemination (reviewed in (39, 65)).  
The regulatory cytokine IL-10 is now known to play as important a role in susceptibility to L. major as IL-
4. While for some strains of L. major, removal of both IL-4 and IL-13 responses from BALB/c mice is 
not enough to confer resistance, removal of IL-10 in addition to these two Th2 cytokines does render 
mice resistant to L. major, and IL-10-/- mice on a BALB/c background show reduced lesions and parasite 
burdens (66). Naturally occurring CD4+ CD25+ T regulatory cells (nTregs) which produce IL-10 are able 
to confer susceptibility to L. major infection in otherwise healing mice, suggesting that nTregs are a major 
source of suppressive IL-10 (65). However, other studies indicate that IL-10 derives from other cell types 
also, and that nTregs may suppress resistant mechanisms in other ways, such as contact dependent 
mechanisms (67). Interestingly, in addition to their roles in suppression of protective responses, it appears 
that nTregs are important in maintaining concomitant immunity to L. major, by suppressing responses 
that clear parasites, but allowing development of immunological memory and protection against re-
infection with L. major (68). Whilst C57BL/6 mice are considered resistant to L. major (lesions show an 
acute phenotype and heal), L. major parasites persist in the skin of these mice after healing.  This 
persistence is achieved due to the induction of nTregs, which suppress effector Th1 CD4 T cells from 
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completely clearing the infection (68). However, when mice lack suppressive mechanisms in the form of 
IL-10, the immunity to re-infection is lost, compared to WT mice which show a significantly reduced 
parasite load upon a second infection (68). Thus, regulatory activity appears to have a role for both 
parasite persistence, and long term immunity for the host (Figure 4). In addition, Th1 cells can produce 
high levels of regulatory IL-10 when they are over-activated in a highly inflammatory setting, when 
infected with a virulent strain of L. major (69).  
 
 The adaptive immune responses associated with susceptibility and non-healing in CL. Figure 4.
The adaptive immune responses that leads to parasite killing is indicated below (labelled in black), with 
the production of IL-12 and IFNγ promoting the expansion of Th1 cells, which produce cytokines (IFNγ, 
TNFα) that drive the classical activation of MΦs leading to parasite killing. Alternatively (labelled in red), 
DCs and other APCs exposed to Leishmania parasites may drive the expansion of specific Th2 cells by 
production of IL-4 (1a.); Th2 cells producing IL-4 and IL-13 (1b.) drive the alternative activation of 
infected MΦs, which by producing arginase, breaks down L-arginine to polyamines, which allows for 
parasite survival and growth (1c.). Parasite killing is also suppressed by the production of IL-10 by highly 
activated Th1 cells (2). In addition, the expansion of T regulatory cells (Treg) (3a.) leads to the production 
of regulatory cytokines TGFβ and IL-10 which act to suppress either or both Th1 and Th2 cells (3b), which 
can lead to either increased parasite survival or reduced disease exacerbation depending on the model. B 
cells producing antigen specific IgG1 antibody (4) facilitates parasite survival in a mechanism whereby 
ligation of IgG1 bound parasites to the FcγRIII receptor promotes IL-10 production.  
In the C57BL/6 and L. mexicana infection model, IL-10 plays an important role in the chronicity of the 
infection (70). A healing response was observed in mice lacking IL-10 that was mediated in part by IL-
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12p40, which has previously been shown to play no role in disease progression. This suggests that IL-10 
acts to suppress the Th1 response mediated by IL-12p40 in WT C57BL/6 mice (70). IL-10 production 
during infection with L. mexicana is thought to be due to ligation of antibody specific to amastigotes 
binding to receptors which bind the crystallisable fraction of antibody (Fc receptors, FcRs) of MΦs. 
Primed MΦs produce greater levels of IL-10 when exposed to antibody opsonised L. mexicana 
amastigotes, when compared to un-opsonised amastigotes (70). Furthermore, mice deficient in the 
antibody receptor FcRγ showed the same phenotype as IL-10-/- mice when infected with L. mexicana (70). 
Thus, this specific immune response mechanism, whereby antibody binding to amastigotes promotes 
dissemination of parasites into uninfected MΦs and promotion of IL-10, greatly contributes to the 
chronicity of L. mexicana complex infections (52, 70, 71).  
Recent studies have added further complexity to the adaptive immune factors that are involved in the 
immunopathogenesis of CL infections. The Th17 pro-inflammatory CD4+ subset has been associated 
with susceptibility to L. major; the IL-17+ CD4+ T cells present in high numbers in L. major-infected 
susceptible BALB/c mice are thought not to influence the Th1/Th2 development, but instead to increase 
susceptibility in these mice due to increasing neutrophil recruitment (72, 73). Th9 cells, which are 
considered by some as a subset of Th2 cells, have been linked to increased susceptibility in L. major 
infection, as have follicular helper T cells (Tfh) which act to facilitate B cell activation which has been 
previously linked with increased susceptibility to infection (70, 71, 73-75).  
Early events after infection, and interaction of Leishmania parasites with different 
cell types 
Once within the mammalian host, Leishmania promastigotes immediately encounter the complement 
system, and are quickly taken up by phagocytic cells, particularly neutrophils, MΦs and dendritic cells 
(DCs). The mechanism of uptake has been attributed to a number of different receptor mediated 
interactions, which differ between parasite species and morphological forms, and between different host 
cell types in different environments, as reviewed in (10).  
MΦs are the important location of parasite replication in leishmaniasis  
Leishmania parasites are phagocytosed by three main cell types: MΦs, neutrophils and some DCs. But it is 
within MΦs that Leishmania parasites are able to replicate, and they are able to do this within the harsh 
environment of the phagosome, which has adapted to destroy ingested pathogens. MΦs actively 
phagocytose pathogens, apoptotic cells and other debris and they also play an important role in priming 
adaptive immune response by presenting antigen to T cells. Leishmania parasites can be taken up by MΦs 
by a number of different mechanisms and they then become the final definitive site for parasite 
replication (76). Promastigotes are less able to withstand the harsh conditions of the MΦ compared to 
amastigotes, and so instead they delay the maturation of the phagosome to allow them to transform to 
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the amastigote, which is better adapted for survival in the MΦ. The characteristics of the promastigote-
containing phagosome therefore differ to those which harbour amastigotes, as reviewed in detail by 
Moradin and Descoteaux (34). LPG is the major promastigote molecule that has been linked with the 
ability to delay phagosomal maturation (77).  
In their steady state, MΦs exist in tissues and are very efficient at phagocytosis. They can be activated by 
internal and external signals and depending on the signals they will assume a particular activated 
phenotype (Figure 4). The two major types of activated MΦ are: 1) classically activated MΦs (cMΦ), 
which develop in response to TLR ligands and Th1 cytokines (particularly IFNγ) and are designed to kill 
intracellular pathogens via production of NO and 2) alternatively activated MΦs (aaMΦ), which are 
associated with Th2 responses and are important in wound healing and immune responses to helminth 
infections (78). Whereas cMΦs produce the enzyme iNOS, which breaks down L-arginine to form NO, 
aaMΦs use the enzyme arginase, which breaks down L-arginine to form polyamines. In Leishmania 
infections, the phenotype of the infected MΦ has a crucial impact on infection, with cMΦs allowing for 
sufficient parasite killing (55) and aaMΦs being associated with increased parasite growth (76, 79) (Figure 
4). Indeed, in addition to the multiple mechanisms of immune subversion employed by Leishmania to 
prevent or shift the immune response away from the classical activation of MΦs, it has recently been 
shown that Leishmania possess their own arginase enzyme which augments aaMΦ activation and promotes 
parasite survival (79, 80). Infected MΦs can promote a protective Th1 response by acting as APCs and 
producing IL-12, but the ability of MΦs to produce IL-12 is impaired upon infection with Leishmania 
parasites (17, 81). The balance of the activation status of the infected MΦs in Leishmania infection, which 
is influenced by many different host and parasite derived factors, is therefore what determines the 
eventual outcome of infection with Leishmania parasites (76).  
The role of neutrophils 
Neutrophils are innate immune cells that are particularly important for early defence against pathogens 
and are rapidly recruited to inflammatory sites. In leishmaniasis, a massive recruitment of neutrophils to 
the site of infection occurs following inoculation of parasites whether infection is mediated via needle or 
sandfly (and in either case in the absence of parasites) (82, 83). Recruitment of neutrophils to the 
infection site is achieved by the local production of IL-8 in humans, and chemokine (C-X-C motif) ligand 
1 (CXCL1)) and CXCL2 in mice (84). Interestingly, even at this early stage the phenotypes of neutrophils 
exposed to L. major infection appear to be different between healing and non-healing mouse strains. For 
example, the expression levels of the Toll-like receptors (TLRs) TLR2, TLR7 and TLR9 are greater in L. 
major-exposed neutrophils from mice which heal leasions, when compared to those from a non-healing 
strain (85).  Furthermore, the ability of the exposed neutrophils to attract DCs to the site of infection is 
greater in healing C57BL/6 mice, compared to non-healing BALB/c mice (86). The mechanism of DC 
recruitment by neutrophils is believed to be via the production of the chemokine (C-C motif) ligand 3 
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(CCL3), as CCL3 deficient mice on a resistant background failed to recruit DC to the infection site at the 
level of WT mice, an effect which was reversed upon transfer of WT neutrophils (86). Lack of neutrophil-
derived CCL3 during this initial phase of infection hindered the development of an effective Th1 
response mediated by CD4+ T cells in mice resistant to L. major (86). A study using a model of L. 
braziliensis infection found that neutrophils were important mediators for control of parasite growth in vivo 
and in vitro via their ability to induce MΦs to kill intracellular amastigotes via cell-contact as well as 
production of TNFα (87). Furthermore, neutrophils can account for the earliest source of IL-12 in 
response to infection (85). 
Whilst the presence of neutrophils at the site of infection has been known for a while, the importance of 
phagocytosis of promastigotes by neutrophils occurring prior to ingestion by MΦs in the initial phase of 
infection has only recently been realised. A number of studies have shown that L. major and other species 
are able to survive inside neutrophils and remain infective to other cells (82, 88, 89). In vivo imaging of L. 
major injection to the mouse ear dermis has revealed that injected promastigotes are relatively immobile 
after they have been injected into the mammalian host, and they are rapidly ingested by the neutrophils 
which have migrated to the site of infection. Mice depleted of neutrophils before infection with L. major 
showed a reduction of viable parasites in the infected tissue, both immediately after infection, but also 
weeks after, suggesting that the early presence of neutrophils is important for disease progression in this 
model (82). Specific markers can be used to identify which of the distinct neutrophil granules are 
employed in the attack against Leishmania within the infected neutrophil. It appears that azurophilic 
(primary) granules are selectively fused with the phagosome containing the Leishmania parasite, but that 
fusion with specific and tertiary granules does not occur (89). Thus, L. major is able to avoid parasite 
killing via respiratory burst and acidification in the neutrophil, as in the MΦ.  L. major is also known to 
delay the apoptosis of neutrophils, perhaps by interfering with the caspase-3 pathway (90). Nevertheless, 
neutrophils infected or exposed to L. major do still undergo apoptosis, which allows a mechanism of 
‘silent’ uptake into MΦs, which rapidly engulf apoptotic cells without activating antimicrobial effector 
mechanisms (91). Indeed, it has been shown that human MΦs are able to ingest L. major infected 
apoptotic neutrophils, and that this resulted in the release of TGF-β, an anti-inflammatory cytokine (88). 
Thus, in addition to their role as an innate effector cells in fighting the infection, it is believed that 
neutrophils can also exacerbate infection by acting as ‘trojan horses’ for Leishmania parasites, by providing 
them with a temporary home as well as a safe entry into the MΦs, in the initial stages of infection (91). 
However, in vivo studies have yet to provide evidence for MΦ ingestion of infected neutrophils (82). 
Whether neutrophils play a protective or exacerbating role in leishmaniasis therefore appears to depend 
on the model used, and may be species dependent (41).   
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DC subsets play distinct roles in Leishmania infection 
DCs are professional APCs which play an important role in antigen uptake and presentation to T cells, 
and thereby act as the sentinels of the immune system. It is therefore unsurprisingly that in CL, DCs have 
been shown to be crucial for the priming of a protective Th1 response. There are many different subsets 
of DCs which are present in different tissue sites and can play differential roles in initiating adaptive 
immune responses. Different subsets of DCs have been shown to have differential ability to produce IL-
12 upon infection with Leishmania parasites in vitro (92), and the interactions between parasites and DCs 
vary greatly between species of Leishmania, and also depend the host genetic background (reviewed in 
(93)). Langerhans cells reside in the epidermis and were initially thought to play an important role in 
Leishmania infection in vivo (94), but this was disputed by another study which found that antigen 
presentation by Langerhans cells, MΦs or B cells was not required for resistance to L. major and instead 
dermal DCs were the crucial DC subset for priming Th1 cells (95). Plasmacytoid DCs (pDCs) are 
recruited to the infection site, but they do not phagocytose Leishmania parasites. Despite this, pDCs are 
likely involved in controlling infection to L. major, as adoptively transferred pDCs were able to provide 
protection to recipient mice (96). pDCs are activated by Leishmania antigens to produce IL-12 and IFNαβ, 
and this is the mechanism by which pDCs are believed to contribute to the control of infection (97).  
Leon et al reported that monocytes recruited to the site of L. major infection in C57BL/6 mice 
differentiate into monocyte-derived DCs (mDCs) and it was found to be these mDCs that were crucial 
for priming Th1 cell development, via the production of IL-12, after they had migrated to draining lymph 
nodes from the site of infection (98). Differences between DC functions in healing and non-healing 
mouse strains has been explored in mouse models of CL, but there is yet to be conclusive evidence that 
such differences account for the differential phenotypes that occur upon infection (76).  
Natural killer cells are important for the protective response to Leishmania 
Natural killer (NK) cells are innate immune cells which play an important role in clearance of tumour 
cells, rejection of tissue transplants and pathogens that infect host cells. The effector functions of NK 
cells are the destruction of target cells and release of inflammatory cytokines such as IFNγ, TNFα and 
GM-CSF (99). NK cells are recruited to the infection site within 24 hours of infection with L. major, and 
their recruitment is mediated in part by CXC10 (84). IL-12 production is crucial for activating this early 
NK cell response (97). Activated NK cells act to control Leishmania infection by providing an early source 
of IFNγ, and by associating directly with myeloid DCs (mDCs) to activate them and help promote a Th1 
response (100, 101). In turn, mDCs are crucial for mediating the NK cell response, as mice depleted of 
mDCs, but not pDCs, depleted L. infantum infected mice of an NK cell response (97).  
Wound repair as an alternative mechanism involved in parasite clearance 
The polarization of host immunity has become a dogma for explaining the patterns of disease progression 
in models of leishmaniasis. This has recently been questioned by an analysis of the genes from 3 distinct 
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loci involved in infection with L. major, which differ between healing C57BL/6 and non-healing BALB/c 
mice. The loci were termed L. major response - (lmr-) 1, lmr-2 and lmr-3. Studies on the effects of these 
distinct loci on the course of L. major infection have shown that their influence on disease outcome are 
independent of adaptive immune responses (102). Mice congenic for lmr genes from donor strains have 
been used to explore the functions of these loci. Resistant C57BL/6 mice with the lmr genes from 
BALB/c mice are less able to control disease with L. major, whilst BALB/c mice with lmr genes from 
C57BL/6 mice are more resistant (103, 104). Interestingly, healing of non-infected wound tissue is also 
affected by the lmr loci genes, attributing the role of these loci to a healing response in general (104). 
Resistant mice are able to deposit collagen at a faster rate than non-healing mice, and this activity is linked 
to the lmr1 and lmr2 loci (103).  When a natural model of infection was used to explore the role of the lmr 
genes, where small numbers of L. major were injected intradermally into the ear, the lmr loci were shown 
to exert their effects on wound healing locally at the site of infection, and independently of the lymph 
node and systemic responses (103). Thus, it appears that a wound healing responses to Leishmania 
infection can influence disease progression and outcome, and that this occurs independently of the 
immune response.  
The role of the sandfly bite and promastigote secretory gel (PSG) 
An important role for the sandfly bite in the outcome of Leishmania infection was first demonstrated in 
1988 by Titus et al, when it was found that the co-injection of lysates of the salivary glands of the sandfly 
vector Lutzomyia longipalpis resulted in the exacerbation of infection with L. major (105). This effect was 
later attributed in part to a peptide from sandfly saliva called maxadilan, which is a vasodilator and 
promotes Th2 cytokine production over Th1 cytokines by exposed human PBMCs (106). It has also been 
shown that maxadilan can alter the phenotype of MΦs towards an alternatively activated state (107), as 
well as influence DC function and T cell activation (108), which may help explain its ability to exacerbate 
infection. Other components of saliva have also been linked to its immunmodulatory properties, such as 
AMP and adenosine (108). It is important to note that sandfly saliva is immunogenic, and individuals 
living in areas where sandflies are prevalent will likely have been exposed and so have secondary immune 
responses to salivary proteins. These immune responses will also play an important role in the immune 
responses to an infection. In some cases, levels of antibodies to salivary components have been linked to 
enhanced protection (such as for protective responses to VL infection in infants in Brazil (109), whilst 
several studies have linked increased anti-saliva antibodies to increased susceptibility to CL in different 
settings(108).  
In addition to the effects of the sandfly saliva, an important feature of Leishmania infected sand flies is the 
presence of the promastigote secretory gel (PSG), which forms a ‘plug’ in the anterior regions of the 
midgut around which the infective metacyclic promastigotes accumulate in the latter stages of infection 
(110).  Importantly, when a comparison was made between the injection of L. mexicana parasites by needle 
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or sandfly to murine hosts (using a comparable dose), the sandfly-transmitted infections showed more 
profound disease progression in two strains of mouse. Furthermore, sandfly transmission resulted in the 
formation of chronic non-healing lesions in CBA/Ca mice, whereas an acute disease phenotype was 
observed upon needle challenge (111). The main factor involved in this sandfly bite-mediated disease 
exacerbation is the parasite-derived filamentous PPG (fPPG), which comprises most of the PSG plug. 
More specifically, the glycan moieties of fPPG are responsible for exacerbating disease (111). The 
mechanism of disease exacerbation has been attributed to the ability of PSG to recruit MΦs to the 
infection site in the skin, and further to facilitate survival within MΦs by increasing alternative activation 
and arginase production, which enhance parasite growth (112). The sandfly derived infection was also 
found to increase the recruitment of neutrophils to the site of infection, which acted to favour parasite 
survival in a model of L. major infection (82).  
These findings demonstrate a clear role for the transmission of Leishmania parasites by sandfly vectors in 
the outcome of infection. The infectious dose administered by sandfly can range from a few hundred to 
around 10,000 parasites per bite, and averages at approximately 1000 per bite (111, 113). This is lower 
than the doses administered in most experimental models where a needle is used, where doses can be as 
high as 107 per injection. Furthermore, sandfly-transmitted promastigotes were found to be highly 
enriched in metacyclic forms (111). The mode of transmission should therefore be taken into account 
when considering the outcomes of infection in an experimental model setting.  
Current methods of treatment and control of leishmaniasis 
Leishmaniasis in humans is primarily treated in a clinical setting by using one of a handful of 
chemotherapy options available. Pentavalent antimonials (e.g. sodium stibogluconate and meglumine 
antimoniate) are the most widely used treatments, as they are the WHO recommended first-line of 
treatment (4), and they have been used to treat the disease for over 70 years. Miltefosine is also a common 
treatment choice, particularly as resistance to antimony is increasing in major endemic areas such as the 
Indian subcontinent. A newer chemotherapy option is Amphotericin B, which was initially inappropriate 
for widespread use due to its high cost and toxic effects. Fortunately, these issues have in recent years 
been alleviated by the development of the less toxic liposomal form of delivery (AmBisome ®), and the 
reduction in price of the drug to 10% of the original cost in developing countries (114). Despite these 
developments, treatments are costly and difficult to administer, and are still not accessible for many 
affected individuals living in remote areas and/or in poverty.  
The most widely used methods of prevention focus on interruption of transmission by 
eliminating/treating animal reservoirs, and/or by targeting the sandfly vectors. There is currently no 
vaccine for human leishmaniasis which is widely available. Our in-depth understanding of the immune 
responses involved in Leishmania infection, and those which are required for control of infection, together 
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with evidence of long-term protective immunity following natural exposure, should facilitate and promote 
the development of an effective vaccine, or a variety of vaccines, for the diseases associated with 
leishmaniasis.  
Vaccine development for leishmaniasis 
Leishmanisation 
Leishmanisation is the practice of purposefully inoculating uninfected individuals with live Leishmania 
parasites, and it has been practiced for centuries in many endemic areas, in order to prevent natural 
infection in visible sites on the body (115-117). In most cases, this practice was highly successful in 
causing very mild disease which healed and provided long-term immunity to subsequent infection. In fact, 
this approach is still the most effective method of prevention ever tried in human populations, as up to 
100% protection was reported in one small clinical trial using challenge with live L. major as a vaccine in 
Iran (116). However, due to issues over quality control, safety and the increasing prevalence of immune 
disorders such as HIV, the use of Leishmanisation has been discontinued in many endemic countries 
(118). Nevertheless, it provides important proof-of-concept that vaccination is a viable intervention for 
leishmaniasis. 
Killed Leishmania vaccines 
First generation vaccines containing killed parasites have been explored extensively over decades in an 
attempt to develop a safe and effective vaccine for leishmaniasis. Whilst this approach may be feasible 
and scalable, issues over standardisation exist with the use of cultured parasites, which would be a major 
barrier for the registration of a vaccine (118). Studies in mice and humans have found killed parasites to 
be safe and immunogenic vaccines, but with poor efficacy in protecting against leishmaniasis (41, 118).  
New strategies for leishmaniasis vaccine design 
Developments in vaccine design in recent years have led to the use of many different types of 
experimental vaccine in models for leishmaniasis, some of which are outlined below.  
Subunit vaccines 
Subunit vaccines involve the use of defined immunogenic molecules, singularly or in combination, which 
have advantages over the use of killed parasites in terms of standardisation, scalability and cost. Several 
candidate antigens have been identified by different research groups. Gp63 was one of the first candidate 
antigens, which when delivered with various adjuvant formations demonstrated efficacy in some, but not 
all, mouse models and human immunogenicity studies (119-122). Other antigens that have been used 
singularly in experimental subunit vaccines include LACK, gp46, cysteine proteases and kinetoplastid 
membrane protein 11 (KMP-11), which have also demonstrated varying levels of efficacy in models (41, 
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120, 121, 123, 124). In recent years the field has moved towards using more than one antigen in subunit 
vaccines. A recombinant polyprotein containing several immunogenic and conserved proteins of 
Leishmania, Leish-111f, has been used in many experimental models and in Phase I and II human clinical 
trials, and has been found to be safe and immunogenic (125-128), and improve treatment outcome when 
used in combination with treatment with antimonials (126). Other vaccines containing a combination of 
protein antigens, such as the Leish-KSAC vaccine, are being evaluated in pre-clinical studies (129).  
DNA vaccines 
A relatively new approach to vaccine design has been the use of genetically modified DNA containing the 
candidate antigen(s) of interest. Many of the single or polymeric antigens that have been explored for use 
in subunit vaccine preparations have been tested as DNA vaccines. This method has several attributes 
which make it desirable for a Leishmania vaccine, such as being able to activate cytotoxic T lymphocyte 
(CTL) responses (130, 131). Whilst this approach seems favourable given the promising findings in terms 
of efficacy and long term immunity elicited from DNA vaccines in rodent experimental models (130-
136), DNA vaccination has not yet been approved for use in humans, and it is not clear if similar levels of 
efficacy are achievable in a DNA vaccine in humans (114, 123). 
Sandfly saliva as a vaccine target 
Given that the immune response to saliva has been shown to influence outcome upon infection in 
various endemic areas, as well as in rodent models of infection (108), components of saliva have become 
an exciting target for Leishmania vaccine development. Several groups have explored different approaches 
to anti-saliva vaccines, and as a result some key target antigens have been identified. Interestingly, a study 
by Oliveira et al found that DNA immunisation with two distinct saliva antigens conferred different 
immune responses in mice, which lead to either increased resistance or disease exacerbation upon 
challenge (137). Antigens which have shown promising results in vaccine studies are LJM11 and LJM19 
of Lutzomyia longipalpis, and PpSP15 of Phlebotomus papatasi (108). However, there are issues that need to be 
overcome in terms of the influence of long term exposure to sandfly bites, genetic and antigenic variation 
in salivary proteins amongst sandfly populations and as with other Leishmania vaccines, defining reliable 
immune correlates of protection.  
Other approaches 
Other approaches that have been adopted in vaccine studies for Leishmania include DC vaccines (138, 
139), vaccines against salivary components, the use of attenuated/genetically modified Leishmania 
parasites, and incorporation of Leishmania antigens into a viral vector, all of which have resulted in good 
efficacy in pre-clinical vaccine studies (123, 129, 140).  
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Immune correlates of protection 
An important aspect of vaccine discovery and design is identification of measureable immune responses 
which relate/correlate to the level of protection against the disease in question.  Identifying so-called 
immune correlates of protection is important in vaccine development as it is not always desirable or 
possible to test all vaccines in terms of efficacy to protect against disease (such as for HIV infection), but 
it may be possible to test for the immune correlates of protection. It also greatly informs the design of 
new vaccines by allowing researchers to choose vaccine approaches and components which promote the 
responses that are associated with protection.  
In recent years, multiparameter flow cytometry has been used to analyse the type of immune response 
which confers protection post vaccination to infectious agents (141). This technique allows for analysis of 
qualitative cytokine production at a single cell level and has revealed that multifunctional CD4+ T cells 
which simultaneously produce IL-2, TNFα and IFNγ show the highest correlation with protection against 
infection with L. major post vaccination (142). Darrah et al used a live L. major inoculation as a positive 
control (as this remains the best known method of protection), as well as other Leish-111f vaccine 
formulations. They found that the number of triple cytokine producing (multifunctional) CD4+ T cells 
generated in response to vaccination correlated with the level of protection (142). Raman et al developed a 
mouse model for immunotherapeutic vaccines, in which Leish-111f formulations were tested on L. major 
infected mice. In contrast, this study found that multifunctional CD4+ T cells were not produced in the 
highest levels in the group that showed the best responses to the therapeutic vaccine (143). Instead, the 
mice that received the most effective therapeutic vaccine showed the lowest number of multifunctional 
IL2+ TNFα+ IFNγ+ CD4+ T cells, but the greatest number of terminal effector, IFNγ-producing CD4+ 
cells (144).  Furthermore, contrary to the view that a strong Th1 response will be required for protective 
immunity with Leishmania vaccines, the immune response generated by vaccination with the attenuated L. 
major lpg2-/- vaccine strain, was not associated with a strong Th1 response (145). In a vaccine model 
exploring the use of a live vaccine (comparable to that used in humans for leishmaniasation) in mice, 
which was shown to be more effective than a killed vaccine at protecting against sandfly-mediated 
challenge with L. major, the enhanced protection was linked to an absence of neutrophils at the site of 
infection upon challenge (146). A study using a DNA vaccine encoding the LACK antigen observed that 
protection and long term immunity was dependent on CD8+ T cells (131). Therefore, there is currently 
little or no consensus on the optimal immune correlates that are associated with protective immunity to 
Leishmania vaccines and our current knowledge demonstrates a complex array of diverse immune 
responses associated with different vaccination approaches and models. Further studies to define the 
characteristics of protective immune responses against Leishmania vaccination that are predictive of 
protective immunity in humans is therefore warranted.  
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Adjuvant discovery and design 
A key development which is required for all new vaccines is adjuvant discovery and design. It is hoped 
that our increasing understanding of innate immune responses to Leishmania and their role in disease 
outcome will inform vaccine adjuvant design and selection for new Leishmania vaccines. Toll-like 
receptors (TLRs) are important components of the innate immune system and targets for adjuvant action 
and development. Investigating the role of TLRs in Leishmania should inform vaccine adjuvant design for 
Leishmania vaccines.  
Toll-like receptors 
In 1991 Charles Janeway speculated that the immune system must use a mechanism to discriminate 
between ‘infectious non-self and non-infectious self’, and proposed that this was achieved by receptors 
that were able to recognise microbial patterns (147). Since then, there have been major developments in 
immunology research to corroborate this, including the discovery of many types of pattern recognition 
receptors (PRRs) which are responsible for sensing molecular patterns from external sources, particularly 
microbial organisms. TLRs were the first group of PRRs to be discovered, and they include 13 different 
receptors (10 found in humans, 12 in mice) responsible for recognising a wide range of pathogen 
associated molecular patterns (PAMPs), from nucleic acids to large surface glycoprotein structures, from 
all types of microbe (148, 149). TLRs can be subdivided into groups according to their cellular location. 
TLR3, TLR7, TLR8 and TLR9 are intracellular TLRs, whilst TLR1, TLR2, TLR4, TLR5, TLR6, TLR10 
and TLR11 are present on the cell membrane. In this review of TLRs, their ligands, activation and 
function, special attention will be given to TLR2 and its co-receptors.  
Pathogen-derived TLR ligands 
Many different microbial PAMPs have been identified as ligands for TLRs, and they are summarised in 
Figure 5 below. Intracellular TLRs recognise the DNA and RNA of viruses, as well as the DNA of 
bacterial and protozoan microbes. Surface glycogen and protein containing PAMPs of all classes of 
microbe are recognised by extracellular TLRs. TLR2 has been implicated in the recognition of a wide 
range of PAMPs from all four major classes of microbe, including virus glycoproteins, bacterial 
lipoproteins and lipopeptides, zymosan from fungi and GPI anchored molecules from protozoan 
parasites (148). 
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 TLRs and other PRRs recognise a diverse range of PAMPs from different classes of Figure 5.
microbes. Figure taken from (150) with permission. 
Endogenous TLR ligands 
The term ‘endogenous ligand’ was coined when heat shock proteins (HSP) were found to cause the 
production of proinflammatory cytokines by host cells, and this activity was linked to TLR4 complex 
activation (151). Since then, many other non-microbial molecules which are capable of activating TLRs 
and other PRRs, termed damage-associated molecular patterns (DAMPs), have been identified (152). 
However, the ability of HSP preparations to activate TLR4 was later attributed to LPS contamination 
(153). Indeed, a number of proposed endogenous TLR ligands may also have shown TLR activity as a 
result of contaminating bacterial ligands (154).  
The majority of the DAMPs that have been linked to TLR activation are either extracellular matrix 
(ECM) components, released intracellular components, or modified lipids. In most cases the reported 
TLR activity is via TLR2 or TLR4 (152), which are the receptors for the common contaminants of 
biological preparations, lipopeptides and endotoxin (LPS). Whilst many studies have used routine tests to 
exclude the activity of such contaminants, many of these tests have been found to lack the specificity and 
robustness to definitively exclude contamination with some of the most potently active molecules known. 
Indeed, there are reports that when using only low endotoxin reagents, no TLR activity was found when 
using endogenous oxidised phospholipids or low density lipoproteins (LDL) in their assays (155). Erridge 
proposes that many endogenous ligands may act to increase TLR activity to exogenous ligands such as 
LPS, either by directly binding ligands and enhancing their binding to TLRs, or by increasing cellular 
sensitivity to the ligands (155). Nevertheless, there remains a growing body of evidence from more recent 
studies that some host-derived molecules can directly stimulate immune responses in a TLR dependent 
fashion. Such endogenous ligands are often produced upon cell death or injury (hence the term DAMPs), 
although ligands from tumour cells have also been reported (152).  
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TLR structure, activation and signalling  
The structure of TLRs can be broken down into 3 main components: the extracellular domain, which 
contains leucine-rich repeats (LRRs), the transmembrane domain, and the intracellular Toll/interleukin-1 
receptor (TIR) domain. In response to recognition of a ligand, the extracellular domains of TLRs form 
dimers, an event that is required for activation and subsequent downstream signalling. TLRs can either 
form homodimers or heterodimers, depending on the specific TLR. Note that intracellular TLRs do not 
strictly speaking have an ‘extracellular’ domain, as this domain exists within the endosome inside the cell. 
TLR2 forms heterodimers with either TLR1 or TLR6 in response to presence of a ligand. The current 
paradigm in relation to the specificity of TLR2 to lipopeptides, is that recognition is dependent on the 
heterodimer formed, with TLR2/1 responding to triacylated lipopeptides and TLR2/6 to diacylated 
lipopeptides (156). Until recently, these two complexes were believed to be the only functional TLR 
heterodimers, but in 2009 Stewart et al reported the formation of the TLR4/6 heterodimer in response to 
CD36 binding of altered endogenous components (157), and TLR11/12 heterodimers have recently been 
purified from mouse cells (158). Binding of ligands to TLRs often requires cooperation from soluble 
components and/or co-receptors. For example, for LPS activation of TLR4, a series of components are 
needed for binding and activation (159). LPS binding protein (LBP) is a serum glycoprotein which can 
bind LPS and cause its removal from the bacterial membrane, LBP subsequently presents LPS to the cell 
surface receptor CD14. CD14-bound LPS can be presented to the LPS receptor complex, which consists 
of a homodimer of TLR4 and an MD-2 bound to each TLR4 molecule. Both CD36 and CD14 are also 
co-receptors for TLR2 heterodimers. Soluble CD36, binds negatively charged diacylglycerol ligands 
extracellularly, and can deliver these ligands to TLR2/6 via membrane bound CD14 (160), but is not 
thought to be involved in the binding of triacylglycerol ligands of TLR2 (161). The discrimination of 
different lipopeptide structures has been explored by Omueti et al with the aid of synthetic structures with 
varying numbers, and positioning, of acyl groups. Surprisingly, it was not the number of acyl groups that 
defined TLR1 or TLR6 co-receptor activity, but the chirality of the group(s) in relation to the central 
carbon atom (162). A monoacylated synthetic lipopeptide PamCSK4 was found to weakly activate 
TLR2/1, and R isomers were found to be more potent ligands than S isomers (162). Naturally occurring 
lipopeptides of bacteria possess specific chiralities and acylation patterns, and thus the dogma that diacyl 
lipopeptides are recognised by TLR2/1 and triacyl lipopeptides by TLR2/6 remains true for these ligands. 
Whether TLR2 can be activated without either TLR1 or TLR6, and if this occurs in vivo, remains unclear. 
Whilst diacylated lipopeptides have been shown to activate cells deficient of TLR6 or TLR1 (163), this 
does not rule out any compensatory co-receptor activity from the TLR which is not knocked out. The 
crystal structure of the TLR2/1 complex, bound to the synthetic triacylated lipopeptide ligand, Pam3CSK4 
(Pam3) was determined by Jin et al in 2007 (164).  Structural studies of ligand-TLR complexes have shed 
light on the specific components involved, and interactions between the various components in the 
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binding complex. The mininal TLR2 stimulatory component of lipopeptides has been identified as the N-
terminal acyl glyceryl cysteine (165).   
There is a need for structural studies of more TLR-ligand complexes, such as for parasite GPI anchors 
and TLR2, in order to determine exactly which patterns are recognised by each complex, and how 
additional factors such as co-receptors are involved in complex formation with different ligands. Thus, 
there remain gaps in our knowledge about the structural determinants involved in TLR2 activation by 
different PAMPs. It is thought that when TLRs dimerise upon activation, a subsequent dimerisation of 
the intracellular TIR domains occurs, and this initiates recruitment of the adaptor proteins (166) (Figure 
6).  
 
 Recognition of bacterial PAMPs by surface TLR complexes. LPS is recognised by a Figure 6.
homodimer of TLR4 in combination with MD-2, diacylated and triacylated lipopeptides are recognised by 
TLR2/1 and TLR2/6 heterodimers respectively, and flagellin is recognised by a homodimer of TLR5. 
Upon dimerization of the TLR receptors and formation of these complexes, activation of adapter 
molecules such as TIRAP and MyD88 (all these TLR complexes), or TRAM and TRIF (TLR4 only) 
results in the activation of NF-κB, leading to production of inflammatory cytokines. Figure taken from 
(148) with permission.  
Adaptor proteins are recruited to the TIR domains leading to induction of a signalling cascade; these 
include Myeloid differentiation primary response 88 (MyD88), MyD88 adaptor-like protein (Mal), TIR 
domain-containing adaptor inducing IFNβ (TRIF), and TRIF-related adaptor molecule (TRAM). These 
adaptor molecules contain a TIR domain, which allows for their binding to the TIR domain of activated 
TLRs. MyD88 is involved in the signalling events associated with all TLRs with the exception of TLR3, 
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where a TRIF-dependent pathway is utilised. TLR4 mediates signalling via either MyD88 or TRIF, whilst 
all remaining TLRs (TLR2/1, TLR2/6, TLR5, TLR7, TLR8, TLR9) signal via a MyD88-dependent 
pathway (148). After recruitment of the various adaptor molecules, a number of kinases are activated, and 
eventually transcription factors (such as NF-κβ) are activated to enter the nucleus and upregulate 
expression of genes encoding pro-inflammatory mediators.  
TLRs play a role in adaptive immune responses 
Although speculated by Janeway in 1989 (167), it wasn’t until 1997 that Medzhitov and Janeway found 
that adaptive immune responses could be triggered by the recognition of PAMPs via a ‘human 
homologue of Drosophila Toll’, now known as TLR4, by triggering the expression of co-stimulatory 
molecules and proinflammatory cytokines (168). This was later confirmed in vivo by the characterisation of 
the TLR4 gene locus in mice, and the finding that defective TLR4 genes in two strains of mice made 
them susceptible to E. coli infection due to their inability to respond to LPS and mount an appropriate 
immune response to infection (169). Since the discovery of multiple other TLRs, their ligands, and the 
exploration of their role in vivo, it is now clear that TLRs play crucial roles in the priming of adaptive 
immune responses in many different settings (170). Given their crucial role in innate and adaptive 
immune responses to pathogens, it is unsurprising that TLRs have been found to play roles in resistance 
and/or susceptibility to infection with a wide range of microorganisms (discussed further below). 
However, despite great progress in terms of the characterisation of TLR ligands, binding complexes and 
signalling pathways, the precise factors involved in the initiation of different types of adaptive immune 
response in vivo still require further elucidation (170, 171). 
TLR crosstalk and interaction with other PRR signalling 
It is now becoming clear that the scale and type of resulting immune response to a pathogen or other 
stimulus is determined by a combination of different signals recognised by a wide variety of PRRs (172). 
C-type lectins (CLRs) are a sub-family of carbohydrate-binding proteins, which contain a conserved 
calcium-dependent carbohydrate recognition domain (173). Important CLRs that are involved in the 
innate immune recognition of microbes are Dectin-1, DC-Specific Intercellular adhesion molecule-3-
Grabbing Non-integrin (DC-SIGN; present in humans, not mice), SIGN-R1 and Langerin. Both DC-
SIGN and SIGN-R1 are CLRs, which have been linked with promoting Th2 responses (173). NOD-Like 
Receptors (NLRs) are intracellular proteins, expressed mainly by APCs and epithelial cells, which can 
bind to microbial proteins, usually bacterial cell-wall components, within the host cell cytosol. Upon 
binding of PAMPs to NLRs, signalling cascades are activated which result in changes of gene 
transcription, and results in inflammation. Nucleotide-binding oligomerization domain-containing protein 
2 (NOD2) is an NLR, which recognises muramyl dipeptide of bacterial peptidoglycan, and upon 
activation up-regulates the transcription factor NF-κβ and promotes inflammatory responses (174).  
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Zymosan and β-1,3-glucan are fungal PAMPs, which activate innate immune cells by interacting with 
both TLR2 and Dectin-1 (175). Initially reported to result in inflammatory responses, these 
TLR2/Dectin-1 activating fungal ligands have recently been shown to activate regulatory responses in 
APCs, which promote antigen specific tolerance (176). However, β-glucan ligands from fungal microbes 
have also been shown to activate Th1 and Th17 responses through Dectin-1, in the absence of 
TLR/MyD88 signalling (177).  In Mycobacterium tuberculosis infection, NOD2 and TLR2 act synergistically 
to induce inflammatory cytokine production. But as NOD2 and TLR2 double deficient mice are still able 
to control M. tuberculosis infection, it is believed other PRRs are also important in this infection (172). 
Thus, multiple PRRs from different families can be activated at the same time within one cell, and the 
interactions between the signalling events that occur can result in various different responses to the 
stimulus/stimuli. This allows the innate immune system to act as a comprehensive and selective 
surveillance network that can sense microbial invasion and potential danger signals in a number of 
different ways.  
The role of TLR2 in bacterial, viral and fungal infections 
The major TLR2 ligands characterised so far are lipoproteins of bacteria. Whilst all bacteria express 
lipoproteins, they are found abundantly on the surface membrane of Gram-positive bacteria in particular 
(178). TLR2 activation has been linked to the outcome of infection with different pathogenic bacteria. 
TLR2-/- mice infected with M. tuberculosis presented with increased bacterial loads and succumbed more 
readily to infection (179). In Staphylococcus aureus infection, TLR2 activation during infection was linked 
with susceptibility to disease, as LTA binding to TLR2 increased IL-10 production, which resulted in 
decreased MHC II presentation (180). There is also increasing evidence that TLR2 plays an important 
role in the protective immune response to certain viral infections. For example, TLR2-/- mice are more 
susceptible to infection with Cytomegalovirus (CMV), and this increased susceptibility was attributed to 
an impaired NK cell response (181).  
In fungal infections, TLR2 is involved in the innate recognition of fungal cell walls in addition to TLR4 
and Dectin-1 (178). The combined activation of TLR2, Dectin-1 and the NOD-like receptor family, 
pyrin-domain-containing 3 (NLRP3) inflammasome by fungal pathogens is important for an adequate 
induction of IL-1β response, which helps leads to clearance (182), indicating an importance for PRR 
synergy in immune responses to fungal pathogens. Studies using TLR2 deficient mice have yielded 
opposing results in terms of the importance of TLR2 in clearance of infection with fungal pathogens, but 
they consistently report a role for TLR2 in a pro Th1 inflammatory response to infection (178). 
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TLRs in parasitic disease 
Parasite derived TLR ligands 
Many in vitro studies have attributed TLR activation activity to parasite PAMPs. One of the more studied 
ligand groups are GIPLs and GPI anchors from Trypanosomes, which have been known to stimulate 
inflammatory immune responses for some time. In 1997 Camargo et al found that T. cruzi derived GPI 
mucin preparations were found to stimulate NO and IFNγ production by exposed MΦs and could also 
facilitate intracellular killing of T. cruzi or Leishmana spp (in conjunction with IFNγ), but that Leishmania 
derived LPG or GIPLs were unable to potentiate NO responses (183). Almeida et al demonstrated that 
highly purified GPI mucins from T. cruzi trypomastiogotes, but not epimastigotes, were potent activators 
of inflammatory responses, and are active at nanomolar concentrations (184). Structural comparisons 
between trypomastigote and epimastigote GPIs suggest that the activity of the bioactive GPIs can be 
attributed to the unsaturated fatty acid in the alkyacylglycerolipid component (184). Subsequent studies 
have attributed the pro-inflammatory activity of GPI anchors and GIPLs from T. cruzi to activation of 
TLR2 in combination with CD14 (185), and as a heterodimer with TLR6 (186). Although earlier studies 
suggest that TLR4 is not involved in GIPL recognition (185), TLR4 in combination with MD-2 has since 
been reported to respond to ceramide-containing GIPLs from T. cruzi (187).  
A number of in vitro studies have identified TLR2-dependent activation of inflammatory responses by 
Leishmania LPG (26, 27). Similarly to T. cruzi GIPLs, L. major LPG was unable to elicit a TLR2 mediated 
response from MΦs when the lipid portion was removed (26), indicating that the lipid of the unique GPI 
anchor of LPG is responsible for TLR2 signalling. However, de Veer et al reported that TLR2 activation 
by other Leishmania glycolipids, which also contain GPI anchors, did not occur. Another interesting 
finding from this study was the lack of TLR2 activation from L. mexicana LPG, in comparison to L. major 
LPG, which contradicts the idea that the lipid moiety is responsible for TLR2 signalling, as this is 
identical in both species (29). Becker et al report TLR2-dependent activation of NK cells by L. major LPG 
(27). This study demonstrates that LPG from infective metacyclic L. major was a more potent activator of 
TLR2 than LPG from procyclic L. major. As the modifications of LPG that occur during 
metacyclogenesis involve addition of glycan chains to the phosphosaccharide repeats, this finding 
suggests that this region is somehow involved in TLR2 recognition of LPG (27). There is a need to 
elucidate further whether LPG is an authentic ligand of TLR2, and what specific components of LPG are 
required for this activity.  
GPI anchors from Plasmodium falciparum (causative agent of malaria) have been shown to activate TLR2/1 
heterodimers, and both TLR2 and TLR4 have been linked to inflammatory responses mediated by 
Toxoplasma gondii GPI anchor structures (188). There is increasing evidence therefore, that protozoan 
GPI-anchored molecules can activate cells in a TLR-dependent fashion. As with all studies on TLR ligand 
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characterisation, the risk of contaminating structures or the use of supraphysiological concentrations may 
lead to erroneous designations of authentic TLR-ligand binding. 
TLR9 is an intracellular TLR, which is activated by unmethylated CpG DNA, and was first identified as a 
receptor for bacterial DNA. However, recent evidence indicates that TLR9 is also stimulated by 
protozoan DNA, as L. infantum, T. cruzi and T. brucei DNA activated DCs and MΦs in a TLR9 dependent 
fashion (97, 189, 190). A non-DNA ligand for TLR9 has been proposed in Plasmodium spp infections, in 
the form a haemozoin, a product of digestion of haemoglobin by the malaria parasite (191). However, it 
has since been shown that haemozoin does not activate TLR9 directly, but can enhance TLR9 activation 
by delivering malaria DNA to the receptor (188, 192). As discussed above, there is a need for the 
structural components involved in TLR-parasite ligand interaction to be determined, as they have been 
for some bacterial ligands.  
In vivo evidence for a role of TLRs in parasitic disease 
There is increasing evidence therefore, that protozoan ligands can activate TLRs using in vitro studies. 
Infection experiments employing knockout mice lacking TLRs or signalling pathway components have 
explored the roles of TLRs in parasite infection and disease dynamics. 
Trypanosoma cruzi 
TLR4 has been implicated in the control of T. cruzi in vivo. C3H/HeJ mice, which do not express 
functional TLR4, were found to be more susceptible to T. cruzi infection than C3H/HeN mice, which 
have functional TLR4 molecules (193). A role for GIPLs in TLR4 responsiveness was determined in vivo, 
as injection of GIPLs into C3H/HeJ mice resulted in the absence of an inflammatory response (193).  
Despite in vitro evidence that GPI mucins from T. cruzi trypomastigotes stimulate TLR2, infected TLR2-/- 
mice developed T. cruzi infection in a similar way to WT mice, and were able to generate robust immune 
responses (194). MyD88-/- mice however, show reduced immune responses during T. cruzi infection, and 
were more susceptible to infection than WT and TLR2-/- mice (194). TLR9-/- mice are more susceptible 
to T. cruzi infection than WT mice, showing an increased parasitaemia and mortality levels, although not 
to the same extent as MyD88-/- mice. When both TLR2 and TLR9 are absent from the murine host 
(TLR2-/-/TLR9-/- mice) however, the parasitaemia increases to levels equivalent to MyD88-/- mice (189). 
These results are important for indicating a cumulative effect of TLR signalling during parasitic infection; 
whilst TLR2 signalling alone appears to have no effect on disease outcome in T. cruzi infection, TLR2 and 
TLR9 signalling combined is linked to an increased level of resistance (189).  
Toxoplasma gondii 
T. gondii is an apicomplexan protozoan parasite which resides intracellularly in infected mammalian hosts. 
It can infect many types of mammal and is known to be present in over 60% of the human population, 
causing asymptomatic infection in most cases. Disease can occur after T. gondii infection in certain 
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settings, such as when the host is immunosuppressed or when primary infection occurs during pregnancy 
when infection of the unborn child can result in preterm abortion (195). TLRs were implicated in 
resistance to T. gondii in mouse models by the finding that MyD88-/- mice are susceptible to T. gondii 
infection and rapidly succumb to the disease, and this is linked with their inability to produce IL-12, when 
compared to resistant WT mice, which have a strong IL-12 response to the parasite (196). TLR2, TLR4 
and TLR11 were implicated as they have been shown to recognise the T. gondii parasite, or parasite-
derived PAMPs in vitro (197, 198). TLR11 was found to recognise a profilin-like protein from T. gondii and 
is required for IL-12 production in response to T. gondii by DCs (198). However, a recent study found 
that the previously uncharacterised TLR12 was also involved in the recognition of T. gondii profilin-like 
protein and could function as either a homodimer or heterodimer with TLR11 to respond to the parasite 
(158). Its function as a homodimer in pDCs in upregulating IL-12 production was found to be crucial for 
resistance in mice, and was more important than the TLR11 function (158).  
Leishmaniasis 
The TLR signalling components that have been linked to Leishmania infections are summarised in Figure 
7.  The first studies to indicate a role for TLRs during Leishmania infection involved the use of mice 
deficient in MyD88. Mice lacking MyD88 (on a C57BL/6 background) were found to have increased 
susceptibility to L. major infection (26, 199). Interestingly, the disease progression in these MyD88-/- mice 
was similar to that of the susceptible BALB/c strain, where progressive lesion development is coupled 
with an inappropriate Th2 immune response (199). Thus MyD88 signalling is an important part of 
developing a Th1 response in mice which are able to heal lesions.  MyD88-/- mice also had exacerbated 
disease when infected with L. braziliensis in a separate study (200), and MyD88 signalling was found to be 
necessary for maturation of DCs during L. donovani infection (201), indicating that MyD88 is important 
for protection in different species of Leishmania. These results indicate that TLRs may play an important 
role in resistance to Leishmania infection, but as MyD88 is also involved IL-1 signalling, a TLR-
independent role for MyD88 in these models cannot be ruled out.  
Two studies by Kropf et al explored a possible role for TLR4 in L. major infection and found that TLR4-/- 
mice on a C57BL/6 background had larger lesions and greater parasite burdens during the early stages of 
infection (202, 203). However, these mice did resolve the lesions, indicating that TLR4 alone does not 
contribute to the level of susceptibility seen in MyD88-/- mice. Infection with L. pifanoi resulted in an 
increased parasite burden in mice lacking TLR4 compared to WT mice, at one week post infection (204). 
The disease progression was not monitored for longer than 1 week in this study, so the full infection and 
disease dynamics of the TLR4-/- mice in this model remains unclear. Interestingly, a novel glycoprotein 
complex of L. pifanoi, proteoglycolipid complex P8 (P8 PGLC), was found to be a ligand of TLR4, 
indicating a direct role for TLR4 in parasite recognition during infection (204). These results should be 
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taken with caution however, as it is well-known that proposed TLR ligands are often mistaken findings 
due to the contamination of trace endotoxin or other PAMPs (154).  
 
 The role of TLRs in Leishmania infection. Various studies have identified a role for TLRs Figure 7.
in the recognition of Leishmania parasites in vitro and in vivo. The surface TLRs TLR2 and TLR4 can be 
activated by surface glycolipid and glycolipid complexes, such as LPG and P8 (26, 204, 205) and TLR4 
plays a role in disease outcome in vivo (202, 203). Intracellular TLRs TLR9 and TLR3 sense DNA from the 
Leishmania parasite: TLR9 recognises unmethylated DNA from the parasite and this plays an important 
role in priming a protective immune response to infection in vivo (97, 206, 207), whilst TLR3 is stimulated 
by the Leishmania RNA virus and this has been linked to the increased immunopathology (metastases) in 
infections by parasites with higher titres of the virus (208, 209).  
It has been widely hypothesised that TLR2 may be responsible for the role of MyD88 during infections 
with Leishmania spp, as LPG has been found to act as a ligand of TLR2 in vitro (see above). However, 
contrary to expectations, the lack of TLR2 increased resistance to infection with L. braziliensis, as TLR2-/- 
mice developed smaller lesions and TLR2-/- dendritic cells induced stronger immune responses to 
parasites in vitro (200). These results suggest that TLR2 somehow exacerbates disease during L. braziliensis 
infection, and perhaps that the parasite exploits TLR2 signalling to promote its growth. However, as 
TLR2-/- mice showed only increased lesion size, but no increase in parasite burden or duration of lesion 
formation (200), the role of TLR2 in this model appears to be one of reducing tissue damage in the 
lesion, as opposed to direct control of parasite growth and dissemination.  
Abou Fakher et al explored the role of TLR9 during L. major infection of C57BL/6 mice by using 
knockout strains and found that TLR9-/- mice had higher levels of parasitaemia and larger lesions than 
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WT mice (207). Furthermore, DCs lacking TLR9 were not activated to prime a protective Th1 immune 
response when exposed to L. major parasites or DNA, further indicating an important role for TLR9 in 
this model, and that TLR9 activation may be the mechanism for driving protective immune responses 
(207). In a model of L. infantum infection, TLR9 activation of mDCs was found to be crucial for the 
activation of NK cells, and their production of IFNγ (97).  
Recently, a role for an RNA virus, which infects some species and strains of Leishmania (the Leishmania 
RNA virus, LRV) in the immunopathology of new world MCL has been identified (208). Although LRV 
was detected in Leishmania parasites several decades ago, it was not thought to play any role in the 
outcome of Leishmania infection until recently (209). Ives et al identified that L. guyanensis, a new world 
species of Leishmania that causes CL and MCL, results in differing pathologies depending on the strain of 
parasite. A strain that was associated with increased metastatic disease (MCL) was found to have higher 
titres of LRV, and this resulted in hyper-activation of immune response via activation of TLR3 by the 
LRV, leading to exacerbated disease (208).  
TLR ligands as vaccine adjuvants 
Advances in our understanding of innate immune responses and the crucial role they play in shaping 
adaptive immunity has led to increased interest in trying to understand how existing effective vaccines, 
and in particular adjuvant components, work. Whilst adjuvants used to be considered ‘the immunologist’s 
dirty little secret’ (167) as it was not understood how they were able to boost immune responses to 
antigens, we are now uncovering the mechanisms of adjuvants which have been previously used, or are 
currently licensed for use in vaccines for humans (such as Alum and MF59) (210, 211). It appears that all 
adjuvants function in some way to activate the innate immune response at the site of vaccination, and that 
this is likely to be the most important mechanism of action, as opposed to allowing for sustained release 
of antigen (the depot effect) which had previously been thought the important mechanism of action of 
many adjuvants (210). For example, Hutchinson et al showed that the ability for Alum to boost antigen 
presentation by various cell types, T cell expansion, antibody production and memory responses, was 
unaffected by the removal of the injection site at as early as 2 hours after injection (212), strongly 
disputing any need for a depot effect at the injection site. Indeed, other studies have disputed whether 
Alum remains adsorbed to antigen for a sustained period of time, and whether this is linked to 
adjuvanticity (213, 214).  However, licensed and experimental adjuvants have been consistently shown to 
be strong inducers of local chemokine and cytokine production, to increase recruitment of cells to the 
injection site and to increase uptake and presentation and antigen by APCs, as well as increase APC 
maturation (particularly DCs) (210, 212, 215-217).  
As a major development in innate immune research in recent years has been on TLR activation and 
signalling, TLR ligands have become an area of intense interest in vaccine and adjuvant design (218). They 
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are the most well-defined activators of PRRs known, and offer a great deal of potential for adjuvant 
development (173). Many existing vaccines employ the use of killed or attenuated microbes, which 
containing many different PAMPs intrinsically, and thereby activate TLRs and other PRRs (i.e. they 
contain natural adjuvants). For example, the yellow fever vaccine acts to stimulate DCs by the activation 
of TLR2, 7, 8 and 9 (219), and the BCG vaccine activates immune response by interaction with many 
PRRs including TLR2, 4 and 9 (220, 221). It is hoped that our increased understanding of the mechanism 
of adjuvants, combined with the function of PRRs and other innate immune processes, we can design 
and develop adjuvants and delivery systems, consisting of basic PRR agonists and particulates, which are 
capable of promoting a strong antigen specific immune response, with the desired effector and memory 
responses (210). One TLR ligand, the TLR4 ligand 3-O-desacyl-4’-monophosphoryl lipid A (MPL), a 
non-toxic derivative of LPS from Salmonella minnesota is incorporated in the Adjuvant System 04 (ASO4; 
GlaxoSmithKline) oil-in water adjuvant, which has recently been licensed for use in two human vaccines 
(217).  
 
Project aims 
This thesis aims to investigate the role for TLR2 and its co-receptors in the control of cutaneous 
leishmaniasis in vivo, in order to inform rational vaccine and adjuvant design for future leishmaniasis 
vaccine candidates.  
The aims of this project can therefore be summarised as: 
1. To determine the role of TLR2 and co-receptors TLR1 and TLR6 in CL infection 
2. To design a vaccine for CL containing TLR2 ligand adjuvants 
3. To explore the efficacy of the vaccines + TLR2 ligand adjuvants in a vaccine models for CL (Th1 
immunity) and lymphatic filariasis (Th2 immunity) in comparison to standard adjuvants, and 
determine immune correlates of protection in these models. 
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Chapter 2. Methods 
This chapter provides detailed methodology for all of the experiments performed and presented in this 
thesis. In individual results chapters (Chapters 3-7), brief descriptions of the methods used are given, 
which refer back to the methodology given in this chapter, as well as providing specific details that apply 
only to those chapters.  
Reagents and equipment 
Details of powder and liquid reagents that were used in this study are given in full in Table 2, along with 
their sources. All were kept in the conditions required as stated in the manufacturer’s storage instructions.  
Category Name Company 
 
Powders 
Agarose Sigma 
Bovine Serum Albumin (BSA) Sigma 
Calcium chloride dehydrate (CaCl2.2H20) Sigma 
Concanavalin A (ConA) Sigma 
Glycine Sigma 
Heparin sulphate  Sigma 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Sigma 
Imidazole Qiagen 
Isopropylthio-β-galactoside (IPTG) Qiagen 
Kanamycin sulphate Invitrogen 
LB Broth  Miller 
Leupeptin hydrochloride Sigma 
Lysozyme Sigma 
Magnesium sulphate (MgSO4) Sigma 
Manganese (II) chloride (MnCl2) Sigma 
3-(N-Morpholino)propanesulfonic acid, 4-
Morpholinepropanesulfonic acid (MOPS) 
Sigma 
N-tosyl-L-lysinechloromethyl ketone (TLCK) Sigma 
Potassium acetate Sigma 
Potassium Chloride (KCl) BDH 
Potassium phosphate monobasic (KH2PO4) VWR 
Rubidium Chloride (RbCl) Sigma 
Sodium dodecyl sulphate (SDS) Fisher 
Sodium bicarbonate (NaHCO3) Sigma 
Sodium carbonate (Na2CO3) Sigma 
Sodium chloride (NaCl) Sigma 
Sodium phosphate dibasic (Na2HPO4) BDH 
Sodium phosphate monobasic (NaH2PO4) BDH 
Tris Base (Tris, or Trizma) Sigma 
Tris.Borate EDTA Buffer 5 x sachets Sigma 
Tris.HCl Sigma 
Urea Qiagen 
X-gal (Ultra-pure) Invitrogen 
 
Liquids 
 
 
 
 
Liquids (continued) 
100 x BME vitamins Sigma 
2-Mercapthoethanol (2-ME) 50 mM Invitrogen 
2-Propanol (isopropanol) Sigma 
3,3′,5,5′-Tetramethylbenzidine (TMB) Liquid Substrate System 
for ELISA 
Sigma 
Ampicillin solution Invitrogen 
Dimethyl sulfoxide (DMSO) Sigma 
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Category Name Company 
Dimethylformamide (DMF) Sigma 
Dulbecco’s Modified Essential Medium (DMEM) Invitrogen 
Dulbecco’s Phosphate Buffered Saline (DPBS) Sigma 
Ethidium Bromide solution Sigma 
Foetal bovine serum “gold”, heat-inactivated (HI-FBS gold) PAA 
Formaldehyde Sigma 
Gentamicin sulphate  Sigma 
Giemsa staining solution BDH 
Glycerol Sigma 
Grace’s Insect Medium Invitrogen 
Hank’s Balanced Salt Solution (HBSS) Sigma 
Hydrochloric acid (HCl) AnalaR 
L-glutamine solution 200 mM Sigma 
Medium 199 1x Invitrogen 
Methanol (HPLC grade) Fisher 
Non-essential amino acids (NEAA), 100 x Sigma 
Nuclease-free water Ambion / Sigma 
Penicillin-Streptomycin Invitrogen 
RBC lysis buffer, 1 x  eBioscience 
RNA later Ambion 
Roswell Park Memorial Institute (RPMI) 1640 medium Invitrogen 
SOC medium Invitrogen 
Sodium hydroxide (NaOH) solution, 5 M Prepared in-house 
Sulphuric acid (H2SO4) AnalaR 
TE Buffer Ambion 
Trypan blue solution, 4 % Invitrogen 
Tween-20 Sigma 
 
The details of the solutions, buffers and media reagents made freshly in the laboratory are given in Table 
3. Double distilled water (dH20) was prepared in-house and sourced from specialised taps in the 
laboratories. To measure and alter pH, an UltraBasic UB-10 benchtop pH meter was used (Denver 
Instruments) and pH was adjusted using HCl and/or NaOH unless stated otherwise.  
Solution name Components Concentration Diluent Adjustments 
10 x PBS NaCl 
KCl 
Na2HPO4 
KH2PO4 
80 g/l  - 1.37 M 
2 g/l  - 27 mM 
14.4g/l – 81 mM 
2.4 g/l – 15 mM  
dH20  
PBS 10 x PBS 1 x dH20 pH 7.2 
Sterile filtered 
70 % Ethanol Ethanol 70 % v/v dH20  
Complete M199 HI-FBS gold 
gentamicin sulphate  
BME vitamins  
20 % 
25 µg/ml 
1 x 
Medium 199 Sterile filtered, kept at 4°C 
Complete Grace’s 
medium 
HI-FBS gold 
gentamicin sulphate  
BME vitamins 
20 % v/v 
25 µg/ml 
1 x 
Grace’s 
Insect 
Medium 
pH 5.5 
Sterile filtered, kept at 4°C 
Table 2.  List of powder and liquid reagent names and their sources.   
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Solution name Components Concentration Diluent Adjustments 
Complete DMEM extra HI-FBS gold 
Penicillin-
Streptomycin 
L-glutamine 
2-ME 
NEAA 
10 % v/v 
50 U/ml, 50 µg/ml 
2 mM 
0.1 mM 
1 x 
DMEM Sterile filtered, kept at 4°C 
Complete DMEM HI-FBS gold 
Penicillin-
Streptomycin 
10 % v/v 
50 U/ml, 50 µg/ml 
DMEM Sterile filtered, kept at 4°C 
Complete RPMI extra HI-FBS gold 
Penicillin-
Streptomycin 
L-glutamine 
2-ME 
NEAA 
10 % v/v 
50 U/ml, 50 µg/ml 
2 mM 
0.1 mM 
1 x 
RPMI Sterile filtered, kept at 4°C 
Complete RPMI HI-FBS gold 
Penicillin-
Streptomycin 
10 % v/v 
50 U/ml, 50 µg/ml 
RPMI Sterile filtered, kept at 4°C 
Basic RPMI  Penicillin-
Streptomycin 
50 U/ml, 50 µg/ml RPMI Sterile filtered, kept at 4°C 
ELISA coating buffer Na2CO3 
NaHCO3 
3.03 g/l 
6 g/l 
dH20 pH 9.6 
ELISA blocking buffer BSA 1 % w/v PBS Made fresh each use 
Cytokine ELISA 
reagent diluent 
BSA 1 % w/v PBS pH 7.2 – 7.4 
Sterile filtered 
IFNγ reagent diluent Tris 
NaCl 
BSA 
20 mM 
150 mM 
0.1 % 
dH20 pH 7.2 -7.4 
Sterile filtered 
Ab ELISA reagent 
diluent 
Tris  
NaCl 
BSA 
Tween 20 
50 mM 
0.14 M 
1% 
0.05% 
dH20 Kept at 4°C, made fresh 
each use 
Stop solution H2SO4 0.9 M / 1.8 N dH20  
LB medium LB Broth Powder 
 (Tryptone 
  Yeast extract 
  NaCl) 
2.5 % (w/v) 
1 % (w/v) 
0.5 % (w/v) 
1 % (w/v) 
dH20 Autoclaved 
LB Agar LB Broth Powder 
Agar 
2.5 % (w/v) 
1.5 % Agar 
dH20 Autoclaved 
5 X TBE Buffer 5 x TBE Buffer 
blend  
(Tris-borate 
 EDTA) 
5 x / 1 sachet/litre 
(0.445 M 
 10 mM) 
dH20  
TBE Buffer 5 x TBE buffer 1 x / 20% v/v dH20  
10 x Running Buffer Tris  
HEPES 
SDS 
1 M 
1 M 
1 % w/v 
dH20 Dissolve Tris base first 
and adjust to pH 8.3  
Running Buffer 10 x Running buffer 1 x / 10% v/v dH20  
10 x Transfer Buffer Tris 
Glycine 
250 mM 
1.92 M 
dH20 Dissolve Tris base first 
and adjust to pH 8.3 
Transfer Buffer 10 x Transfer Buffer 
Methanol 
1 x / 10% v/v 
20% v/v 
dH20 Keep at 4°C or below 
Tris-Buffered Saline-
Tween 20 (TBST) 
Tris 
NaCl 
Tween 20 
50 mM 
150 mM 
0.05%  v/v 
dH20  
TFB1 Buffer RbCl 
MnCl2 
Potassium acetate 
100 mM 
50 mM 
30 mM 
dH20 Adjust to pH 5.8, sterile 
filter 
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Solution name Components Concentration Diluent Adjustments 
CaCl2.2H20 
Glycerol 
10 mM 
15 % v/v 
TFB2 Buffer MOPS 
RbCl 
CaCl2.2H20 
Glycerol 
10 mM 
10 mM 
75 mM 
15% v/v 
dH20 Adjust to pH 6.8 using 
KOH, sterile filter 
Psi Broth MgSO4 
KCl 
4 mM 
10 mM 
LB medium  
Native Lysis Buffer NaH2PO4 
Tris.Cl 
Imidazole 
Lysozyme 
100 mM 
10 mM 
10 mM 
1 mg/ml 
dH20 Adjust to pH 8.0, 
lysozyme is added to 
buffer just before use.  
Denaturing Lysis Buffer NaH2PO4 
Tris.Cl 
Urea 
100 mM 
10 mM 
8 M 
dH20 Adjust to pH 8.0 
Native Protein Wash 
Buffer 
NaH2PO4 
NaCl 
Imidizole 
50 mM 
300 mM 
20 mM 
dH20 Adjust to pH 8.0 
Native Protein Elution 
Buffer 
NaH2PO4 
NaCl 
Imidazole 
50 mM 
300 mM 
250 mM 
dH20 Adjust to pH 8.0 
 
Denaturing Wash 
Buffer 
- - Denaturing 
Lysis Buffer 
Adjust to pH 6.3 
Elution Buffer D - - Denaturing 
Lysis Buffer 
Adjust to pH 5.9 
Elution Buffer E - - Denaturing 
Lysis Buffer 
Adjust to pH 4.5 
FACS Buffer BSA 
EDTA 
0.5 % w/v 
2 mM 
PBS Sterile filtered, kept at 4°C 
The details of plastic consumables used are given in Table 4 below. 
Name Company 
0.5, 1.5 and 2 ml microcentrifuge tubes (sterile) Starlab 
1, 1.2 and 2 ml cryopreservation tubes NUNC, Starlab 
1, 2, 5, 10 and 25 ml serological pipettes (sterile) Starlab / VWR 
1, 2.5, 5, 10, 20 and 50 ml luer-lock syringes BD Plastipak 
10, 100, 200 and 1000 µl graduated pipette tips (sterile, with or without filters) Starlab 
100 x 15 mm2 sterile petri dishes  NUNC/ VWR 
15 ml centrifuge tubes (sterile) Starlab 
20 ml conical falcon tubes (sterile) Sterilin 
25, 75 and 175 cm2 culture flasks Fischer Scientific / NUNC 
2HB High-binding plates for ELISA Immulon 
48-well and 96-well flat bottom plates (sterile) Thermo Scientific / NUNC 
50 ml centrifuge tubes (sterile) Starlab 
70 µm cell strainer (sterile) BD 
8-well PCR tube strips (clear) Starlab 
96-well high-profile white PCR plates Starlab 
96-well U bottom plate (sterile) Thermo Scientific / NUNC 
Glass microscope slides VWR 
Poly-L-lyseine frosted microscope slides  
Syringe needles (various sizes) (sterile) Terumo Neolus 
 
Table 3.  Buffers, solutions and cell culture media 
Table 4.  Details of plastic consumables 
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Details of the origin and other descriptives related to the type and preparation of animals, parasites, 
antibodies, machines, software, kits, and other such “specific-use” reagents, are given in the appropriate 
methods sections below.  
Animals, cell culture, and parasite life-cycle maintenance 
Mice and Gerbils 
TLR1-/-, TLR2-/-, TLR4-/- and TLR6-/- mice were originally obtained from Professor Akira’s laboratory 
(Laboratory of Host Defense, Osaka University, Japan) and have since been maintained in the Biomedical 
Services Unit, Duncan Building, University of Liverpool. C57BL/6 mice were purchased from Charles 
River and BALB/c mice were purchased from Harlan. Naive Mongolian Jirds were purchased from 
Charles River, whilst Jirds already infected with Brugia malayi were purchased from TRS Laboratories, 
USA.  All procedures involving animals were approved by the Home Office and the LSTM and 
University of Liverpool Ethics Committees. Procedures took place either in the Biomedical Services Unit 
(BSU), Duncan Building, University of Liverpool, or the BSU animal facility in the Ronald Ross Building, 
University of Liverpool where animals are housed in individually ventilated cages (IVCs) with air filtered 
with High-efficiency particulate air (HEPA) filters. The location of animals used in individual experiments 
is detailed in the methods sections for each result chapter. 
Cell culture 
Cells and parasites were cultured in vitro in the conditions indicated in Table 5 below:  
Cell type Culture media Incubator 
conditions 
Volumes and containers 
Leishmania promastigote parasites Complete M199 26°C 1-7.5 ml (25 cm2 flask) 
5-20 ml (75 cm2 flask) 
20 – 75 ml (175 cm2 flask) 
Leishmania amastigote parasites Complete Grace’s 32°C 1-7.5 ml (25 cm2 flask) 
5-20 ml (75 cm2 flask) 
20 – 55 ml (175 cm2 flask) 
Mouse splenocytes or DLN cells Complete DMEM extra 
or complete RPMI extra 
37°C, 5 % CO2 100 – 200 µl  (96 well flat-
bottom plates) 
Mouse peritoneal exudate cells 
(PECs), MΦs, HEK cells, B. 
malayi parasites 
Complete RPMI 37°C, 5 % CO2 100 – 200 µl  (96 well flat-
bottom plates) 
1-7.5 ml (25 cm2 flask) 
5- 20 ml (75 cm2 flask or petri 
dish) 
E. coli  SOC medium or 
Complete LB with 
supplements 
37°C with 
continual 
shaking 
5-6 ml (20 ml conical flask) 
Table 5.  Culture conditions for different cell types and parasites.  
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Counting of cells 
Mammalian and parasite cells were counted using either a haemocytometer or an automated cell counter 
(the method used in each experiment is indicated in corresponding methods sections). The cell 
suspension to be counted was gently disrupted to allow for equal distribution of the cells before dilution, 
if necessary, in DPBS. Then 10 µl was removed and placed in either a well of a 96-well flat-bottom plate 
or a microcentrifuge tube and mixed with an equal volume of trypan blue solution by gentle pipetting. 
For motile cells, such as cultured Leishmania promastigotes, cells were fixed prior to staining in 4 % 
formalin in PBS solution (at a ratio of 1:1). Cells which form clumps in culture, such as Leishmania 
amastigotes, were disrupted using a 1 or 2.5 ml syringe and a blunt-end dosing needle prior to counting.  
Haemocytometer 
For counting using a haemocytometer, the counting chambers were prepared by placing thick coverglass 
over the two grids of the haemocytometer (Assistent) and ensuring a tight grip. Then 10 µl of the 
cell/trypan blue mix was placed next to the counting chamber of a haemocytometer to allow for it to fill 
by capillary action. Cells were allowed to settle for 1 minute prior to counting using the x20 objective of a 
light microscope. The number of cells per 1 mm2 was counted by recording the number of cells in the 
central grid; this was repeated and the average of two readings was multiplied by the conversion factor (x 
104) for the number of cells per ml.  
Automatic cell counter 
In some cases, mammalian cells were counted using a TC-10 ™ Automated Cell Counter (BioRad). In 
such instances, cells were prepared as described above, and 10 µl cell/trypan blue mix was placed in the 
well of a TC-10 cell counting slide (BioRad) and allowed to settle for 1 minute. The slide was then placed 
in the Automatic Cell Counter and the number of live cells per ml was calculated and displayed on the 
screen.  
Cryopreservation of cells 
Cultured cells were frozen in media solutions (as detailed in Table 5) containing either glycerol (10 %) or 
DMSO (10 %) as a cryoprotectant, depending on the cell type. Leishmania promastigotes were 
cryopreserved by placing log-phase parasites into complete M199 containing 7.5 – 10% glycerol, in 
cryopreservation tubes, and freezing slowly to -80°C using a Mr Frosty container (Nalgene) containing 
isopropanol. Leishmania amastigotes were cryopreserved as above but instead using complete Grace’s 
containing 10% DMSO as the freezing medium; mammalian cells were also cryopreserved using culture 
media containing DMSO. After freezing, the vials were kept in long-term storage in either liquid nitrogen 
or at -80°C. Cryopreserved promastigotes were recovered from storage by defrosting and slowly diluting 
(drop-by-drop) into fresh complete M199. Frozen amastigotes or mammalian cells were recovered from 
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storage by defrosting the vials quickly, centrifuging and removing freezing medium quickly, and placing 
cells into fresh culture medium. 
Mycoplasma detection 
Cell cultures (kept for longer than 7 days in culture) were regularly checked for mycoplasma 
contamination using the MycoAlet MycoplasmaTM Detection Kit (Lonza) according to manufacturer’s 
instructions. Briefly, 100 µl cleared cell supernatant from each cell culture sample was added to a well of a 
96-well flat-bottom plate (Wallac – for use with 1450 MicroBetaTM) along with 100 µl reconstituted 
MycoAlert Reagent and allowed to incubate for 5 minutes. Using a 1450 MicroBeta Trilux liquid 
scintillation and luminescence counter (Wallac) a 1 second reading was taken for each well before adding 
100 µl MycoAlert substrate to each sample and waiting 10 minutes at RT before taking another reading. 
The ratio of the second reading to the first is used to determine presence of mycoplasma contamination, 
with values over 1.2 considered positive, those under 0.9 considered negative and those in between 
considered borderline and therefore needing to be retested. A positive control (MycoAlert Assay control 
Set, Lonza) and negative control (culture medium alone) was included for each assay.   
Leishmania life cycle maintenance 
Leishmania cell culture 
Leishmania major FV1 (MHOM/IL/80/Friedlin; clone V1), L. major LV39 (MRHO/SU/59/P), L. 
mexicana (MNYC/BZ/62/M379) and the genetically modified L. mexicana lpg1-/- (also M379) were 
provided by Professor Paul Bates and Dr Rod Dillon. Promastigote parasites were cultured in complete 
M199 medium at 26ºC. Axenic amastigotes (of L. mexicana parasites only) were cultured in complete 
Grace’s medium at 32ºC. In the case of both promastigotes and amastigotes, parasites were kept in 
volumes of 5 – 55 ml volumes and were sub-passaged at a ratio of 1:2 – 1:20 in fresh medium every 5 – 
10 days according to growth rate (typically 1:10 every 7 days). Growth was monitored by counting the 
concentration of parasites in culture using a haemocytometer and/or by visual inspection of cultured cells 
using an inverted microscope.  
Passage of parasites through animals 
Infectivity of parasites was maintained by regular passage of parasites through a susceptible animal. For 
this purpose, stationary phase promastigotes (day 6+ of culture) or axenic amastigotes were washed in 
HBSS twice, and resuspended in sterile HBSS. Between 105 and 106 parasites in a 100 µl volume of HBSS 
were injected into the shaven rump of female BALB/c mice and lesions were allowed to develop for 6 
weeks or more. Mice were then sacrificed to obtain parasite infected tissues. Lesion-derived amastigotes 
were obtained by mechanically disrupting cutaneous lesion tissue or infected draining lymph nodes 
(DLNs) using sterile scissors, forceps, a metal gauze (for cutaneous lesion tissue) or a 70 µm cell strainer 
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(for DLN) and cells were collected into either complete M199 or complete Grace’s medium for the 
generation of promatigotes or amastigotes respectively.  
B. malayi life cycle maintenance 
The life cycle of B. malayi was maintained by the Filariasis laboratory staff (Andrew Steven and Dr Darren 
Cook) at LSTM and the BSU staff, University of Liverpool. For B. malayi life cycle maintenance, all 
procedures on live animals were performed in the BSU in the Duncan Building, University of Liverpool.  
Jirds infected in the peritoneum with adult B. malayi parasites were originally purchased from TRS 
laboratories, USA. Microfilariae (Mf) produced by B. malayi adults in these animals were obtained every 2 
weeks (maximum) by a peritoneal tapping method, as described by Griffiths et al, 2010, (222) and 
performed by Dr Darren Cook and/or Mrs Pamela Pask. After counting, 15,000 mf/ml were mixed with 
human blood for feeding to adult female mosquitoes. L3 infective larval stages were collected after 14 
days by crushing the mosquitoes into basic RPMI medium and allowing the L3 larvae to pass through a 
Baermann’s apparatus. L3 were counted and collected by manually picking individual L3 into 50 – 100 µl 
volumes of fresh basic RPMI. 
Infections 
Experimental infection with Leishmania spp 
Age-matched female mice (8-12 weeks at beginning of experiment) from each group of mice (5-8 per 
group) were infected on the same day for each infection experiment. Stationary-phase promastigotes (day 
7-10 of culture) of L. major (FV1 or LV39) or L. mexicana (WT or lpg1-/- M379), or axenic amastigotes of 
L. mexicana (WT) were used for infections. Parasites used for infections were passaged only once or twice 
after recovery from lesion amastigotes to reduce the loss of infectivity in culture. Furthermore, the 
proportion of metacyclics was increased in some promastigote cultures by transferring promastigotes 
grown in complete M199 medium for 7 days to complete Grace’s medium and cultured at 26ºC for a 
further 3 days as described elsewhere (223); these are referred to as metacyclic-enriched promastigotes 
(the use of this method for individual infection experiments is indicated in the methods sections of each 
chapter). For infections of the rump, the area was shaved and wiped with 70% Ethanol prior to injection, 
then 100 µl HBSS containing the parasite inoculum (105 parasites) was injected subcutaneously 
approximately 1 cm above the base of the tail using a 1 ml syringe and a 27 gauge needle. For infections 
of the foot, parasites were resuspended in a volume of 20 µl HBSS per mouse and were injected 
subcutaneously to the central part of the upper hind right foot using an insulin needle and syringe.  
Slides were made of samples used for infections by placing 10 – 20 µl parasites on a poly-lysine slide and 
allowing it to air dry. Parasites were fixed on to the slide by incubation in methanol for 1 minute, before 
staining with 10% Giemsa solution for 10 minutes. After slides had dried, they were preserved by 
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mounting a coverslip using Low Viscosity DPX mounting solution (BIOS Europe). The proportion of 
metacyclic parasites in promastigote samples was determined by inspecting Giemsa stained slides using 
the x100 objective of a light microscope, and recording the number of cells of different forms, as 
described by Rogers et al (110).  
Measurement of cutaneous lesions 
Lesion sizes were monitored by measuring the diameter of lesions in the infected area using a metric dial 
calliper every 7 days. Diameter measurements were recorded for lesions on the rump; multiple 
measurements of diameter were recorded for those lesions with a non-circular circumference to gain and 
average diameter value. Mice often had more than one lesion present, and in this case diameter 
measurements of each lesion were taken. Lesion size was defined as the total area of lesion present (mm3, 
calculated using diameter measurements), in order to account for variation in lesion shape and numbers 
(see Figure 8). Lesion area was found to correlate more closely with parasite burdens than the diameter 
measurement (data not shown), which is more frequently used in other published studies.  
 
 Examples of the appearance of lesions on mice infected with L. major or L. mexicana. Figure 8.
Diameter measurements of lesion were taken using a dial calliper (A), and where the lesion was non-
circular, several diameter measurments were taken. Some lesions were a regular, circular shape (B), whilst 
other were irregular (A), or there were multiple lesions (C). These mice were infected with L. mexicana 
promastigotes for 14 weeks.  
For lesions of the foot, the thickness of the infected foot (from central part of footpad to central part of 
upper foot) was recorded as well as the thickness of the contralateral uninfected foot. The difference 
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between these two measurements was taken as the lesion size. The presence of ulcerated lesions was also 
recorded each week.  
Removal of cutaneous lesions and limiting dilution 
The Leishmania-infected lesion tissue was removed from the mouse immediately after schedule 1 killing.  
For lesions of the rump, the area was wiped with 70% ethanol solution before incisions were made to the 
cutaneous tissue surrounding the lesion with sterile stainless steel dissection scissors. The area of skin 
(including the lesion) was then removed from the subcutaneous layer using sterile forceps and scissors. 
For foot lesions, the foot was removed by excision at the ankle to ensure collection of all lesion tissue. 
Lesion tissues were then processed in one of three ways according to their intended use. The lesion tissue 
was then used either for establishment of parasite culture and/or limiting dilution analysis by mechanical 
homogenisation, or was placed in RNA later solution for subsequent DNA extraction and parasite 
burden estimation by qPCR, as detailed later.  
Parasite burden of infected tissues was measured in some instances by limiting dilution analysis as 
described elsewhere (224). Briefly, the infected tissue was cut into small sections into complete M199 
medium using sterile scissors and forceps, a sterile syringe plunger and placed over a sterile metal gauze. 
The cell suspension was collected, whilst removing large sections of remaining tissue or debris by 
allowing these to settle, and serial 1 in 2 dilutions were made of each cell suspension across a 96 well flat-
bottom plate in complete M199 medium, in duplicate. After 7 days the wells of the plates were checked 
for the presence of motile parasites. The highest dilution showing the presence of parasites for each series 
was used to calculate the original parasite concentration and tissue parasite load.   
Experimental vaccine model for B. malayi  
The vaccination model of B. malayi in BALB/c mice was developed with Dr Joseph Turner and Miss Ana 
Guimaraes in LSTM and in based on modifications to previously described models (225). Fifty infective 
B. malayi L3 were collected into 50 – 100 µl warm basic RPMI and were injected into the peritoneal cavity 
of male BALB/c mice using a sterile 1 ml syringe and a 25 gauge needle.  
Measurement of B. malayi parasite burden and collection of PECs 
The collection of parasite and PECs was carried out with assistance from Dr Joseph Turner and Miss Ana 
Guimaraes. Infected BALB/c mice were killed 6 days after infection with B. malayi L3 parasites and the 
peritoneal cavity was washed thoroughly 3 times with 5 ml sterile basic RPMI medium and collected into 
a 15 ml centrifuge tube. Parasites were allowed to settle at the bottom of the tube and were then 
transferred to a 48-well culture plate for counting using a dissection microscope. Motile parasites were 
counted whilst immotile worms and those encased in granulomas were not included for parasite burden 
data. The remaining media sample contained PECs, which were washed in basic RPMI, enumerated using 
the automated cell counter, and kept on ice for further use as described later.  
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Parasite antigens and vaccine components 
Leishmanial antigens 
Leishmania freeze-thaw antigen  
Freeze-thaw antigen (FTAg) was made from cultured promastigotes as described and developed 
elsewhere (51, 71). Stationary-phase promastigotes were washed three times in DPBS and resuspended at 
a concentration of 109/ml, and were then subjected to 5 rapid freezing and thawing cycles at -80°C and 
37°C respectively. Protein concentration was measured using the BCA assay (described later) and aliquots 
of FTAg were kept at -80°C until use.  
Amastigote washed membranes 
For L. mexicana parasites only, washed membrane antigen (WMAg) was generated from cultured axenic 
amastigotes using hypotonic lysis as described by Thomas et al, 2008 (71). Axenic amastigotes were 
washed three times in PBS and counted using a haemocytometer before lysing in nuclease-free water 
containing 0.1 mM TLCK and 1 µg/ml leupeptin at 109 parasites/ ml for 5 minutes on ice. The lysed 
parasites were then frozen at -80°C after addition of an equal volume of 0.1 mM TLCK, 1 µg/ml 
leupeptin, 20 % glycerol. After freezing, the lysed parasites were thawed and centrifuged at 6,100 g for 10 
minutes (4°C) to remove PBS containing soluble protein and protease inhibitors before resuspending 
membranes at 109/ml in PBS. The WMAg solution was assayed for protein concentration using the BCA 
assay and aliquots were kept at -80°C until use.  
Autoclaved Leishmania major 
Autoclaved L. major (ALM) antigen was made using a method described first by Bahar et al (226). Briefly, 
L. major promastigote cultures were grown to log-phase (day 5) in complete M199 and a 50 ml volume 
was transferred into larger cultures by addition of 200 ml complete Grace’s medium and allowed to grow 
for a further 4 days. The promastigote parasites (approximately 109) were then washed three times in 
sterile DPBS and resuspended in 2ml DPBS. This highly concentrated volume of parasites was placed in a 
glass container and autoclaved at 151°C for 15 minutes. Protein concentration was measured using the 
BCA assay and aliquots were stored at -80°C until further use.  
B. malayi antigens 
The methodology for preparation of B. malayi parasite extracts was based on that used for obtaining B. 
malayi adult female extract (BmFE) as described in Turner et al, 2006 (227) with some adjustments. Mf 
obtained from infected Jirds (described above) were separated from cells and other debris using a PD-10 
desalting column (GE Life Sciences). Briefly, a peritoneal exudate sample in a volume of 2.5 ml basic 
RPMI medium, containing 0.5 – 5 x 106 Mf, was loaded on to a prepared column and allowed to pass 
through the column by gravity. Fractions were collected by gradual addition of warm basic RPMI to the 
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column, and were regularly checked for presence of Mf and cells by examination of drops using a glass 
slide and an inverted microscope. Those fractions containing only Mf were pooled and washed twice in 
sterile DPBS by centrifugation at 300 – 400 g for 5 minutes. Mf were enumerated and resuspended in 
sterile DPBS at a concentration of approximately 2 x 106 /ml prior to protein extraction. B. malayi L3 
parasites were collected from an infected mosquito crush, as described above, and were washed by 
centrifugation at 300 – 400 g (5 minutes) and transfer into fresh microcentrifuge tubes, washed 4 times in, 
and resuspended in, sterile DPBS a concentration of 2000 Mf /ml.  
For generation of soluble protein extracts of B. malayi Mf (BmMfE) and L3 (BmL3E), parasites collected 
as indicated in DPBS were sonicated five times for periods of 15 seconds on ice, interrupted by periods 
of resting on ice for 20 seconds, using a Vibracell sonicator and a sterile endotoxin-free sonicator probe. 
The soluble proteins were then extracted from the sonicated parasites into the DPBS by incubating at 4ºC 
overnight with gentle agitation using a rotary shaker. Insoluble material was removed by centrifugation at 
13,000 rpm (microcentrifuge) for 30 minutes at 4ºC. Dead L3 were obtained by heat-killing the L3 larvae 
(in aliquots of 50 L3 in 100 µl basic RPMI) at 65°C for 10 minutes as used in vaccine studies as previously 
reported (228). 
Vaccine formulations 
All individual doses of vaccines were made to a volume of 100 µl or 20 µl in DPBS, with the exception of 
the Live and Dead L3 vaccines where parasites were kept in basic RPMI (also 100 µl). The antigen and 
adjuvant components present in each vaccine are given below (Table 6). Sham inoculated or challenge 
control mice were given 100 µl DPBS. The schedules for inoculations used in the vaccine experiments are 
detailed in the methods section for the corresponding results chapters. The unmethylated CpG 
Oligodeoxynucleotide (ODN) 1826 adjuvant of the sequence 5’- TCCATGACGTTCCTGACGTT -3’ 
(referred to as CpG from hereon) was a kind gift from Lyn Jones and Matthew Selby at Coley (Pfizer). 
Lipopeptide adjuvants S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine (Pam2CSK4, or Pam2 from 
hereon) and N-Palmitoyl-S-[2,3-bis(palmitoyloxy)-(2RS)-propyl]-(R)-cysteine (Pam3CSK4 or Pam3) were 
purchased from EMC Microcollections. CpG, Pam2 and Pam3 were dissolved in nuclease-free water and 
kept in 1-10 mg/ml stocks at -80°C before use. Imject® Alum Adjuvant (Alum) was purchased from 
Thermo Scientific and was mixed with antigen according to manufacturer’s instructions. Briefly, Alum 
was added dropwise to protein antigen mixtures until a 1:1 ratio was reached and was continually mixed 
for a further 30 minutes at 4°C, using a rotary shaker. 
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Vaccine name Volume /dose Antigen Quantity /dose Adjuvant  Quantity / dose 
Adjuvants only 20 µl - - CpG 
Pam2 
Pam3 
50 µg 
10 µg 
10 µg 
CpG 100 µl - - CpG 50 µg 
rKMP-11 + CpG 100 µl rKMP-11 10 µg CpG 50 µg 
ALM 20 µl ALM 50 µg - - 
ALM + CpG 20 µl ALM 50 µg CpG  50 µg 
ALM + Pam2 20 µl ALM 50 µg Pam2 10 µg 
ALM + Pam3 20 µl ALM 50 µg Pam3 10 µg 
ALM + 
Adjuvants 
20 µl ALM 50 µg CpG 
Pam2 
Pam3 
50 µg 
10 µg 
10 µg 
Dead L3 100 µl Heat killed L3 50  - - 
BmMfE 100 µl BmMfE 50 µg - - 
BmMfE + Alum 100 µl BmMfE 50 µg Alum 50 µl 
BmMfE + Pam2 100 µl BmMfE 50 µg Pam2 10 µg 
Tissue/cell collection and immunological techniques 
Collection of blood plasma from mice 
For the collection of blood plasma, mice were killed by a schedule 1 method which was confirmed by 
performing a cardiac puncture and blood was collected into a 1.5 ml microcentrifuge containing 10 µl 
heparin sulphate in PBS (10,000 U/ml, sterile filtered). Samples were kept on ice and then spun down at 
13,000 rpm for 30 minutes at 4°C. Plasma was removed from the blood cell pellet into aliquots and at -
20°C until further use.   
Obtaining splenocytes and draining lymph node cells from mice 
The spleen and/or DLNs were removed from mice after collection of blood and parasite tissues, using 
sterile scissors and forceps, and were placed in complete medium (either DMEM or RPMI depending on 
the experiment). The tissue was then disrupted using a sterile syringe plunger and a cell strainer (70 µM) 
and a single cell suspension was collected into a petri dish before transferring to a centrifuge tube and 
placing on ice. Cells were then washed in cold medium twice before being counted.  
Culture and stimulation of immune cells 
The splenocytes and DLN cells were resuspended into either complete RPMI extra or complete DMEM 
extra at a concentration of 4 or 8 x 106 cells/ml and were plated in duplicate or triplicate on 96 well plates 
in 100 µl volumes (i.e. 4 or 8 x 105 cells/well). Antigens and control stimulations were diluted in the same 
medium to double the final concentration in 100 µl and added to the cells. The controls, antigens and the 
final concentrations used were as follows: negative control (media alone); 10 µg/ml Leishmania FTAg; 10 
µg/ml Leishmania WMAg; 20 µg/ml BmL3E, 20 µg/ml BmMfE,  2.5 µg/ml Con A; 10 µg/ml anti-mouse 
Table 6. Vaccine formulations used in vaccination experiments. The volume and the quantities of antigen 
and adjuvant/s for each dose are given.  
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CD3 antibody (eBioscience). For the anti-CD3 stimulations, wells were first coated with the antibody, by 
diluting in DPBS and incubating on the plates for 30 minutes at 37°C to allow for coating of the wells, 
before removal and gentle washing with DPBS, and addition of cells and media. After addition of all 
antigens, plate containing cells were incubated at 37°C and 5 % CO2 for 72 hours before removal of the 
supernatants for storage at -20°C.  
Cytokine Enzyme-Linked Immune-sorbent Assay (ELISA) 
Cytokine levels in supernatants from cell cultures were measured for the following cytokines by ELISA 
DuoSet kits (all R&D) according to manufacturer’s instructions: mouse IFNγ, IL-10, IL-13, IL-4 and IL-
5. Briefly, wells of 96-well 2HB high binding plates were coated with 50 µl/well capture antibody diluted 
in PBS overnight at room temperature (RT). Plates were washed three times in ELISA wash buffer. Plates 
were blocked for 1 hour at RT with 300 µl reagent diluent then washed three times before addition of 
samples and standards, diluted in medium (complete RPMI or DMEM depending on which was used in 
the original cell culture) and plated in duplicate, and incubated for 2 hours at RT. Plates were washed 
three times before addition of 50 µl/well detection antibody and incubated at RT for 2 hours before 
washing a further three times and incubating with the working concentration of streptavidin-HRP in 
reagent diluent and incubation at RT for 20 minutes. Plates were washed thoroughly a further 3 times 
before addition of 50 µl/well TMB substrate and incubation in the dark for up to 20 minutes. The 
reaction was stopped by addition of 25 µl/well stop solution to the wells.  
Antibody isotype ELISA 
Mouse plasma samples were tested for levels of antigen specific antibody isotypes IgG1, IgG2a (for 
BALB/c mice) and IgG2c (for C57BL/6 mice) using Immunoglobulin Quantitation kits from Bethyl 
Labs according to manufacturer’s instructions with minor modifications. Wells of 96-well 2HB high 
binding ELISA plates were coated with 100 µl/well of either coating antibody in the appropriate 
concentration (for the standard wells only) or parasite antigens FTAg, WMAg or BmMfE at a 
concentration of 10µg /ml (for the sample wells), all diluted in ELISA coating buffer, and incubated 
overnight at 4°C. Plates were washed 3 times in ELISA wash buffer between each step as described 
above. Wells were blocked with 200 µl ELISA blocking buffer for 1 hour at RT, then washed before 
addition of plasma samples or standards diluted in Ab ELISA reagent buffer. For some experiments, 
plasma samples were initially pooled for each experimental group and a dilution series of between 1/10 
and 1/1280 (8 x 2-fold serial dilutions) of sample were used, to identify the concentration of plasma 
sample appropriate for use in an ELISA including all individual samples. All samples were plated in 
duplicate, as well as standard plasma samples if concentrations of antibody were being measured. Plates 
were then washed before addition of detection antibody linked to HRP, diluted in Ab ELISA reagent 
buffer and incubated for 2 hours at RT. Plates were washed for the final time before addition of TMB 
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substrate solution, and the reaction was allowed to develop for approximately 15-20 minutes before 
addition of stop solution.  
ELISA measurements and working 
After addition of stop solution to plates, the absorbance of light at 570 and 450 nm was measured in each 
well by reading the plate in a Varioskan plate reader (Thermo Electron Corporation). The absorbance 
values of the 570 reading were subtracted from the 450 reading to give an overall absorbance value. For 
determination of the absorbance values and concentration of cytokine/antibody in each sample, the 
average absorbance values of the wells which had only diluent in for the sample step (blanks) were first 
subtracted from all other wells. The average values for each sample were then calculated, before the 
standard curve (absorbance vs. concentration) was generated. A line of best fit (2 parameter curve in most 
cases) was fitted on a plot of absorbance against concentration to generate an equation for calculating 
concentration in the sample-containing wells for that plate. Concentrations recorded for each samples 
then multiplied by the dilution factor to give the final concentration of cytokine/antibody per sample.  
Tissue fixation and staining 
Tissues from adjuvant swelling reactions were removed using sterile dissection scissors and embedded in 
4% formalin.  Sections of 4 μm fixed tissue were cut by microtome and mounted by electrothermal bath 
at 45°C on Poly-L-lysine slides by the Department of Veterinary Pathology, Animal and Population 
Health, University of Liverpool. Haematoxylin-Eosin (H&E) staining was performed by serial passages in 
Harris Haematoxylin (2 minutes), 1% Acid Alcohol (5 seconds), Scott’s Tap Water (30 seconds) and 
Eosin (2 minutes). Each step was followed by a rapid wash in running tap water. Slides were then 
dehydrated by rapid passages in 70%, 90%, 100% ethanol and xylene (all by staff at the Department of 
Veterinary Pathology, Animal and Population Health, University of Liverpool.  
Flow cytometry 
Mouse PECs were characterised using flow cytometry. After washing and counting of cells using the 
automated cell counter, PECs were washed three times in, and resuspended into, FACS buffer, and kept 
on ice for the rest of the staining process. Fc receptors were blocked on cells by incubating cells in FACS 
buffer containing 1% v/v normal rat serum (Invitrogen) and 0.5% v/v anti-CD16/CD32 (eBioscience) 
for 30 minutes (at a concentration of 1 x 106 cells/ 100 µl). Cells were then stained with conjugated 
antibodies specific for surface markers of interest, or isotype controls, in FACS buffer at a concentration 
of 1 x 106 cells/ 100 µl, for 30 minutes in the dark. The antibodies used were the following (company, 
clone, final concentration used): Rat anti-mouse F4/80 Antigen eFluor® 450 (eBioscience, BM8, 1 
µg/ml); Rat IgG2a K Isotype Control eFluor® 450 (eBioscience, eBR2a, 1 µg/ml); Rat anti-mouse Siglec-
F PE (BD Pharmingen, E50-2440, 1 µg/ml); Rat IgG2a K Isotype Control PE (BD Pharmingen, R35-95, 
1 µg/ml); Rat anti-mouse CD206 (MΦ Mannose Receptor) Alexa Fluor® 647 (AbD Serotec, MR5D3, 2.5 
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µg/ml); Rat IgG2a Isotype Control Alexa Fluor® 647 (AbD Serotec, IgG2a, 2.5 µg/ml). Each sample 
was stained with marker-specific antibodies, or isotype controls, or a combination of the two, to assess 
for non-specific staining. Samples were either analysed straight away or fixed in FACS buffer containing 
2% formaldehyde and kept at 4°C before analysis within 3 days. Stained samples of cells were run 
through a BDTM LSRII (BD Biosciences) flow cytometer using FACSDivaTM (BD Biosciences) software. 
At least 10,000 cells were collected for each sample. Unstained and single stained cell samples were used 
for compensation for each experiment, and isotype control stained cells were used to determine levels 
non-specific staining. FCS data files were analysed using FlowJo (Tree Star) software.  
Wound healing 
To assess wound healing in mice, a sterile 4 mm punch biopsy tool was used to make a clean circular 
wound to the shaven rump (sterilised with 70 % ethanol). Healing was then measured by taking regular 
measurements of the diameter of the lesion using a dial caliper. 
Molecular techniques 
DNA Extraction 
DNA was extracted from mouse tissue (including leishmanial lesions) and cell pellets using the DNA 
Blood and Tissue Kit (Qiagen) according to manufacturer’s instructions, with some modifications. Mouse 
tissue was weighed and 25 mg of tissue per MiniSpin column was used as instructed. The tissue lysis step 
was performed for tissue samples only, with incubation of tissue in ATL buffer and proteinase K at 56ºC 
overnight for mouse tissues. After addition of AL buffer a 10 minute incubation was performed at 72ºC 
for 10 minutes for tissue samples, and at 56°C for cell pellet samples. In an attempt to increase 
throughput, the use of 96 well DNA column plates was compared to that of the Qiagen MiniSpin 
columns in terms of quality and quantity of DNA extracted. It was found that the MiniSpin columns gave 
higher yields and greater purity of DNA, thus this method was used for the extraction of DNA from all 
tissue and cell preparations.  
Checking DNA concentration 
The concentration of DNA in samples was determined using a NanoDrop machine (ThermoScientific) 
and supporting ND-1000 v.7 software.  
Primers, PCR equipment and general PCR procedure 
A list of the primers used and their sequences is given in Table 7 below. All primers were produced by 
Integrated DNA Technologies (IDT) using desalting conditions. Upon receipt, primers were resuspended 
in TE Buffer at a stock concentration of 100 µM, before further dilution in nuclease-free water and 
storage in aliquots at -20ºC.  
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Primer name Sequence Origin 
TLR1 a 5'-GAT GGT GAC AGT CAG CAG AAC AGT ATC-3'  
 
 
 
 
(229) 
TLR1 b 5'-AAG GTG ATC TTG TGC CAC CCA ACA GTC-3' 
TLR1 c 5'-ATC GCC TTC TAT CGC CTT CTT GAC GAG-3' 
TLR2 a 5'-GTT TAG TGC CTG TAT CCA GTC AGT GCG-3' 
TLR2 b 5'-TTG GAT AAG TCT GAT AGC CTT GCC TCC-3' 
TLR2 c 5'-ATC GCC TTC TAT CGC CTT CTT GAC GAG-3' 
TLR4 a  5'-CGT GTA AAC CAG CCA GGT TTT GAA GGC-3’ 
TLR4 b 5'-TGT TGC CCT TCA GTC ACA GAG ACT CTG-3’ 
TLR4 c 5'-TGT TGG GTC GTT TGT TCG GAT CCG TCG-3’ 
TLR6 a 5'-GAA ATG TAA ATG AGC TTG GGG ATG GCG-3' 
TLR6 b 5'-TTA TCA GAA CTC ACC AGA GGT CCA ACC-3' 
TLR6 c 5'-ATC GCC TTC TAT CGC CTT CTT GAC GAG-3' 
JW11 5’-CCT ATT TTA CAC CAA CCC CCA GT-3’ (230) 
JW12 5’-GGG TAG GGG CGT TCT GCG AAA-3’ 
KMP-11 FWD 5’-CGG GAT TCA TGG CCA CCA CGT ACG-3’ Designed in-house 
KMP-11 REV 5’-CGC AAC CTT TTA CTT GGA CGG GTA C-3’ 
AM1 5’CGC GTG TCG TTC GGC TTT ATG TG 3’ Sequences provided by 
Paul Bates (unpublished) AM2 5’CTT ACG GAG CTT GCT GAG GTG AGG 3’ 
PCR procedures were optimised by varying the following (in this order): primer concentration, amount of 
DNA template per reaction, the annealing temperature, followed by MgCl2 concentration (only if deemed 
necessary) to find the best conditions for optimal product amplification and reduced primer-dimer 
formation. PCR reactions contained the following components: target DNA (usually 5-10% final 
volume), forward and reverse primers (0.05 -1 µM), DNA polymerase (Taq, Phusion (both NEB) or 
SybrGreen (Qiagen)), dNTPs (if no pre-made master mix is used), MgCl2 (NEB, if needed in addition to 
any contained within mastermix), and nuclease-free water. The components for each PCR reaction are 
detailed in later methods sections. In all cases, the master mix for each PCR was made in a designated 
DNA-free room, by combining all of the products needed in each reaction, but without the template 
DNA, before aliquoting the desired quantity into wells/tubes. DNA was then added to appropriate wells 
in a separate room, within a safety cabinet, before the plates/wells were sealed. For normal PCR 
reactions, a BioRad iCycler machine was used whilst for quantitative PCR (qPCR), a Chromo 4TM System 
for real-time PCR detection (BioRad) was used and data was collected using MJ Opticon Monitor 
Analysis Software Version 3.1 (BioRad).  
Table 7. List of primers. The names and sequences of primers are given, along with a reference from the 
publication they were taken from, if applicable.  
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Gel electrophoresis for DNA 
Agarose gels were prepared with  100 – 150 ml of 0.5 – 1 % TBE Buffer from the 5 x TBE buffer stock 
in a glass container of at least 2 x the volume of liquid. Between 1-2 % w/v agarose powder was added 
before the solution was heated by microwaving on full power for 2 minutes using a 800 W (E) Proline 
Powerwave machine, until the solution was clear. After the solution had cooled sufficiently, 4 µl/ 100 ml 
ethidium bromide was added and the solution was mixed before pouring into the gel mould. PCR/DNA 
samples and 100bp and/or 1kb ladder markers were mixed with loading dye (both NEB) before 
dispensing into wells of the gel, which was submerged in 0.5 – 1 % TBE buffer within a gel tank. DNA 
fragments within each sample were then separated (100 V, 150 mA) for approximately 40 minutes. DNA 
fragments were then visualised under UV light and image capture using an Ingenius UV Illuminator and 
Genesnap software (both Syngene).  
Genotyping of TLR-/- mice 
To routinely check the genotype of TLR-/- mice kept in out colonies, and to confirm that the mice used in  
experiments were of the expected genotype, mouse lesion or tail snip DNA was checked for presence of 
either the WT gene or the KO construct, using primer pairs that were designed by the Akira lab where 
the TLR KO mice were originally generated (229), see Table 7. Primers a and b were used to amplify the 
WT TLR gene, whilst primers b and c were used to amplify the construct used to generate the knock-out. 
Reactions were carried out in a total volume of 25 µl containing 1 x Taq Mastermix (NEB) 200 µM each 
primer, 1 µl DNA and nuclease-free water. The reaction conditions for all reactions were as follows: 4 
minutes at 95ºC followed by 35 cycles of 94ºC for 30 seconds, 55ºC for 1 minute and 74ºC for 1 minute. 
A final incubation at 74ºC for 10 minutes was included to ensure full extension of the PCR products. The 
presence or absence of each product was determined by visualising on agarose gels under UV light. 
Genotyping of parasite DNA 
To confirm that parasites used in experiments were of the correct species, DNA preparations were used 
to amplify an intergenic region between the RPS7 genes on chromosome 1 of the Leishmania parasite 
genome. Sequences for the AM1 (forward) and AM2 (reverse) primers were provided by Professor Paul 
Bates, and are given in Table 7. Reactions were carried out in a total volume of 25 µl containing 1 x Taq 
Mastermix (NEB) 0.5 µM each primer, 2 µl DNA and nuclease-free water. The reaction conditions for all 
reactions were as follows: 30 seconds at 95ºC followed by 30 cycles of 95ºC for 30 seconds, 57ºC for 30 
seconds and 68ºC for 1 minute. A final incubation at 68ºC for 5 minutes was included to ensure full 
extension of the PCR products. The 1100- 1400 bp product was then digested with MspI enzyme (in the 
presence of Buffer 4, both NEB) at 37°C for 2 hours. The presence or absence of each product was 
determined by visualising the products on agarose gels under UV light. The pattern of bands formed 
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differs between species: 2 bands of different sizes between the range of 300-350 bp indicates L. mexicana, 
whilst 1 band of approximately 500bp and another of approximately 300bp indicates L. major.  
Cloning and Expression 
PCR for cloning 
For cloning purposes PCR products were amplified from target DNA using a high fidelity DNA 
polymerase (Phusion, NEB) to ensure errors in amplification were kept to a minimum. Primers for 
amplifying the L. mexicana KMP-11 gene were designed to incorporate restriction digest sites (BamHI for 
the forward primer; HindIII for reverse), a clamp region (C or Gs) at the 5’ end, and correspond to the 
opposing ends of the KMP-11 gene. Thus the primers KMP-11 forward (5’-CGG GAT TCA TGG CCA 
CCA CGT ACG-3’), and KMP-11 reverse (5’-CGC AAC CTT TTA CTT GGA CGG GTA C-3’) (Table 
7) were designed, and were purchased from Integrated DNA Technologies. The PCR reaction 
components in either a 20 or 50 µl volume were as follows: 0.02 U/ml Phusion DNA Polymerase (NEB), 
1 x Phusion HF Buffer (NEB), 200 µM dNTPs, 500nM forward and reverse KMP-11 primer, 1-2.5 µl L. 
mexicana DNA, and nuclease-free water.  The PCR conditions were as follows: denaturation for 30 
seconds at 98˚C, followed by 35 cycles of denaturation for 10 seconds, annealing for 20 seconds and 
extension for 30 seconds at 98˚C, 67˚C and 72˚C respectively. An additional extension step at 72˚C for 10 
minutes was included to ensure proper elongation of the amplicon.To allow for incorporation into the 
TOPO cloning vector, A-overhangs were added by incubating the PCR product with 0.05 U/ml Taq 
DNA polymerase (Qiagen) for 9 minutes at 72˚C. The amplified PCR product with A overhangs was 
purified using a QIAquick column (Qiagen) according to manufacturer’s instructions.  
Cloning into TOPO2.1 
For the first cloning attempt, amplicons were incorporated into the TOPO2.1 vector (Invitrogen) by 
mixing DNA product (4 µl) with 1 µl TOPO2.1 and 1 µl salt solution gently at room temperature for 5 
minutes, before transformation into 10-beta E. coli chemically competent cells (NEB) according to 
manufacturer’s protocol. Briefly, 4 µl of the TOPO reaction was added to E. coli 10-beta cells (NEB) that 
had been defrosted on ice, the tube was flicked 4-5 times then incubated on ice for 30 minutes prior to 
heat-shock at 42ºC for 30 seconds and a further 5 minute incubation on ice. SOC medium (950 µl) was 
added to cells and incubated at 37ºC for 1 hour with continual shaking. Before use, 40 µl of 40 mg/ml X-
gal in DMF was prepared and added to LB Agar plates, which were pre-warmed to 37°C. Cells were 
diluted into SOC medium at different concentrations and were incubated overnight on LB Agar plates. 
Positive clones were selected first by blue-white screening and were then selected for further tests after 
subsequent growth of individual colonies in 5-10 ml LB medium supplemented with 100 µg/ml 
ampicillin. Pelleted cells from E. coli [TOPO] colonies grown overnight could then be used for extraction 
of plasmid and further analysis. For this, TOPO2.1+construct vectors were eluted from pellet cultured 
cells into EB Buffer using a QIAprep mini prep kit (Qiagen) according to manufacturer’s instructions.  
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Sub cloning, and expression of KMP-11 in pQE-30 plasmid 
To prepare competent cells, E. coli M15 [pREP4] cells (supplied in QIAexpress Type IV kit) were 
streaked onto LB agar plates containing 25 µg/ml and cultured overnight at 37°C.  One colony was 
selected for growing in liquid LB broth containing 25 µg/ml kanamycin up to a total volume of 100 ml at 
37°C with continual agitation, until an OD600 of 0.5 was reached. The OD600 of the bacterial culture was 
determined by placing 1 ml of culture in a cuvette and measuring using a UV Visible Spectrophotometer 
(CARY /Varian) The culture was then cooled on ice and centrifuged at 400 g, at 4°C for 5 minutes 
before resuspending cells in 30 ml ice-cold TFB1 Buffer (see Table 3) and kept on ice for 90 minutes. 
Cells were then centrifuged as before and resuspended in 4 ml ice-cold TFB2 buffer and aliquotted into 
100 -200 µl volumes in 1.5 ml tubes and frozen on dry ice before storing at -80°C. 
Stock samples of pQE-30 were linearised by digesting with BamHI and HindIII enzymes at 37°C for 2 
hours, ran on an agarose gel before being removed and cleaned using the QIAquick gel extraction kit. 
The target gene KMP-11 for subcloning was removed from selected TOPO vector by digesting 
TOPO.KMP-11 constructs with BamHI and HindIII enzymes for 2 hours at 37°C. The digested DNA 
was ran on an agarose gel to visualise the separated BamHI-KMP-11-HindIII construct, which was 
excised from the gel and purified using a QIAquick column (Qiagen) according to manufacturer’s 
instructions. The construct could then be incorporated into the expression vector pQE-30 by mixing 
insert and vector DNA at 1 7:1 molar ratio, in the presence of 1.5 U T4 DNA ligase (NEB) and DNA 
Ligase Buffer at 16°C overnight. Competent E. coli M15 [pREP4] cells were transformed to harbour 
either the expression vector pQE-30, the ligated pQE-30.KMP-11 reaction, or the control pQE-40 
plasmid,  by mixing 100 µl cells with the approximately 1 µl vector DNA and leaving on ice for 20 
minutes before incubating at 42°C for 90 seconds. Psi broth (500 µl) was then adding to transformed cells 
and they were grown at 37°C for 60-90 minutes with continual shaking, before being spread on LB agar 
plates containing 25 µg/ml kanamycin and 100 µg/ml ampicillin. Selected colonies were grown up in 10 
ml LB medium with 25 µg/ml kanamycin and 100 µg/ml ampicillin and checked for presence of the 
KMP-11 gene as above.   
Selected positive E. coli [pQE-30-KMP-11] colonies were grown in the presence of IPTG to induce 
expression of rKMP-11 and 2 ml of each culture was taken for screening for rKMP-11 expression. Cells 
were pelleted and resuspended in Native Lysis Buffer at 2ml /g wet weight and left on ice for 30 minutes 
before sonicating on ice for 6 x 10 seconds at 200-300 W with a 10 second rest between each burst. 
Lysates were centrifuged at 10,000 g for 25 minutes at 4°C to remove insoluble material. For a positive 
control E. coli [pQE40] cells were grown and collected as above, but were lysed using Denaturing Lysis 
Buffer at 5 ml/g wet weight with gentle vortexing at RT; lysates were collected by centrifugation as above. 
All lysates were ran on SDS PAGE gels and stained with GelCode blue for visualisation of proteins. 
Uninduced cultures (i.e where no IPTG was added) were prepared as above as controls. Colonies were 
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screened for production of recombinant proteins (rKMP-11 at 11 kDa and rDHFR at 26 kDa). Once a 
positive colony was selected, a 100 ml culture of E. coli [pQE-30-KMP-11, pREP4] (or control E. coli 
[pQE40, pREP4]) was grown in LB medium containing 25 µg/ml kanamycin and 100 µg/ml ampicillin 
was prepared at 37°C, before IPTG was added at a final concentration of 1M and cultures were grown at 
30°C overnight with continual shaking throughout. These cultured cells were centrifuged at 4,000 g at 
4°C for 20 minutes. Pellets were lysed in the appropriate Lysis Buffer as described previously. 
Checking for transformation by PCR and restriction enzyme analysis 
In some cases, small samples of individual E. coli colonies were added directly to PCR tubes containing 
the PCR mastermix using a 10 µl pipette tip, prior to the PCR cycles being performed in the PCR 
machine (i.e. without extraction of DNA from bacterial cells). Alternatively, plasmid DNA extracted from 
selected colonies was used in PCR reactions and resulting products were checked for product 
amplification by running on an agarose gel.  
For restriction digest analysis, plasmid DNA samples to be tested were incubated with one of the 
following restriction enzymes along with the appropriate buffer according to manufacturer’s instructions: 
EcoRI, HindIII, SalI and BamHI (all NEB). Typically, samples were incubated at 37°C for at least 40 
minutes. The DNA products from the digest were visualised on an agarose gel under UV light.  
Sequencing 
For sequencing analysis, plasmids containing inserts were eluted using a mini prep kit as described above, 
but into nuclease-free water and according to the guidelines of the DNA Sequencing Core, Cardiff 
University, along with appropriate primer preparations. Results were returned in the form of ab1 files, 
which could then be assessed for sequence and quality using ChromoLite software. Satisfactory sequences 
could be checked for alignment against a target sequence using ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/).  
qPCR for preparations containing Leishmania DNA 
For quantification of parasites in lesion tissue, a qPCR method was developed based on that described by 
Nicolas et al (230) with modifications. The protocol was adapted by optimising of the following: primer 
concentration, reaction volume, annealing temperature, MgCl2 concentration, DMSO concentration. The 
following components were used in each 20 µl reaction: 1 x SybrGreen Mastermix (Qiagen), 500 nM 
JW11 and JW12 primers, nuclease-free water and 2 µl DNA (samples had concentration between 35 and 
150 ng/µl), to amplify a 120 bp region of kinetoplastid DNA. Reactions were performed in duplicate for 
each sample, in wells of a 96-well high profile white PCR plate (Starlab). The reaction conditions were as 
follows: 95ºC for 15 minutes, followed by 40 amplification cycles of 95ºC for 15 seconds, 60ºC for 15 
seconds and 72ºC for 15 seconds. A melting curve was then generated by increasing the temperature 
from 50 – 95 °C and reading the plate at each 1 degree increment. A standard curve was included on each 
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plate, where 8 x 10-fold serial dilutions of DNA from cultured L. major or L. mexicana parasites were 
diluted in nuclease-free water and spiked with DNA from naive mouse tissue. The number of parasites 
per 2 µl sample of standard parasite DNA was plotted against CT value and a standard curve was 
generated which represented 0.01 – 1 x 105 parasites, with a typical CT range of 16 – 36 and a cut off Ct 
of 35 (< 0.1 parasites). The following controls were included on each plate in duplicate: no template 
control (NTC), nuclease-free water, DNA from Leishmania-positive lesion, and DNA from naive mouse 
tissue. Average parasite numbers for reactions were used to estimate total parasite burdens per lesion, by 
adjusting for total DNA volume from the initial DNA extraction. The results of the melting curve were 
used to determine the presence of product and/or any primer dimer formation. 
Protein purification and analysis 
Purification of His-tagged recombinant proteins rKMP-11 and rDHFR 
Recombinant proteins were generated using the QIAexpressionist system (Qiagen), using the expression 
vector pQE-30 and E. coli M15 cells, producing His-tagged recombinant proteins which were purified 
from lysates using Nickel column chromatography, according to manufacturer’s instructions, with minor 
modifications. To purify rKMP-11 a 50% Ni-NTA slurry was added to lysate at a ratio of 1:4 and mixed 
gently at 4°C for 1 hour. The mixture was first purified by loading onto a polypropylene column and 
allowed to flow through. The column was washed twice in Native Protein Wash Buffer, before eluting in 
Native Protein Elution Buffer containing increasing concentrations of imidazole. The control protein 
rDHFR was purified as above but under denaturing conditions by washing with Denaturing Purification 
Buffer, then Eluting first in Protein Buffer D and then Protein Buffer E. To increase the purity of the 
rKMP-11, a large batch of rKMP-11 purified using the column method was further purified using the 
ÄKTA prime plus system (GE Healthcare), according to manufacturer’s instructions, to allow for gradual 
increase in imidazole concentration. The eluents were collected and stored after each step (or every 0.5 ml 
for AktaPrime) and checked for protein content and purity by SDS PAGE. Eluted fragments containing 
sufficient purified protein were collected and dialysed to remove imidazole or urea using a Slyde-A-Lyzer 
Casette (ThermoScientific) by first washing in the corresponding Lysis Buffer without imidazole or urea 
for 2 hours at 4°C with continual stirring, and then placing in DPBS overnight at 4°C with continual 
stirring. Endotoxin was removed and samples were checked for endotoxin levels, and yield was 
determined using the BCA Assay, as described.  
Protein concentration 
Concentration of protein-containing solutions was determined using the BCA Assay (Pierce), according 
to manufacturer’s instructions. Briefly, the sample of interest was placed, either neat or diluted further in 
diluent, in duplicate wells of a 96 well plate and in a volume of 10 or 25 µl, before addition of 200 µl of 
BCA working reagent (WR) to give a ratio of 1:20 or 1:8 sample:WR respectfully. A standard curve of 
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protein (albumin) diluted in the diluent as the sample (usually DPBS) was used on each plate. The 
sample/WR mix was left to incubate at 37°C for 30 minutes before the absorbance at 562 nm was 
measured using a plate-reader. The absorbance values from the wells containing diluted standards were 
used to generate a standard curve by fitting a line of best fit; this was used to calculate the concentration 
of protein in sample wells.  
SDS PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS PAGE) was performed by mixing 
protein-containing samples were mixed with NuPAGE sample loading buffer (Invitrogen) and NuPAGE 
reducing buffer (Invitrogen), and heated at 96°C for 10 minutes before transferring to ice for immediate 
loading on to the SDS PAGE apparatus. The SDS PAGE mini cell apparatus (BioRad) was assembled to 
include pre-made Precise Protein Tris-HEPES-SDS Gels (Pierce; with either 10, 12 or 15 lanes and either 
a 12 or 4-20% gradient of SDS gels) submerged in Running buffer (see Table 3). Protein solutions were 
then loaded into individual lanes on the pre-cast gels. For estimation of protein size, a pre-stained 
Kaleidescope Precision Plus Protein Standard (BioRad) was also loaded. The gel ran at 150 V for 30 – 40 
minutes.  
Gels were washed 3 times in dH20 with continual agitation for 15 minutes, before submerging in 
GelCode Blue (ThermoScientific) and agitating at RT for 1 hour. Gels were de-stained by rinsing several 
times in dH20 for approximately 1-2 hours.  
Western Blot 
For immunoblotting /western blot, SDS PAGE gels were generate containing proteins of interest, as 
described above. These were immediately submerged in ice-cold Transfer Buffer, along two pieces each 
of sponge and filter paper, for 15 minutes. The PVDF membrane was activated by submerging in 
methanol for 15 seconds, in dH20 for 2 minutes, then in Transfer Buffer for 15 minutes. A blot module 
was assembled in a cassette, in which the gel and PVDF membrane were placed next to each other, 
surrounded by filter paper and sponges on each side. Cassettes were placed in a mini cell submerged in 
ice-cold Transfer Buffer. To keep the reagents cool, an ice pack was also placed in the cell. The tank ran 
at 350 mA for 50 minutes to transfer proteins from the gel from the PVDF membrane.  
PVDF membranes could then be stained using immunoblotting. The general procedure for this was as 
follows: firstly, membranes were blocked in 4 % milk in PBST for 2 hours with continual agitation. The 
membranes were then stained with primary antibody, diluted in 4% milk in TBST, and incubated at 4°C 
overnight with continual agitation. The membrane was then rinsed in TBST at RT for 15 minutes once, 
then for 5 minutes three times, before incubation with secondary antibody diluted in 4% milk for 1 hour, 
before a period of washing in PBST as before. Details and concentrations of antibodies used are indicated 
in individual methods and results sections.  
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Removal of endotoxin 
Endotoxin was removed from rKMP-11 preparations using Detox-Gel and Columns (ThermoScientific) 
according to manufacturer’s instructions. Samples were tested before and after endotoxin removal for 
levels of endotoxin by using a pre-paid endotoxin testing service (Lonza).  
Statistical Analysis 
Data was collected into excel spreadsheets and explored and analysed using both SPSS 20 © and R 
(version 2.15.2) © software packages.  Datasets were tested for normality and other typical distributions, 
before deciding on the appropriate statistical methods. Parametric tests were used when data was found 
to be normal, to fit another typical distribution (e.g. Poisson or negative binomial), or could be 
normalised by transformation. However parametric tests were only used if all comparable datasets could 
also be analysed in the same way. As indicated in the results chapters, in many cases both approaches 
were taken and the findings were compared. To explore differences in variation in outcomes between 
groups, ANOVA or Kruskall-Wallis tests were used, for parametric or non-parametric analysis 
respectively. However, to compare averages between two groups, the student’s t test or Mann-Whitney U 
test was used, for parametric or non-parametric analysis respectively, instead of using post-hoc tests using 
the multivariate techniques. This is because, after considerable exploration of the datasets and discussion 
with a statistician, it was decided that multivariate analyses to compare groups were not appropriate for 
this type if study where small sample sizes are generally used. Although this approach risks increasing the 
number of type I errors recorded, this is only an issue in those cases where the significance is low (p = 0.1 
– 0.5). Indeed, bivariate analysis is also an approach widely used by many others exploring the outcomes 
of parasitic infection in mouse models (43, 70, 86, 203, 231, 232) . Correlation of non-parametric variables 
was achieved using Spearman’s rank test. Graphs were generated using GraphPad Prism 5 © software.   
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Chapter 3. The role of TLRs in Leishmania major infection 
Abstract 
The role of TLR2 and its co-receptors during infection with L. major is not currently known, despite 
several studies reporting a role for TLR2 in the recognition of surface glycolipids from the parasite. In 
this study, a role for TLR2 in control of L. major in vivo was confirmed, as mice deficient in TLR2 
presented with larger lesions and higher parasite burdens than their WT counterparts at the height of 
infection. A role for TLR4 was also found in reducing disease after L. major infection, as has been 
reported in other studies. Recall immune responses by DLN cells in vitro, and heightened levels of antigen 
specific IgG1 in the plasma of infected TLR2-/- mice suggests that TLR2 acts to reduce development of 
regulatory and Th2 responses to L. major, which act to exacerbate infection. Surprisingly, neither of the 
known co-receptors for TLR2 (TLR1 and TLR6), was found to have a role in controlling L. major in 
combination with TLR2, as mice lacking these co-receptors did not develop exacerbated disease. 
Interestingly, TLR6-/- mice appear to have increased resistance to L. major and are able to heal lesions 
faster than WT mice and other groups, suggesting TLR6 exacerbates infection in WT mice. Together 
these results demonstrate an important role for TLR2 in the control of Leishmania in vivo and regulation of 
protective Th1 immunity and show TLR2 recognition occurs independently of the canonical TLR2 co-
receptors, TLR1 and TLR6, and that paradoxically TLR6 deficiency promotes a more rapid healing 
phenotype.  
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Introduction 
Background 
The mouse model of L. major infection in mice (particularly BALB/c and C57BL/6 strains) has been 
extensively studied for markers of resistance and susceptibility and has given insight into the nature of 
immune responses, which are required for control of intracellular pathogens such as Leishmania spp. In 
particular the adaptive immune response has been comprehensively examined in C57BL/6 and BALB/c 
mice infected with L. major, and from this we now understand the key elements that are required for 
control of infection (39). The most important protective response is a robust Th1 response characterised 
by production of IFNγ, leading to classical activation of MΦs, production of TNFα and NO, and finally 
to intracellular killing of parasites. Whilst many studies have explored the innate immune response to L. 
major parasites by distinct cell subsets in vitro, a limited number of in vivo studies exploring the role of the 
innate immune response during chronic infection have been reported. Such in vivo studies would help us 
to understand a role for innate immune responses to parasites in controlling disease during infection and 
how these influence adaptive immune responses. Studies using knockout mouse strains have identified a 
role for TLR pathways as mice lacking the adaptor molecule MyD88 were highly susceptible to L. major 
and mounted an inappropriate Th2 response (26, 199, 233). This suggested that TLR activation during 
infection may have a role in priming the production of IL-12 and a switching to a protective Th1 
response. A role for TLR4 in controlling L. major infection has been suggested by in vivo studies by one 
group (202, 203), although disputed by another (207), and TLR9 has been shown to play a role in 
controlling L. major infection in vivo (206). TLR2 has been implicated in the recognition of Leishmania 
parasites in vitro, and in particular the recognition of LPG, the major surface glycolipid present on the 
infective promastigote stage (26). It has been reported that activation of TLR2 by LPG results in both a 
pro-inflammatory phenotype as shown by increased Th1 cytokine production by NK cells (27) and NO 
production in MΦs (205), but also a regulatory phenotype as shown by increased expression of 
suppressors of cytokine signalling (SOCS) molecules SOCS-1 and SOCS-3 in murine MΦs (26). 
Furthermore, different forms of LPG (i.e. soluble or membrane bound) have been shown to result in 
differently activated phenotypes of PBMCs after TLR2 engagement (234). 
Aim of the study 
In this study, mice lacking TLR2, TLR1, TLR6 and TLR4, were infected with L. major to determine the 
role of TLR2 and its known co-receptors in vivo, and to compare this to TLR4, which has previously been 
reported to control L. major.  
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Methods 
Mice, parasites and infections 
All procedures involving live animals were performed at the BSU in the Duncan Building, University of 
Liverpool. Female age matched WT (C57BL/6), TLR2-/-, TLR1-/-, TLR6-/- and TLR4-/- mice were 
infected with either 105 L. major FV1 stationary-phase promastigotes by s.c. injection to the shaven rump 
in a 100 µl volume of HBSS, or with 105 L. major LV39 to the upper side of the LHF. These parasites 
cultures were confirmed to be negative for mycoplasma contamination. Lesion progression was 
monitored by taking weekly measurements of lesion size using a metric dial calliper, and these 
measurements were used to generate area under the curve (AUC) values. At the end of infection 
experiments, mice were culled via cardiac puncture to allow for the collection of blood for plasma 
samples (with the exception of the first experiment). The lesion was removed and either processed for 
limiting dilution or placed in RNA later, and the spleens and DLNs were removed under sterile 
conditions and processed for cell stimulation experiments or parasite burden analysis (DLN only, 
experiment 1).   
Parasite burden 
The parasite burden of tissues was estimated by qPCR using JW11 and JW12 primers as described. This 
method was first validated against the more widely used method of limiting dilution. For this validation, 
lesion (n = 4) or DLN tissues (n = 29) were homogenised and passed through a cell strainer to obtain a 
single cell suspension in a fixed volume of complete M199. Half of this was used for limiting dilution, 
whilst the other half was used for qPCR by centrifugation of cells and extraction of DNA using a Qiagen 
Blood and Tissue Kit.  
Cell stimulations and immunological techniques 
For these experiments, DLN cells and splenocytes were used a concentration of 4 x 105 cells/ well. Cells 
were cultured for 72 hours in the presence of either 20 µg/ml L. major FV1 FTAg, 2.5 µg /ml ConA or 
media alone in a total volume of 200 µl/well. Culture supernatants were then removed and stored at -
20°C until analysis for IFNγ and IL-10 levels using cytokine ELISA. The levels of antigen specific IgG1 
and IgG2c in plasma samples from mice were measured using antibody ELISA with L. major FV1 FTAg 
as the capture antigen. 
Wound healing 
To assess wound healing in WT and TLR6-/- mice, 6 mice of each genotype were given a 4 mm circular 
wound using a punch biopsy tool, and healing was measured by recording the diameter of the wound at 
regular timepoints as indicated.  
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Results 
Lesion development  
To measure development of L. major infection, the lesions of mice were measured every week until the 
end of the infection in two experiments; in the first experiment mice were all culled at week 12 and in the 
second experiment some mice were culled at either week 10 or 18; results are displayed in Figure 9 and 
Figure 10. All groups showed similar patterns of lesion development, with appearance of lesions between 
4-6 weeks p.i. and a peak in lesion size at 10 – 12 weeks, before reduction in lesion size and healing at 
approximately 18 weeks. Mice lacking TLR2 showed larger lesions than WT mice at week 10 in 
experiment 2 and at week 12 in experiment 1 but were able to control the infection eventually as shown 
in Figure 9A and Figure 10A, suggesting that these mice are less able to control lesion development but 
that TLR2 is not crucial for the eventual healing of L. major lesions in C57BL/6 mice. Similarly, TLR4-/- 
mice had larger lesions at time points between week 9 and week 12 post infection in both experiments, 
but were also able to eventually control the growth of lesions after infection with L. major (Figure 9D and 
Figure 10C).  
Mice which lacked TLR1, a known co-receptor of TLR2, did not show any difference in development of 
lesions compared to WT mice in the first experiment. The average lesion size was smaller than that of 
TLR2-/- mice in the later stages of infection, but this difference did not reach significance (p = 0.064 for 
lesion area at 12 weeks p.i.). As there was no difference to control mice in experiment 1, a group of 
TLR1-/- mice was not included in experiment 2. TLR6-/- mice showed a different phenotype of lesion 
development to the other groups, with lesions being larger than in WT mice soon after their initial 
appearance (weeks 4-7), but healing earlier so having smaller lesions in the later stages of infection (week 
11-12 in experiment 1 and week 13 in experiment 2), as shown in Figure 9C and Figure 10B. 
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 Lesion development in WT and TLR-/- mice infected with L. major (experiment 1). Figure 9.
Lesion development in WT mice is presented in all charts, and was compared to that of TLR2-/- (A), TLR1-
/- (B), TLR6-/- (C) and TLR4-/- (D) mice infected with L. major, experiment 1. Data points indicated the 
mean values for each group +/- SEM (n = 5-7). Groups were compared using the Mann-Whitney U test (* 
p<0.05). 
The overall lesion development seen in such infection experiments can be represented by calculating the 
AUC for the lesion sizes over time for each individual. The average AUC values are displayed in Figure 
11. The datasets were found to be log-normally distributed so parametric tests were possible for the 
logged values, and groups were compared using the independent samples t test. These data indicate more 
severe disease overall in TLR4-/- mice in particular, with AUC values being significantly greater than WT 
mice at week 10, 12 and 18 p.i. in this group. Whilst no other significant differences in AUC values were 
seen, the general pattern was found to be the same as indicated by the lesion sizes over time – with TLR2-
/- mice having exacerbated disease compared to WT, and TLR6-/- mice having reduced disease in the later 
timepoints, especially compared to TLR2-/- and TLR1-/- mice (p=0.011 at week 12). 
The AUC values for the first experiment (week 12) show a decoupling of TLR6-/- mice from either TLR2-
/- or TLR1-/- mice – with significantly lower AUC values in this group (Figure 11B). The reduction in 
lesion size and development was not as evident for TLR6-/- mice in the second experiment, although the 
TLR6-/- mice did heal lesions earlier than the other groups (Figure 10B), which is reflected in the AUC 
values.  
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 Lesion development in WT and TLR-/- mice infected with L. major (experiment 2). The Figure 10.
lesion development of WT mice is presented in all charts, and was compared to that of TLR2-/- (A), TLR6-
/- (B), and TLR4-/- (C) mice, infected with L. major for 18 weeks. Data points indicated the mean values 
for each group +/- SEM (n = 4-9); note that some mice were sacrificed at week 10. Groups were compared 
using the Mann-Whitney U test (* p<0.05). 
In the first experiment, the number of lesions that ulcerated was recorded at week 8 and week 9 when the 
ulcerations were first noticed. At week 10 in the first experiment no lesions remained ulcerated. In the 
second experiment the presence of ulceration was recorded at every time point, so that a % of lesions that 
ulcerated could be calculated (Figure 11 E) for each group. The level of ulceration recorded was generally 
greater in the second experiment, and TLR2-/- mice showed the greatest tendency towards ulcerations, 
with 100% have a lesion which was ulcerated at some point during infection with L. major FV1 in the 
second experiment.  
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 AUC analysis and levels of ulceration for L. major infection experiments 1 and 2. Average Figure 11.
AUC values are shown (mean + SEM) for each group in the different experiments and at different 
timepoints (A-C) Bars represent mean values + SEM. Groups were compared using the Mann-Whitney U 
test (* p<0.05). The maximum percentage of lesions that ulcerated was recorded in each group of mice, at 
any one time during the infection experiments, was calculated and is presented in (D). The percentage of 
lesions that ulcerated was recorded for each group at each time point, and the percentages of the groups 
used in experiment 2 are given in (E), along with the area under the curve values for the ulcerated lesion 
percentage data, over the entire of experiment 2 (F).  
Development of qPCR method for quantifying parasites in infected tissue 
samples 
In order to accurately quantify parasite burden in lesion tissues, a qPCR method was developed based on 
that published by Nicolas et al (230) but with modifications for use with a real-time thermocycler machine 
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and SybrGreen. To compare this method with a more widely used method of limiting dilution, two types 
of infected tissue (DLN and rump lesion) were first homogenised and processed for limiting dilution, and 
a proportion of each sample was also taken for parasite quantification by qPCR. In both cases the average 
test result was used to calculate the overall parasite burden in the starting sample. The results of the qPCR 
quantification for each tissue were much greater (roughly 100 x greater) than that given by limiting 
dilution, suggesting the method is more sensitive at detecting individual parasites compared to limiting 
dilution However, whereas limiting dilution is a measure of the number of viable parasites within the 
lesion tissue, the qPCR method will also potentially measure the DNA of dead parasites (prior to 
sufficient DNA degeneration) as well as living viable parasites in the lesion.  
A plot of limiting dilution against qPCR parasite burden values is given in Figure 12. Neither variable 
follows a normal distribution so the relationship between the two measurement methods was measured 
using the Spearman rank-order correlation method, which found there was a significant monotonic 
relationship between the two measurements (Correlation coefficient = 0.633; p<0.001). Thus it was felt 
the qPCR method was both more sensitive, and validated against, the standard method of limiting 
dilution.  
 
 Limiting dilution vs qPCR. L. major infected tissues (DLN = black; lesion = red) were Figure 12.
disrupted and analysed for parasite burden using both limiting dilution and qPCR methods. The values 
obtained using each method were plotted against each other and correlated using the spearman’s rank-
order correlations as neither population was normally distributed. This gave an r value of 0.633, p<0.001.  
Parasite burden data 
The parasite burdens in collected lesion tissue samples were quantified by using the validated qPCR 
method. CT values obtained from duplicate reactions for each lesion DNA sample were used to quantify 
parasites per µl DNA using the standard curve containing DNA extracted from quantified parasites 
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spiked with naïve mouse DNA. The results were then adjusted for total DNA volume to give an overall 
value for parasites per lesion.   
Analysis using parametric methods 
The mean and standard deviations of the parasite burden data per genotype is given in Table 8.  
Group Week 10 (experiment 2) Week 12  (experiment 1) Week 18 (experiment 2) 
n Mean SD n Mean SD n Mean SD 
C57BL/6 4 1003933.25 1966764.268 6 235495.50 468475.433 5 395.49 547.499 
TLR2-/- 5 3588890.00 134342.421 7 6557664.29 9403765.772 4 7827.67 12838.64 
TLR1-/- - - - 6 64100.17 81510.392 - - - 
TLR6-/- 5 319478.14 427381.360 5 5784.00 8051.109 4 10.65 9.727 
TLR4-/- - - - 7 1011047.57 1742798.361 5 47595.09 67541.265 
The parasite burden data show extra-Poisson dispersal (i.e. the variation is greater than the mean), as is 
typical for count data, so groups were compared by fitting parasite count data to a negative binomial 
model using a generalised linear model function, which seemed to fit well. Comparisons between groups 
are made by generating incidence rate ratios and identifying the confidence intervals, as displayed in Table 
9.  
Comparison Week 10 (experiment 2) Week 12 (experiment 1) Week 18 (experiment 2) 
IRR 95% CI P value IRR 95 % CI P value IRR 95 % CI P value 
TLR2-/- / WT 3.575 0.66 – 
19.37 
0.140 27.85 4.82 – 
160.99 
<0.001 19.80 3.39 – 
115.68 
0.001 
WT / TLR1-/- - - - 3.67 0.66 – 
20.61 
0.139 - - - 
WT / TLR6-/- 3.142 0.44 – 
22.44 
0.254 40.72 6.62 – 
250.59 
<0.001 37.66 9.88 – 
143.55 
<0.001 
TLR4-/- / WT - - - 4.24 0.66 – 
27.95 
0.127 120.37 25.43 – 
569.67 
<0.001 
TLR2-/- / TLR1-/- - - - 102.30 26.45 – 
395.73 
<0.001 - - - 
TLR2-/- / TLR6-/- 11.23 3.77 – 
33.46 
<0.001 1133.7
6 
260.92 – 
4926.42 
<0.001 745.50 151.01 – 
3680.38 
<0.001 
TLR2-/- / TLR4-/- - - - 6.49 1.39 – 
30.19 
0.017 - - - 
TLR4-/- / TLR2-/- - - - - - - 6.08 1.02 – 
36.13 
0.047 
TLR1-/- / TLR6-/- - - - 11.08 2.64 – 
46.45 
0.001 - - - 
TLR4-/- / TLR1-/- - - - 15.77 3.51 – 
70.93 
<0.001 - - - 
TLR4-/- / TLR6-/- - - - 174.80 34.98 – 
873.53 
<0.001 4532.86 1163.37 – 
17661.43 
<0.001 
The parasite burden data, graphically displayed in Figure 13, indicate that parasite burdens in the infected 
mice generally follow the same trend as seen with lesion sizes – i.e. TLR2-/- and TLR4-/- mice display 
larger parasite burdens than WT mice, and this is more evident in the later timepoints post infection, 
Table 8.  Average parasite burdens in lesions of WT and TLR-/- mice at different time points post infection 
with L. major. Means and standard deviations are given for each timepoint. 
Table 9.   Incidence Rate Ratios (IRRs) comparing average lesion parasite burden between genotypes. 
Only the IRRs where values are greater than 1 were displayed to avoid duplication.  
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whereas TLR6-/- mice show smaller parasite burdens compared to WT and other groups, and again this is 
more prominent at the later time points. As with the lesion and AUC results, TLR1-/- mice showed no 
difference in parasite load compared to WT mice at week 12 (experiment 1), but had larger parasite 
burdens compared to TLR6-/- mice and smaller parasite burdens compared to TLR2-/- mice.  
 
 Parasite burden of lesions of WT and TLR-/- mice at 10, 12 and 18 weeks post infection Figure 13.
with L. major, compared using parametric methods (* p<0.05; **p<0.005; ***p<0.001). Individual parasite 
burdens are displayed, as well as the mean + SD.  
Analysis using non-parametric methods 
As the datasets in this study are quite small, it is not entirely clear whether the negative binomial model is 
the best method for analysing the data, and the convention elsewhere in similar studies is to use non-
parametric tests. Thus, groups were also compared to each other using the Mann-Whitney U test, and the 
results are given in Table 10 below. 
 Week 10 Week 12 Week 18 
Comparison U/W z p U /W z p U /W z p 
WT vs TLR2-/- 3 / 13 -1.715 0.111 1 / 22 -2.857 0.002 2 /17 -1.96 0.063 
WT vs TLR1-/- - - - 14 /35 -0.641 0.589 - - - 
WT vs TLR6-/- 10 /25 0 1.00 3 /18 -2.191 0.030 2 /12 -0.196 0.063 
WT vs TLR4-/- - - - 13 /34 -1.143 0.295 10 /25 -0.522 0.690 
TLR2-/- vs TLR1-/- - - - 0 /21 -3.00 0.001 - - - 
TLR2-/- vs TLR6-/- 0 /15 -2.611 0.008 0 /15 -2.84 0.003 0 /10 -2.309 0.029 
TLR2-/- vs TLR4-/- - - - 7 /35 -2.236 0.026 9 /24 -0.245 0.905 
TLR1-/- vs TLR6-/- - - - 7 /22 -1.461 0.177 - - - 
TLR1-/- vs TLR4-/- - - - 10 /31 -1.571 0.138 - - - 
TLR6-/- vs TLR6-/- - - - 1 /16 -2.68 0.005 3.5/13.5 -1.599 0.111 
The results from these tests give similar findings to when fitting the negative binomial model, i.e. TLR2-/- 
mice had significantly greater parasite burdens compared to WT (week 12), TLR1-/- (week 12), TLR6-/- 
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Table 10.  Comparison of parasite burdens in WT and TLR-/- mice using non-parametric tests.  
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(week 10, 12 and 18) and TLR4-/- (week 12) mice. TLR6-/- mice have reduced parasite burdens, with a 
significantly lower burden compared to WT at week 12 and at all time points when compared to TLR2-/- 
mice. 
 
 Parasite burdens in WT and TLR-/- mice at 10, 12 and 18 weeks post infection with L. Figure 14.
major, compared using non-parametric methods (* p<0.05; **p<0.005; ***p<0.001). Individual parasite 
burdens are displayed, along with the median value for each group. Zero values were reported for the week 
18 time point (for one TLR6-/- and one TLR4-/- mouse) but do not appear on the charts due to the use of 
logarithmic scale on the y axis.  
One major exception in the findings using non-parametric comparison tests (compared to parametric) is 
that no differences in parasite burden are found between WT and TLR4-/- mice at the time points 
measured, despite the elevated lesion sizes and AUC values found in this group. Also, TLR2-/- mice did 
not show significantly greater parasite burdens when compared to WT mice at week 18 when compared 
using the Mann-Whitney U test, although the p value indicates this difference is almost significant 
(p=0.063).  
Parasite burden in DLNs of mice, week 12 
As the DLN tissue was taken for validation of the qPCR method of quantifying parasite burden, the 
values could be used to quantify the parasite burdens in the DLN of mice from the different groups. The 
results indicated extra-Poisson dispersal as with the lesion parasite data, thus the data was fitted to a 
generalised linear model using a negative binomial model to compare parasite burdens by group of mice 
using parametric methods, as described above. As shown in Figure 15, TLR2-/- mice had the highest 
parasite burdens in the DLN tissue compared to other groups, and the burden was significantly greater 
than in WT mice when compared using both parametric and non-parametric tests. In addition, TLR2-/- 
displayed higher DLN parasite burdens compared to both TLR1-/- and TLR6-/- mice according to the 
parametric tests.  
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DLN Parasite Burden Week 12
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 Parasite burden in DLN tissue in WT and TLR-/- mice at week 12 p.i. with L. major FV1, Figure 15.
analysed using parametric and non-parametric tests (* p<0.05; **p<0.005; ***p<0.001). A shows the 
individual parasite burden data plotted, with mean + SD and significant differences as identified by 
parametric methods (using generalised linear model and negative binomial distribution), whilst B shows 
data with median values and significant difference as identified by non-parametric methods (Mann-
Whitney U test).  
Cytokine responses in WT, TLR2-/- and TLR6-/- mice at week 10 post infection 
To explore the immune responses in the different mice during infection with L. major, immune cells of 
mice were taken for stimulation assays at the 2 time points when mice were culled in experiment 2: week 
10 and week 18. DLN cells and splenocytes were processed and stimulated with L. major FTAg or 
controls for 72 hours. The supernatants from these stimulations were then used to measure cytokine 
levels using ELISA. The two cytokines chosen for analysis were IFNγ and IL-10, given their known roles 
in resistance and susceptibility, respectively, in this model of infection with L. major. Splenocytes from 
naïve mice of each genotype were used as controls (n=6 total) and there was no detectable cytokine 
response to FTAg in these stimulations, whereas ConA gave increased cytokine production in all cases 
(data not shown). The results for the cytokine responses in stimulations of cells from infected mice at 
week 10 are shown in Figure 16. The results of the cytokine levels found in all experimental groups is 
given in Appendix 2. 
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 Cytokine responses at week 10 post infection. WT, TLR2-/- and TLR6-/- mice were Figure 16.
infected with L. major and infection was allowed to develop for 10 weeks. At the end of the experiment, 
DLN cells and splenocytes were recovered and stimulated in vitro with L. major FTAg antigen and 
controls. After 72 hours the supernatants were removed and were analysed by ELISA for the presence of 
IFNγ and IL-10. Individual points represent the mean average levels of cytokine calculated from duplicate 
cultures per mouse, and horizontal bars represent median averages for each group. The results of IFNγ 
and IL-10 production in FTAg stimulated cells (with media control values subtracted) are shown for DLN 
(A) and spleen (B) cells. The ratio of antigen specific IFNγ:IL-10 produced by DLN cell (C) and 
splenocytes (D) is also shown.   
Although not significant, the TLR2-/- mice showed a trend for elevated antigen specific IFNγ and IL-10 
responses compared to WT and TLR6-/- mice in DLN cells and splenocyte stimulations (Figure 16 A, B), 
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perhaps indicating a greater number of T cells specific for L. major in these mice, although further 
information is required to concluded this (e.g. by performing ELISPOTs). When these values were used 
to measure the ratio of these cytokines produced in response to antigen, the TLR2-/- mice had a reduced 
amount of IFNγ to IL-10 produced in response to the parasite antigen when compared to that seen for 
WT and TLR6-/- mice (Figure 16 C, D), and this was almost significant when compared to TLR6-/- in the 
DLN cell stimulations (p=0.063). This suggests a more regulated immune responses in the TLR2-/- mice 
at week 10 post infection. Indeed, two individuals in the TLR2-/- group produced more IL-10 in response 
to FTAg than in response to the ConA positive control (Appendix 2), suggesting a high level of 
regulatory immune responses to L. major occurring in these mice. 
Cytokine responses in WT, TLR2-/-, TLR6-/- and TLR4-/- mice at week 18 post 
infection 
Immune responses were also recorded for mice at week 18 p.i. with L. major, and the results from the cell 
stimulation cytokine ELISAs are given in Figure 17. As with the week 10 cytokine response, a high level 
of variation was seen in the cytokine responses. Some spontaneous cytokine production (i.e. media alone 
wells) occurred in the stimulations for some DLN and splenocyte cultures. In particular, spontaneous 
IFNγ was produced by DLN cells from all the TLR4-/- mice but none was detected in WT mice, and 
elevated spontaneous IL-10 production was seen in TLR2-/- mice with both DLN and spleen cultures, 
with the latter being significantly greater than that seen for WT mice (Figure 17 A, C). TLR2-/- mice 
showed elevated antigen specific IFNγ and IL-10 responses in the splenocyte stimulations, when 
compared to WT mice (Figure 17D). The IL-10 response was also elevated in the positive control ConA-
stimulated splenocyte cultures from TLR2-/- mice, indicating a universal regulatory response compared to 
the other groups. TLR6-/- mice, which had the lowest parasite burdens at week 18, showed the highest 
ratio of antigen specific IFNγ:IL-10 in the splenocyte cultures, which was significantly greater than WT 
and TLR2-/- mice. However, these mice also surprisingly had relatively low IFNγ:IL-10 responses to 
antigen in the DLN cultures.  
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 Cytokine responses in WT, TLR2-/-, TLR6-/- and TLR4-/- mice at week 18 post infection Figure 17.
with L. major. WT, TLR2-/-, TLR6-/- and TLR4-/- mice were infected with L. major and infection was 
allowed to develop for 18 weeks. At the end of the experiment, DLN cells and splenocytes were recovered 
and stimulated in vitro with L. major FTAg antigen and controls. After 72 hours the supernatants were 
removed and were analysed by ELISA for the presence of IFNγ and IL-10. Individual points represent the 
mean average levels of cytokine calculated from duplicate cultures per mouse, and horizontal bars 
represent median averages for each group. Unstimulated production (A, C), and antigen specific (B, D) 
IFNγ and IL-10 production (calculated by subtracting the cytokine produced in media-control wells from 
those in stimulated well) was measured (A, B – DLN cells, C, D – splenocytes). The ratio of antigen 
specific IFNγ:IL-10 produced by DLN cell (G) and splenocytes (H) is also shown. Groups were compared 
using the Mann-Whitney U test (*p<0.05).  
Antigen specific antibody isotype levels  
Blood plasma samples were taken at the two time points to measure levels of antigen specific IgG 
antibody isotypes using L. major promastigotes antigen (FTAg) for capture in ELISAs. Isotype switching 
of antigen specific antibodies by B cells is influenced by the production of different cytokines. The two 
major isotypes of circulating IgG are therefore biomarkers of the type of immune response, with IgG1 
isotype indicating a Th2–biased response and IgG2a/c indicating a Th1 response in mice (due to a 
requirement of IL-4/IFN in IgG1/IgG2a-c isotype switching (235)). The results are displayed in Figure 
18 and indicate that for all groups, the level of antigen specific IgG1 antibody did not change from week 
10 to week 18 (Figure 18 A), whereas the concentration of antigen specific IgG2c increased in all groups 
from week 10 to week 18. Thus the ratio of IgG1:IgG2c decreased in all groups from week 10 to week 18 
as shown in Figure 18 C indicating a shift towards a dominant Th1 type of immune response. This 
corresponds with a reduction in lesion size and a controlling of the infection in all groups. The most 
evident shift between these two time points is in TLR6-/- mice where a significant increase in the 
concentration of antigen specific IgG2c is seen, and a significant reduction in the ratio of IgG1:IgG2c 
specific for L. major antigen was measured. The overall levels of antigen specific IgG1 collected at both 
time points was significantly higher in the TLR2-/- group compared to WT mice (p = 0.040), indicating an 
overall elevated Th2 response in these mice.  
88 
 
 
 
 IgG antibody isotypes in mice infected with L. major. WT (black circles), TLR2-/- (purple Figure 18.
triangles), TLR6-/- (green diamonds) and TLR4-/- (red triangles) mice were infected with L. major and 
blood plasma samples were collected at either 10 or 18 weeks after infection (when experiments were 
ended). The levels of IgG1 (A) and IgG2c (B) antibodies specific to the L. major FTAg were determined by 
ELISA and the concentrations were determined. Individual points represent the mean average levels of 
antibody from duplicate wells per mouse, and horizontal bars represent median averages for each group. 
The ratio of antigen specific IgG1:IgG2c for each individual was then calculated (C). Groups were 
compared using the Mann-Whitney U test (*p<0.05). 
TLR6-/- mice do not heal cutaneous wounds faster than WT mice 
Models of cutaneous leishmaniasis in mice have implicated various immune factors in skewing towards 
either resistance or susceptibility to infection. Other factors however, such as differences in wound 
healing processes, can also have a role in leading to differential ability to cure Leishmania infection in 
different strains of laboratory mice. It was observed that a proportion (approximately 25-35%) of TLR6-/- 
mice in the colony developed blindness by a process that appeared to be one of healing in the tissue 
surrounding the eye. Thus, it was hypothesised that TLR6-/- mice may have an increased ability to heal, 
and that this may explain the increased rate of cure in these mice in L. major infection. Indeed, TLRs have 
been implicated in the process of wound healing in mouse knockout studies (236). To explore whether 
the increased resistance to L. major observed in TLR6-/- mice is related to an enhanced ability to heal 
wounds, WT and TLR6-/- were given cutaneous wounds at the same site used for the L. major infection 
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(shaven rump) using a punch biopsy tool, and healing was monitored by daily measurements of the 
wound diameter. Results are presented in Figure 19 below.  
 
 Rate of healing of punch biopsy wounds in WT and TLR6-/- mice. WT or TLR6-/- (n=6) Figure 19.
mice were given a circular wound on the shaven rump using a punch biopsy tool. The healing was 
measured by taking regular measurements of the lesion diameter using a dial calliper. The average lesion 
diameter +/- SEM is displayed.  
In all mice, the wounds reduced in size within the first 24 hours and healed completely within 11 days. 
There was no difference in the ability of TLR6-/- and WT mice to heal the wound created by the punch 
biopsy, and if anything the rate of healing was slightly faster in the WT mice. Thus, it appears that TLR6-/- 
mice do not have an increased ability to heal wounds when compared to WT mice, using this method.  
Discussion 
The data presented indicate a role for TLR2 during infection with L. major FV1 in helping to control 
infection, as mice lacking this receptor develop more severe disease. In addition the results confirm a role 
for TLR4 as previously reported (202, 203).  However, neither TLR2 nor TLR4 is crucial for eventual 
control over L. major infection as mice lacking either receptor eventually healed their lesions. What is clear 
from the results presented here is that TLR4-/- mice present with exacerbated disease in the form of larger 
lesions and elevated AUCs over the course of infection. Kropf et al found similar results in terms of 
kinetics of infection when using L. major LV39 in a similar infection model, where lesions in 
C57BL/10ScN mice which lack a functional TLR4 gene had larger lesions just after the acute phase of 
infection (day 53), and higher parasite burdens at several timepoints (early and late stages of infection), 
when compared to their WT counterparts (C57BL/10ScSn) (202, 203). The 10ScN mice were found to 
produce elevated Th1 and Th2 cytokine responses to L. major in DLN restimulations (compared to ScSn 
or WT) including both IFNγ and IL-10, which was not repeated in this study as only elevated IFNγ was 
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observed, although the timepoints post infection at which DLN were taken was very different: week 4 p.i. 
in (203) and week 18 p.i in this study. An additional finding was that MΦs from mice lacking TLR4 were 
found to produce more arginase in response to L. major infection when compared to TLR4-competent 
MΦs, suggesting that TLR4 plays a role in preventing alternative activation of MΦs during infection 
independently of the adaptive immune response (203). A role for neutrophil elastase (NE) in the 
activation of L. major infected MΦs to kill via TLR4 was provided in a study by Ribeiro-Gomes et al, 
where it was demonstrated that neutrophils were able to induce intracellular killing in a TNFα and TLR4 
dependent manner, and NE was responsible for this effect (237). Thus a host derived TLR4 ligand, or 
DAMP, is potentially linked with the role of TLR4 in L. major control.  
In the two L. major infection experiments presented TLR2 was found to have a role in controlling 
development of lesions caused by L. major, and importantly in controlling parasite replication, as mice 
lacking this receptor showed larger lesions and elevated parasite burdens compared to WT mice. Another 
study reported that unpublished experiments showed TLR2-deficient mice were as resistant as WT 
C57BL/6 mice to L. major LV39 strain (207), however as the details of these experiments have not been 
fully reported it is not possible to compare the findings with those reported in this study. These 
unpublished studies may not have been conducted over a long enough time period to detect the point at 
which disease is exacerbated in TLR2-/- mice. It may also be possible that differences in TLR function 
occur between infections with different strains of L. major. Indeed, Revaz-Breton et al reported that the 
immune responses in MyD88-/- mice were markedly different during infection with either L. major LV39 
or L. major IR75, indicating that pathways involving this adaptor molecule (i.e. TLR and/or IL-1) have 
distinct roles even between very closely related L. major strains (238).  Thus, it is possible that TLR2 could 
play a more significant role in infection with L. major FV1 when compared with L. major LV39.  
Certain immune responses were also elevated in TLR2-/- mice, such as antigen-specific IgG1 in the 
plasma and antigen specific cytokine responses, both protective and regulatory (IFNγ and IL-10) from 
splenocytes. Several studies have linked Leishmania-specific IgG (74, 75), and specifically IgG1 antibody 
isotypes (71) to susceptibility to infection with L. major or other Leishmania spp. It is believed that during 
infection, amastigotes are able to infect new MΦs via IgG antibody receptors (FcγRs), which results in 
production of IL-10, thereby regulating protective responses at the site of infection (e.g. cMΦ activation) 
and allowing further parasite replication (70). At the earlier time point of week 10, the ratio of antigen 
specific cytokine production by DLN cells and splenocytes suggested a skew towards a regulatory 
phenotype (lower IFNγ:IL-10 production), although further evidence is needed to confirm this as 
significance was not reached. The overall elevation of antigen specific responses suggests expansion of 
antigen specific T cells was elevated in TLR2-/- mice, which may be secondary to the increased antigen 
exposure due to higher parasite load, or related more directly to the function of TLR2 during infection. 
Interestingly, a study using mice infected with L. braziliensis, a parasite from the Leishmania (Viannia) 
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subgenus causing CL, found that while MyD88-/- mice were more susceptible to infection, TLR2-/- mice 
were more resistant than WT C57BL/6J mice during the acute phase of infection (as measured by lesion 
size, but not parasite burden where no differences were seen) (200). Whilst this finding differs markedly 
from the increased lesion sizes and parasite burdens found in L. major infected TLR2-/- mice in this study, 
Vargas-Inchaustegui et al also reported that TLR2-/- infected mice had elevated numbers of IFNγ 
producing CD4 T cells at week 8, and a sustained production of IFNγ by DLN cells in response to 
parasite antigen, whereas WT mice showed a reduction in IFNγ between week 4 and week 8. These 
results are similar to those reported here, where TLR2-/- mice showed enhanced IFNγ and IL-10 
responses to FTAg in splenocyte restimulations at week 18 p.i. (Figure 17) (200). The same study also 
showed that DCs from TLR2-/- mice were more able to activate CD4 T cells to proliferate and produce 
IFNγ than WT DCs, after infection with L. amazonensis and L braziliensis parasites in vitro (200). Why a lack 
of TLR2 should increase the ability of DCs to activate T cells is unclear, but may be an example of a 
parasite-derived TLR2 ligand which acts to suppress activation of DCs. Whilst we also found evidence for 
an increased number of antigen specific T cells in TLR2-/- mice during L. major infection, this was 
associated with larger lesions and increased parasite burdens. This may suggest that a TLR2-mediated 
downregulation of immune activation during Leishmania infection is able to assist control of L. major, but 
is detrimental during infection with L. braziliensis. 
Studies utilising TLR9-/- mice infected with L. major showed similar disease kinetics to those reported here 
with TLR2-/- and TLR4-/- mice, with increased lesion sizes and parasite burdens during the acute phase of 
infection, but eventual control of the disease (206, 207). In these models, it was found that TLR9 in DCs 
is activated by L. major DNA and this activation promotes priming of a protective Th1 response via 
production of IL-12, activation of NK cells and of IFNγ production, which all act to promote parasite 
killing by iNOS production by MΦs and to suppress non-protective Th2 responses (206, 207). 
Nevertheless, infected TLR9-/- mice were able to mount an appropriate Th1 response and heal their 
lesions, and the deficiency appeared to be a delayed ability to control non-protective Th2 responses. 
Thus, neither TLR2 nor TLR4 nor TLR9 is solely responsible for the important role of MyD88 in 
mounting a protective response to L. major, where mice deficient in MyD88 develop uncontrollable 
disease and insufficient Th1 or entirely inappropriate responses (199, 238). It is known that activation of 
more than one TLR can have either a complimentary, synergistic or antagonistic effect on innate immune 
responses (and subsequent adaptive immune responses) (239), and it may well be that it is a combination 
of TLRs that cooperate synergistically, all via MyD88 signalling, to allow for protective responses. Such a 
phenomenon appears to be the case in infection with a related intracellular protozoan parasite, T. cruzi, 
where mice deficient in both TLR2 and TLR9 were found to be more susceptible than mice deficient in 
either one receptor, and the TLR2-/-TLR9-/- dual deficient mice had levels of susceptibility comparable to 
that of mice deficient in MyD88 (189). It would be interesting to use such double knockout mice, or even 
triple knockout mice (e.g. TLR2-/-TLR4-/-TLR9-/-) in L. major infection experiments to explore whether 
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the combined effect of the different TLRs is able to account for the requirement of MyD88 in protective 
responses and eventual control of infection. As MyD88 is an adaptor molecule for the IL-1R pathway, it 
may also be that there is an important role for this receptor in protection to L. major, in addition to a role 
for TLR activation.  
Given that TLR2 is known to function as a heterodimer, with either TLR1 or TLR6, it was hypothesised 
that one or other of the mice lacking these co-receptors would display the same disease phenotype as that 
of the TLR2-/- mice, thus demonstrating a role for either co-receptor. However, it was found that the 
kinetics and parasite burdens of infected mice lacking either co-receptor differed both from each other 
and from TLR2, suggesting a decoupling of the roles of these three receptor molecules in L. major 
infection. This finding is surprising given our current understanding of TLR2 function and may suggest 
an as-yet unidentified mechanism of TLR2 function, such monomeric TLR2 ligand recognition. We 
attempted to produce mice lacking both TLR1 and TLR6 by cross breeding these two transgenic strains 
to address this question, but no double knockout TLR1-/-TLR6-/- progeny were produced in several 
progenies (data not shown), suggesting that this genotype is not viable.  
Another unanticipated finding was the unique phenotype of infected TLR6-/- mice, which presented with 
lower parasite burdens in the latter stages of infection, and healed lesions faster than WT and other 
groups, suggesting TLR6 has a role in exacerbating infection with L. major and delaying healing. It is 
unclear in what capacity TLR6 exerts this effect, as it would appear to be independent of its known 
function as a co-receptor for TLR2. Furthermore, it does not appear that this increased resistance in 
TLR6-/- is associated with any difference in ability to heal wounds in the absence of L. major infection. It 
would be interesting to determine whether any differences in innate immune signalling occur in WT, 
TLR2-/-, TLR1-/- and TLR6-/- MΦs and/or DCs after infection with L. major, as this may help to explain 
the differences in parasite infection/disease profiles observed.   
In the C57BL/6 model of infection with L. major, nTregs have been shown to play an important role in 
allowing for the persistence of a small number of parasites at the site of infection after healing, which 
allows for continued immune activation and enhanced immune memory and greater protective immunity 
(68). It could therefore be possible that the TLR6-/- mice used in this study had reduced numbers of L. 
major specific nTregs, thus allowing for faster reduction in parasite numbers and lesion sizes, and would 
explain why the highest number of parasites reported in TLR6-/- mice at week 18 was 21 (Figure 14). 
Furthermore, the TLR6-/- mice presented with a more dramatic shift towards a protective Th1 phenotype, 
suggesting that the mice possessing a functional TLR6 (i.e. all other groups) were less able to switch 
readily to a Th1 response, perhaps due to inhibition by nTregs. It would therefore be interesting to 
phenotype the T cell populations in the infected mice using flow cytometry and determine if there are any 
difference in quantities of Th1, Th2, Th17 and nTregs. In addition, it would be interesting to explore if 
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there are any differences in the phenotype of MΦs at the infection site, as the individual TLRs have an 
influence on the activation of MΦs towards a cMΦ or aaMΦ phenotype (78, 240).  
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Chapter 4. The role of TLRs in Leishmania mexicana 
infection 
Abstract 
TLR2 has been shown to play a role in the recognition of Leishmania parasites in vitro and this activation 
has been linked to the activation of both protective and suppressive immune responses. We have 
demonstrated in L. major infection experiments, that TLR2 plays a role in controlling disease cause by L. 
major in vivo, as mice lacking TLR2 develop more severe disease. It appears that TLR2 is playing a role in 
L. major infection without a need for either TLR1 or TLR6. It is unclear which ligand/s of TLR2, whether 
parasite-derived or otherwise, is responsible for this observed susceptibility in TLR2-/- mice. To explore 
whether TLR2 plays a similar role in infection with L. mexicana, we infected WT, TLR2-/-, TLR1-/-, TLR6-
/- and TLR4-/- mice with L. mexicana. As with L. major, TLR2 and not TLR1 or TLR6 appears to play a 
protective role in controlling L. mexicana infection as TLR2-/- mice develop more severe disease. We also 
show that TLR2-/- mice show a skewed Th2 response to L. mexicana during chronic infection suggesting 
that TLR2 activation during infection promotes protective responses. Given that infection of TLR2-/- 
mice with L. mexicana parasites lacking the TLR2 ligand LPG also resulted in exacerbated disease, we 
show that this is not a major or exclusive ligand involved in the TLR2 mediated control during chronic 
infection.  
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Introduction 
Background 
In Chapter 3, data was presented that implicated both TLR4 and TLR2 as having a role in controlling L. 
major infection in C57BL/6 mice. Surprisingly, neither of the known TLR2 co-receptors (TLR1 and 
TLR6) appeared to act as co-receptors for TLR2 in L. major infection, indicating a novel mechanism of 
TLR2 function in Leishmania infection. Furthermore, TLR6-/- mice were found to heal L. major infection 
faster than the other groups, indicating that these mice have increased resistance to infection.  
Aim of the study 
In order to test whether these findings could be replicated in another species that causes CL, we carried 
out similar experiments in the TLR-/- mice using L. mexicana, a causative agent of new-world CL. 
Furthermore, it is unclear whether the role for TLR2 during infection is linked to the recognition of LPG, 
which is the most widely reported ligand of TLR2 from Leishmania parasites (26, 27). Therefore we tested 
whether L. mexicana parasites, which have been genetically modified to lack the surface glycoprotein LPG 
(L. mexicana lpg1-/-), reverted to a WT phenotype in TLR2-/- mice. It is also possible to culture axenic 
amastigotes of L. mexicana (in contrast to L. major), which express almost no LPG on their surface (13) 
and use these for infections to compare with LPG-rich promastigotes. These two approaches allowed us 
to explore whether the TLR2 dependent role in parasite control is restricted to either the promastigote 
stage (during the initial stage of infection before transformation into amastigotes) or the amastigotes 
stage, and more specifically whether LPG is the ligand for TLR2 in vivo.   
Methods 
Mice, parasites and infections 
All procedures involving live animals were performed at the BSU in the Duncan Building, University of 
Liverpool. Female age matched (8-12 weeks old) WT (C57BL/6), TLR2-/-, TLR1-/-, TLR6-/- and TLR4-/- 
mice were infected with 105 L. mexicana WT or lpg1-/- metacyclic-enriched promastigotes, or L. mexicana 
WT amastigotes, by s.c. injection to the shaven rump, in a 100 µl volume of HBSS. These cultures were 
confirmed to be negative for mycoplasma contamination. The percentage of metacyclics in parasites used 
for infection was found to be 43% in the WT promastigote experiment and for lpg1-/- infection it was 
38%. Lesion progression was monitored by taking weekly measurements of lesion size (mm2) using a 
metric dial calliper and the measurements were used to generate AUC values. At the end of infection 
experiments, mice were culled via cardiac puncture to allow for the collection of blood for plasma 
samples (experiment 2 only). The lesion was removed and placed in RNA later, and the spleens and 
DLNs were removed under sterile conditions and processed for cell stimulation experiments.  
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Parasite burden 
The parasite burden of tissues was estimated by qPCR alone, using JW11 and JW12 primers as described.  
Cell stimulations and immunological techniques 
For these experiments, DLN cells and splenocytes were used a concentration of 8 x 105 cells/well. Cells 
were cultured for 72 hours in the presence of either 20 µg/ml L. mexicana FTAg, 20 µg/ml WMAg, 2.5 
µg/ml ConA or media alone in a total volume of 200 µl/well. Culture supernatants were then removed 
and stored at -20°C until analysis for IFNγ, IL-10, IL-4 and IL-13 levels using cytokine ELISA. The levels 
of antigen specific IgG1 and IgG2c in plasma samples from mice were measured using antibody ELISA 
with either L. mexicana FTAg or WMAg as the capture antigen. 
Results 
Parasite burden analysis 
As with the L. major experiments presented in Chapter 3, the data from the L. mexicana infection was 
explored and groups were compared using both parametric and non-parametric tests. The mean and 
standard deviations of the parasite burden results are given in Table 11 below.  
Genotype Promastigote WT Amastigote WT Promastigote lpg1-/- 
n Mean SD n Mean SD n Mean SD 
WT 8 20848487.5 18913227.1 7 1638655.4 4293812.2 5 755780000.0 845855774.9 
TLR2-/- 5 51862000.0 27219992.0 8 2016332.5 2330005.0 5 1321980000.0 988824125.9 
TLR1-/- 8 24613910.0 22056274.4 6 262703.3 251328.7 - - - 
TLR6-/- 8 16429200.0 9808354.5 7 536218.6 716523.9 - - - 
TLR4-/- 5 13626686.0 6578240.0 8 284747.5 782377.1 - - - 
 
Interestingly, the variance in the lesion parasite burdens from the promastigote infection were smaller 
than their mean averages, whilst they were larger for lesions from the amastigote infection and 
comparable in the lpg1-/- infection experiment, indicating a different distribution of data in these datasets. 
Nevertheless, it was possible to fit the data from all experiments to a negative binomial model using R, 
and in all cases this was found to fit better than an intercept only model or using a Poisson distribution. 
The results from the comparisons of IRR values obtained by fitting a negative binomial distribution using 
a generalised linear model function are displayed in Table 12.  
 
 
Table 11.  Mean and standard deviations of parasite burdens in WT and TLR-/- mice infected with 
L. mexicana promastigotes, amastigotes or lpg1-/- promastigotes. 
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Comparison 
Promastigote WT Amastigote WT Promastigote lpg1-/-  
IRR 95 % CI P  IRR 95 % CI P  IRR  95 % CI P  
TLR2-/- / WT 2.488 1.21-5.10 0.013 1.482 0.22- 10.08 0.681 1.749 0.61–5.03 0.299 
TLR1-/- / WT 1.18 0.52-2.70 0.694 - - - - - - 
WT / TLR1-/- - - - 5.407 0.69 -42.46 0.102 - - - 
WT / TLR6-/- 1.269 0.63-2.57 0.507 2.648 0.37 -19.18 0.355 - - - 
WT / TLR4-/- 1.530 0.76-3.08 0.233 4.988 0.73 -33.93 0.094 - - - 
TLR2-/- / TLR1-/- 2.107 1.03-4.29 0.040 8.015 1.08 -59.25 0.038 - - - 
TLR2-/- / TLR6-/- 3.157 1.79-5.55 <0.001 3.927 0.58 -26.71 0.154 - - - 
TLR2-/- / TLR4-/- 3.806 2.18-6.66 <0.001 7.395 1.16 -12.81 0.031 - - - 
TLR1-/- / TLR6-/- 1.498 0.75-3.01 0.256 - - - - - - 
TLR6-/- / TLR1-/- - - - 2.041 0.26 -16.03 0.489 - - - 
TLR1-/- / TLR4-/- 1.806 0.90-3.61 0.095 - - - - - - 
TLR4-/- / TLR1-/- - - - 1.084 0.15 -8.01 0.936 - - - 
TLR6-/- / TLR4-/- 1.206 0.70-2.07 0.498 1.883 0.28 -12.81 0.509 - - - 
When non-parametric tests were used to compare parasite burdens from different groups (see Table 13) 
those that were found to be different differed greatly from those found using the parametric tests. 
 L. mexicana promastigote L. mexicana amastigote L. mexicana lpg1-/- 
Comparison U/W z p U /W z p U /W z p 
WT vs TLR2-/- 4 /40 -2.342 0.019 8 /36 -2.316 0.021 9 /24 -0.731 0.548 
WT vs TLR1-/- 27/63 -0.525 0.645 6 /34 -2.143 0.035 - - - 
WT vs TLR6-/- 31/67 -0.105 0.956 13 /41 -1.469 0.165 - - - 
WT vs TLR4-/- 17/32 -0.439 0.724 26 /62 -0.231 0.867 - - - 
TLR2-/- vs TLR1-/- 7/43 -1.903 0.065 5 /26 -2.453 0.013 - - - 
TLR2-/- vs TLR6-/- 0/36 -2.928 0.002 14 /42 -1.62 0.121 - - - 
TLR2-/- vs TLR4-/- 0/15 -2.611 0.008 6 /42 -2.731 0.005 - - - 
TLR1-/- vs TLR6-/- 27/63 -0.525 0.645 20 /48 -0.143 0.945 - - - 
TLR1-/- vs TLR4-/- 17/32 -0.439 0.724 6 /42 -2.324 0.020 - - - 
TLR6-/- vs TLR6-/- 15/30 -0.732 0.524 12 /48 -1.852 0.072 - - - 
Table 12. Comparisons of parasite burdens in WT and TLR-/- mice infected with L. mexicana 
promastigote (WT or lpg1-/-) or amastigote parasites using parametric methods. Parasite burdens for mice 
of different genotypes (n=5-8) infected with L. mexicana parasites were determined for each experiment. 
These values were fitted to a generalised linear model using a negative binomial function, to allow for 
comparison of means between groups. Incidence rate ratios (IRRs) are presented (IRR = mean1/mean2) 
with their confidence intervals. The average values of groups are considered significantly different when 
the CI values of IRRs do not encompass 1; instances where this is the case are highlighted in bold and 
italics in the P column.  
Table 13. Comparisons of parasite burdens in WT and TLR-/- mice infected with L. mexicana 
promastigote (WT or lpg1-/-) or amastigote parasites using non-parametric methods. Median values of 2 
groups (n=5-8) were compared to each other using the Mann-Whitney U test. Instances where medians 
were found to be significantly different to each other are highlighted in bold and italics in the P column.  
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The parasite burden results from all groups of mice infected with WT L. mexicana promastigotes or 
amastigotes are presented in Figure 20, and the significant different between groups are displayed 
according to both parametric and non-parametric methods of analysis. The parasite burdens of WT and 
TLR2-/- mice infected with L. mexicana lpg1-/- promastigotes are not displayed here as neither method of 
comparing groups used detected a significant difference.  
 
 Parasite burdens in promastigote (A, C) and amastigote (B, D) L. mexicana infected Figure 20.
lesions of WT and TLR-/- mice, with comparisons between groups displayed. For parametric analysis, 
groups were compared by fitting a generalised linear model (A, B), mean values +/-SEM are shown; using 
non-parametric methods groups were compared using the Mann-Whitney U test (C, D) horizontal bars 
represent medians (* p <0.05; ** p<0.005; *** p<0.001). 
From exploring these data, it was evident that the group size and high variance in the parasite burden 
datasets in these experiments influenced the different outcomes between parametric and non-parametric 
statistical analysis. A good example of this is in the amastigote experiment, where despite 2-log-fold 
greater parasite burdens of TLR2-/- infected mice compared to the majority of WT mice, no difference 
between the two groups was found when a parametric test was used, but the Mann-Whitney U test found 
the two groups to be significantly different (Figure 20). Given that it is still not standard practice to use 
parametric methods to compare these kind of results in Leishmania infection experiments, especially using 
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a generalised linear model approach, it was decided after consultation with a statistician to continue 
analysis on results from these experiments using a non-parametric approach, by comparing medians 
between two groups using the Mann-Whitney U test.   
The roles of TLR2, 1 and 6 in controlling L. mexicana infection 
In this study, infection experiments with L. mexicana parasites showed that mice that lack TLR2 
developed larger lesions than WT mice upon infection (Figure 21 A, B), and have larger numbers of 
parasites in lesion tissue at 14 weeks p.i. (Figure 20 C, D and Figure 22). This indicates that TLR2 plays a 
role in controlling parasite replication in the lesion during chronic infection, in a similar way to that found 
for L. major. Furthermore, no clear role was indicated for either TLR1 or TLR6 in controlling infection 
with L. mexicana as co-receptors for TLR2, as mice lacking either co-receptor developed similar disease 
kinetics and parasite burdens to that of WT mice, rather than TLR2-/- mice, with the exception of slightly 
larger lesions in TLR1-/- at some early time points, and larger parasite burdens in these mice after 
infection with amastigotes (Figure 21 & Figure 22). 
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 Lesion progression in WT, TLR2-/-, TLR1-/- and TLR6-/- infected with L. mexicana Figure 21.
parasites.  Mice (n= 6-8 /group) were infected with 105 promastigotes (A, C, E) or amastigotes (B, D, F) to 
the shaven rump and lesion development was monitored by taking weekly measurements of lesion size 
using a dial caliper. Graphs show average lesion area + SEM, groups were compared using the Mann-
Whitney U test at each time point (* p <0.05). In A, B, C, D groups were compared to WT whereas in E 
and F groups were compared to TLR2-/-. *1 indicates TLR6-/- vs TLR2-/-.  
When compared to TLR2-/- mice, lesion size was smaller in TLR6-/- mice at several timepoints during 
infection with both promastigote and amastigote L. mexicana parasites. Whilst no significant difference in 
lesion size was observed between TLR2-/- and TLR1-/- mice in infection experiments, the average lesion 
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size in TLR1-/- mice was consistently smaller than in TLR2-/- mice, and followed the same lesion 
development pattern as the WT mice. Furthermore, infected TLR1-/- mice had significantly lower parasite 
burdens than TLR2-/- mice at 14 weeks post infection with L. mexicana amastigotes (Figure 21 & Figure 
22). 
 
 Final measurements at 14 weeks post infection in WT TLR2-/-, TLR1-/- and TLR6-/- mice Figure 22.
infected with L. mexicana promastigotes (A, B, C) and amastigotes (D, E, F). The lesion areas at the end 
of the experiment (A, D), the parasite burden of lesions (B, E) and the AUC values (C, F). In A, B, D, E, 
individual measurements for each mouse are shown, and horizontal bars represent median values. In C, F, 
bars represent means + SEM. Groups were compared using the Mann-Whitney U test (* p <0.05). 
Infection of TLR2-/- mice with L. mexicana lpg1-/- 
As several studies have shown that Leishmania LPG is a ligand for TLR2, we tested whether amastigote 
stages, which lack expression of LPG, would give a different phenotype in TLR2-/- infected mice (i.e. 
revert to the WT phenotype). However, the phenotypes of both amastigote and promastigote infections 
were strikingly similar between the two experiments, with TLR2-/- mice developing larger lesions in the 
later stages of infection and presenting with higher parasite burdens than WT mice and other groups 
(Figure 22). To explore this finding further, we carried out an infection experiment with L. mexicana lpg1-/- 
parasites, which specifically lack the LPG molecule on their surface. TLR2-/- mice also developed larger 
lesions than WT mice when infected L. mexicana lpg1-/- parasites, suggesting that activation of TLR2 by 
LPG is not the mechanism of TLR2 mediated control of parasite replication in vivo (see Figure 23). The 
average parasite burden in TLR2-/- mice was also greater in TLR2-/- mice infected with L. mexicana lpg1-/- 
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parasites, but this was not found to be significant, perhaps due to the low group size in this experiment 
(n=5).  
 
 Infection of WT and TLR2-/- mice with L. mexicana lpg1-/- promastigote parasites. Figure 23.
C57BL/6 (WT) and TLR2-/- mice (n=5) were infected with L. mexicana lpg1-/- promastigotes and lesions 
were allowed to develop for 18 weeks. The lesion size at weekly time points (A), at the end of the 
experiment (B), AUC values (C) and parasite burden of lesions at week 18 (D). In A, C, bars represent 
means + SEM. In B, D individual measurements for each mouse are shown, and horizontal bars represent 
median values. Groups were compared using the Mann-Whitney U test (* p <0.05). 
The role of TLR4 in L. mexicana infection  
TLR4 has been implicated in the recognition and control of Leishmania parasites in several studies (202-
204, 237), but its role in L. mexicana infection in vivo has not yet been explored fully in a chronic setting or 
using model that closely mimics immune responses found in human disease (such as in C57BL/6 mice). 
In this study, mice which lacked the TLR4 receptor (TLR4-/-) developed lesions that did not differ 
significantly from WT mice when infected with either promastigotes or amastigotes of L. mexicana at any 
time point over a 14 week infection (Figure 24 A, D). In fact, the trend tended towards smaller lesions in 
TLR4-/- infected mice, although no significant differences were seen. Furthermore, there were no 
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differences in either parasite burden or AUC values at 14 weeks post infection (Figure 24 B, C, E, F). 
These results suggest that TLR4 plays no role in controlling L. mexicana infection in this model, in 
contrast to that seen for L. major in the previous chapter.  
 
 Infection of TLR4-/- mice with L. mexicana promastigotes (A, B, C) or amastigotes (D, E, Figure 24.
F). C57BL/6 (WT) and TLR4-/- mice (n=7-8) were infected with L. mexicana promastigotes or 
amastigotes and lesions were allowed to develop for 14 weeks. The lesion size at weekly time points (A, D), 
AUC values (B, E) and parasite burden of lesions at week 14 (C, F) are displayed for promastigote 
infection and amastigote infection experiments, respectively. In A, B, D, E bars represent means + SEM 
are shown. In C, F individual measurements for each mouse are shown, and horizontal bars represent 
median values. Groups were compared using the Mann-Whitney U test. 
Spontaneous cytokine production 
To explore any differences in adaptive immune responses in the infected TLR-/- and WT mice, DLN cells 
were recovered and cultured for 72 hours in the presence of L. mexicana promastigote (FTAg) and 
amastigote (WMAg) antigens and the supernatants were analysed for cytokine levels using ELISA. LN 
cells from naïve controls were included in experiments, and these were not found to produce detectable 
levels of cytokine in media controls or in response to either Leishmania antigen, but did produce cytokines 
in response to ConA as expected (data not shown). Interestingly, many unstimulated DLN cell cultures 
from infected mice produced cytokine responses; this was particularly noticeable for DLN cells from the 
L. mexicana promastigote infection experiment (Figure 25).  
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 Cytokine production by unstimulated DLN cells in culture, from mice infected with L. Figure 25.
mexicana promastigotes (A) or amastigotes (B), 14 weeks after infection. At the end of the infection 
experiments, DLN cells were collected and cultured in vitro for 72 hours and cytokine levels in the 
supernatants were measured for levels of IFNγ, IL-10, IL-4 and IL-13 by ELISA. Individual points 
represent the mean average levels of cytokine from triplicate wells per mouse, and horizontal bars 
represent median averages for each group. Groups were compared using the Mann-Whitney U test (* p 
<0.05; nd = none detected). 
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As the DLN in infected mice are likely to contain high numbers of live parasites at the time of recovery, 
the cytokine production in these cultures may reflect the stimulation of the DLN cells by native parasites 
present in the DLN, and may therefore reflect the parasite burden in the DLN. The reduced lesion sizes 
and parasite burdens in the amastigote infection experiment at week 14 is likely linked to reduced parasite 
burdens in the DLN also, which may explain the lack of spontaneous cytokine production in the DLN 
cultures when compared to those from promastigote infected mice.  
These results may therefore reflect the profile of cytokine responses in DLN of infected mice at this time 
point ex vivo. Promastigote infected TLR2-/- mice showed reduced levels of IFNγ produced spontaneously 
in culture compared to WT, TLR1-/- and TLR6-/- mice, whereas TLR6-/- mice had comparatively lower 
spontaneous production of the Th2 cytokines IL-4 and IL-13 when compared to WT, TLR2-/- and TLR1-
/- mice. This suggests that the immune response in the DLN of TLR2-/- mice is skewed towards a Th2 
response, whilst comparatively the DLN of infected TLR6-/- mice is skewed towards a Th1 response (N. 
B. ratios were not possible to calculate due to the high number of individuals with no detectable 
cytokine). In the amastigote infection experiment, in most cases the only detectable cytokine produced in 
the media control cultures was IFNγ, suggesting that DLN is more skewed towards a Th1 response than 
in the promastigote infected mice. No noticeable differences were observed between spontaneous 
cytokine production by DLN cells from TLR4-/- compared to WT mice.  
FTAg and WMAg specific cytokine production 
The antigen specific cytokine responses by DLN cells were calculated by subtracting the levels produced 
spontaneously from those produced in response to in vitro stimulation with either a promastigote (FTAg) 
or amastigote (WMAg) L. mexicana antigen; the results are displayed in Figure 26 and Figure 27 
respectively. These results again show that TLR2-/- mice have a skewed immune response towards a Th2 
and regulatory type when compared to WT mice, presenting with comparable levels of IFNγ, yet higher 
levels of IL-10, IL-4 and IL-13 in response to either antigen after DLN stimulations from both 
promastigote and amastigote infections. This is further supported when the results are displayed in terms 
of ratios of Th1:regulatory or Th1:Th2 cytokines, where the ratio of IFNγ to either IL-10, IL-4 or IL-3 
was significantly reduced in TLR2-/- mice compared to WT mice, as well as comparing to other TLR-/- 
groups in many cases (see Figure 28). These results suggest that a presence of TLR2 acts to reduce the 
Th2 adaptive immune response, as well as regulatory IL-10, during L. mexicana infection. 
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 FTAg specific production of cytokines by DLN cells from WT and TLR-/- mice infected Figure 26.
with L. mexicana promastigotes (left) or amastigotes (right). At the end of the infection experiments, DLN 
cells were collected and cultured in vitro for 72 hours and cytokine levels in the supernatants were 
measured for levels of IFNγ (A), IL-10 (B), IL-4 (C) and IL-13 (D) by ELISA. Individual points represent 
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the mean average levels of cytokine from triplicate wells per mouse, and horizontal bars represent median 
averages for each group. Groups were compared using the Mann-Whitney U test (* p <0.05; nd = none 
detected).  
In some cases an elevated level of Th2 cytokines was produced by mice lacking TLR2 co-receptors TLR1 
and TLR6 as well as TLR2 in response to L. mexicana antigens (when compared to WT mice, Figure 26), 
even though TLR1-/- and TLR6-/- mice did not develop the same increased susceptibility phenotype as 
seen in TLR2-/- mice. However, when comparing ratios of protective IFNγ to the regulatory and Th2 
cytokines IL-10, IL-4 and IL-13, DLN from TLR1-/- and TLR6-/- mice produced comparable ratios of 
IFNγ to IL-10, IL-4 or IL-13 as WT mice, with the exception of an elevated IFNγ:IL-4 ratio (i.e. Th1 
skewed) in response to WMAg in the case of TLR1-/- mice infected with L. mexicana amastigotes (Figure 
28). Thus, despite elevated immune responses as detected by ELISA, TLR1-/- and TLR6-/- mice do not 
appear to have a consistently altered type of adaptive immune response to L. mexicana during the chronic 
stage of infection, unlike TLR2-/- mice which are more skewed towards responses which exacerbate 
infection. The adaptive immune responses in TLR4-/- mice infected with L. mexicana did not differ from 
WT in most cases, with the exception of L. mexicana amastigote infected mice where TLR4-/- mice 
showed highly elevated levels of IFNγ produced in response to L. mexicana WMAg (Figure 27), and the 
levels of IFNγ produced by these mice were also greater in relation to IL-10, IL-4 and IL-13 production 
(Figure 28), suggesting stronger protective Th1 responses in these mice. Interestingly, the immune 
response in TLR4-/- mice was skewed greatly towards a protective Th1 response when compared to 
TLR2-/- infected mice, as demonstrated by lower production of Th2 cytokines and higher ratio of IFNγ 
to IL-10, IL-4 and IL-13 in many of the restimulation experiments.  
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 WMAg specific production of cytokines by DLN cells from WT and TLR-/- mice infected Figure 27.
with L. mexicana promastigotes (left) or amastigotes (right). At the end of the infection experiments, DLN 
cells were collected and cultured in vitro for 72 hours and cytokine levels in the supernatants were 
measured for levels of IFNγ (A), IL-10 (B), IL-4 (C) and IL-13 (D) by ELISA. Individual points represent 
the mean average levels of cytokine from triplicate wells per mouse, and horizontal bars represent median 
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averages for each group. Groups were compared using the Mann-Whitney U test (* p <0.05, **p<0.005; 
***p<0.001).  
 
 Ratio of antigen specific Th1 to regulatory and Th2 responses in DLN stimulations from Figure 28.
WT and TLR-/- mice infected with L. mexicana parasites. The ratio of production of IFNγ to IL-10, IL-4 
and IL-13 was calculated using cytokine levels calculated by ELISA from DLN cells stimulated with L. 
mexicana FTAg (A) and WMAg (B) antigen. Individual points represent the ratio of the mean average 
levels of cytokine from triplicate cultures per mouse, and horizontal bars represent median averages for 
each group. Groups were compared using the Mann-Whitney U test (* p <0.05, **p<0.005; ***p<0.001). 
TLR2-/- mice showed increased susceptibility to infection with L. mexicana lpg1-/- parasites as well as WT 
promastigotes and amastigotes, as described earlier. The adaptive immune response in these mice was 
measured by stimulating DLN cells from mice infected for 18 weeks, using only FTAg as the antigen. The 
overall trend was that all cytokines were elevated in the cultures with stimulated TLR2-/- DLN cells, 
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perhaps reflecting the higher parasite burden in these mice. The only cytokine with significantly increased 
levels compared to WT was IL-4. No significant differences in the ratios of IFNγ to other cytokines 
produced was found (data not shown).  
 
 Immune responses in DLN cells from WT and TLR2-/- mice infected with L. mexicana Figure 29.
lpg1-/- promastigotes, week 18. DLN cells were isolated from infected mice at 18 weeks p.i. and were 
restimulated in vitro with parasite antigen and controls for 72 hours. Supernatants were analysed for the 
presence of cytokine using ELISA: IFNγ, IL-10, IL-4, IL-13. Individual points represent the mean average 
levels of cytokine from triplicate wells per mouse, and horizontal bars represent median averages for each 
group. Groups were compared using the Mann-Whitney U test (* p <0.05). 
Levels of antigen specific antibody 
Antibody responses have been closely linked with the chronicity of L. mexicana infection, in particular 
antigen specific IgG1 has been linked with IL-10 production and the chronicity of infection in the 
C57BL/6 model. To explore whether levels of IgG1 and IgG2c are influenced by the absence of any of 
the surface TLRs explored in this study, levels of antigen specific IgG1 and IgG2c in plasma samples 
taken from week 14 infected mice were measured by ELISA. Surprisingly, despite elevated IL-10 and Th2 
responses, infected TLR2-/- mice did not show increased levels of antigen specific IgG1, or ratio of 
IgG1:IgG2c  in their plasma compared to WT, TLR1-/- or TLR6-/- mice. The only difference of note was 
the increased levels of both IgG isotypes in TLR2-/- mice compared to TLR6-/- mice (data not shown). 
No differences in levels of IgG1 or IgG2c specific to lpg1-/- FTAg or WT WMAg antigen specific levels 
were detected in the WT and TLR2-/- mice infected with L. mexicana lpg1-/- promastigotes, or in the ratio 
of these two isotypes (data not shown). Plasma from naïve mice was not found to have any antigen 
specific IgG antibody by ELISA.  
Discussion 
This study explored the role of TLR2, TLR1, TLR6 and TLR4 in infection with L. mexicana. The findings 
reproduce many of those found for L. major infection (presented in Chapter 3), particularly in relation to 
TLR2 where mice lacking this receptor developed more severe disease after infection with both species of 
Leishmania. We were therefore able to explore whether this mechanism of TLR2 mediated control was 
due to activation by LPG by using parasites lacking LPG for infection in the form of both the naturally 
occurring lpg-lacking form (amastigotes) and genetically modified parasites which lack the expression of a 
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full LPG molecule. The initial hypothesis was that activation of TLR2 on APCs during the early stages of 
infection is able to boost the activation of immune responses which help to control parasite replication 
during the acute phase of infection (i.e. Th1 type responses), as proposed by Kavoosi et al (241). As 
TLR2-/- mice developed more severe disease (as measured by increased lesion size) when infected with 
these LPG-lacking parasites as well as WT promastigotes, it appears that the activation of TLR2 by LPG 
is not the sole mechanism of TLR2 mediated control in this model. However, as the increase in parasite 
burden in the lpg1-/- infected TLR2-/- mice was not found to be significant, and the increased disease 
severity in TLR2-/- mice (as measured by parasite burden, lesion size and AUC) was in general more 
apparent in the promastigote infection experiment, this may point to a partial role for LPG-TLR2 
interaction (i.e. in addition to non-LPG activation of TLR2). However, when looking at the lesion 
progression curves from two L. mexicana WT experiments (Figure 21) it appears that the lesions started to 
heal more in the amastigote infection than in the promastigote infection at week 18, which may explain 
the greater variance seen in the parasite burden data from this experiment. For the L. mexicana lpg1-/- 
infection experiment, it is likely that the smaller group size (n=5 compared to n=6-8 in the WT 
experiments) affected the lack of statistical significance in parasite burden being observed in the lesions 
from TLR2-/- mice.  
Although the lpg1-/- parasites used in this experiment lack a full LPG molecule, they retain the ability to 
synthesize the membrane anchor of LPG, which includes the acyl group that was found to be crucial for 
TLR2 activation (26). It is not known whether the anchor of LPG is still expressed in high levels in the 
promastigotes of lpg1-/- parasites. Furthermore, it has been suggested that the phosphoglycan chain, which 
is absent in the lpg1-/- parasites, has an important role in the ability to activate TLR2, as shown by other 
studies comparing LPG isolated from different Leishmania species (241). Osanya et al showed that 
synthetically produced tri-mannose molecules based on the cap of LPG (and ManLAM of M. tuberculosis), 
when coated onto the surface of synthetic beads, were able to signal through TLR2 and MR and enhance 
protective Th1 responses when administered with L. major parasites in vivo (242). However, the 
aforementioned study is the first to attribute the TLR2 activating ability of LPG to the mannose cap, and 
is in contrast to most studies using purified LPG which attribute the ability to activate TLR2 to the lipid 
moiety of the GPI anchor (26, 27), and indeed to other studies of TLR2 ligands which have determined 
the crucial acyl group required for efficient TLR2 activation (156, 162, 163, 243). To determine the 
precise mechanism of TLR2 activation by LPG and/or other parasite derived glycosylated molecules, it is 
important to determine the crystal structure of the ligand-receptor complex, as has been achieved for 
LPS-TLR4-MD2, Pam2-TLR2/6, Pam3-TLR2/1 and dsRNA-TLR3 (164, 166).  
It would be interesting to explore infection of WT and TLR2-/- mice with LPG-deficient parasites of 
other Leishmania species (e.g. L. major) to determine if differences found in the ability to activate Th1 
response via TLR2 influences disease severity, particularly as it has been shown that TLR ligands from 
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related but different species of microbe can induce contrasting adaptive immune responses upon TLR 
activation (244).  Nevertheless, these data do suggest at least that there is activation of TLR2 during 
infection with L. mexicana and this activation occurs when LPG is not present in its typical abundance and 
form. Whether the responsible TLR2 ligand/s involved is/are of parasite origin (e.g GIPLs), or a host 
derived DAMP released in the lesion, is unclear. In addition, whether LPG of other species of Leishmania 
play a role in TLR2 activation also remains unknown, as differences in the host and immune factor 
components involved infections with Leishmania species are numerous and complex, such that 
generalisation across all species cannot be made using the findings from one model (245). For example, 
the role for LPG in virulence differs between species, and appears to be far less important as a virulence 
factor for L. mexicana than it is for L. major and L. donovani (21). Furthermore, a study exploring the 
activation of immune responses to the TLR4 bacterial ligand LPS in vivo, found contrasting responses 
induced by LPS from two species of bacteria even though both were potent activators of DCs: E. coli LPS 
promoted a Th1 type response while Porphyromonas gingivalis LPS promoted a Th2 type response (244). 
The innate immune response therefore possesses an additional level of discrimination between microbes: 
i.e. not only can innate immune receptors act to promote different responses when different 
combinations of PAMP/s and DAMP/s are present, but differences in species-specific structures of 
PAMPs can influence these responses. 
The absence of an apparent role for TLR1 or TLR6 in the TLR2-mediated control of L. mexicana and L. 
major points towards a ligand for TLR2 which has an alternative interaction with the receptor to that 
known for bacterial acylated TLR2 ligands, where the ligand-receptor complex has been elucidated in 
great detail. In these cases, the heterodimerisation of TLR2 with either co-receptor determines the 
specificity of the receptor for its ligand, with TLR2/6 recognising triacylated lipoproteins/lipopeptides 
(156) and TLR2/1 recognising diacylated lipoproteins/lipopeptides (243, 246). Whilst the increased 
resistance to L. major by mice lacking TLR6 was observed in Chapter 3, TLR6-/- mice did not have any 
reduced disease severity or parasite burdens upon infection with L. mexicana in this study. This may 
suggest that TLR6 acts to exacerbate infection with L. major, but not L. mexicana, or may perhaps be a 
reflection of the more chronic nature of L. mexicana infection, and in the reduced Th1 response 
involvement when compared to L. major.  
This study was able to explore more comprehensively the adaptive immune responses in mice infected 
with L. mexicana compared to the experiments presented in Chapter 3 for L. major infection.  These recall-
response results show that mice lacking TLR2 showed increased production of IL-10, IL-4 and IL-13 in 
response to L. mexicana antigen, and display a shift towards a regulatory/Th2 phenotype in terms of 
cytokines produced. All of these cytokines have been linked to exacerbating infection in models of L. 
mexicana (37, 247, 248). Interestingly, whilst the ratio of immune responses to antigen clearly demonstrate 
a diminished IFNγ in comparison to IL-10, IL-4 and IL-13 when compared to other groups, the IFNγ 
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responses to antigen by DLN did not differ from other groups. This suggests that TLR2 activation during 
infection acts to reduce expansion of Th2 cells (and perhaps other subsets producing IL-10), rather than 
driving the protective IFNγ response during infection. As IL-10 can be produced by many different T cell 
subsets, as well as APCs (67), it is not possible to determine which cells are responsible for the elevated 
IL-10 levels reported here. Given this skewing towards a Th2 response, it is surprising that infected 
TLR2-/- mice did not also present with heightened L. mexicana specific IgG1 levels in plasma, as was 
found in the L. major infections and which has been linked to elevated IL-10 and non-healing in L. 
mexicana infection (70, 71). Further studies exploring the expansion of adaptive immune cell lineages are 
needed to investigate the differences in adaptive immune response in TLR2-/- mice. Furthermore, the cell 
type responsible for the TLR2 mediated control of infection is unknown, and could be determined using 
conditional knockout mice. Whilst studies have reported differences in activation by DCs of WT and 
TLR2-/- DCs by Leishmania parasites (200), TLR2 is also expressed on monocytes, neutrophils, T cells and 
B cells as well as on keratinocytes in the skin. Therefore several of these cell types may be important for 
TLR2 function during infection with L. major and L. mexicana.  
This study did not identify any role for TLR4 in L. mexicana infection, as mice lacking TLR4 did not 
present with any difference in lesion sizes or parasite burden compared to WT mice upon infection with 
either promastigote or amastigotes of L. mexicana. This is in contrast to the findings with L. major in the 
previous chapter, as well as with other studies using L. major (202, 203) and L. pifanoi (204) (the latter of 
which is closely related to L. mexicana). The study by Whitaker et al where TLR4 deficient mice were 
found to be more susceptible to infection with L. pifanoi amastigotes only measured the parasite burden at 
1 week post infection in BALB/c mice as the disease outcome (204), whereas in the experiments 
presented here the lesion size and parasite burdens during the chronic stages of infection with L. mexicana 
(week 14) in C57BL/6 mice were comparable to WT (Figure 24). The difference in the disease 
phenotypes between L. major and L. mexicana we have observed may indicate a differential role for TLR4 
in acute and chronic infection or relate to differences in the expression or presentation of putative TLR4 
ligands between species.  
A recent study by Naik et al demonstrated a crucial role for cutaneous tissue commensal bacteria in 
shaping the immune responses to L. major infection (249).  By using either specific pathogen free or germ 
free mice, it was demonstrated that cutaneous tissue commensal bacteria are required for lesion 
development upon infection with L. major, but that commensal bacteria are also required for the 
development of an appropriate adaptive immune responses to L. major infection leading to control of 
parasite numbers (249). Thus, commensal bacteria present on the cutaneous tissue play an important role 
in the immune response in CL infection. Furthermore, this role for the skin bacteria in the immune 
response development was dependent on MyD88 and IL-1R signalling (249).  It is therefore possible that 
exposure of host cells to bacteria at the site of the lesion may be responsible for activating TLR2 (via 
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ligation of bacterial TLR2 PAMPs such as lipopeptides) at the site of the Leishmania lesions, and this 
activation has a positive effect on the control of the infection, although the lack of dependency for TLR1 
or TLR6 would rule out commensal bacteria being the sole cause of the TLR2-dependent disease 
exacerbation. Determining the relative roles of exogenous (commensal bacteria) and endogenous PAMPs 
(Leishmania TLR2 ligands) and DAMPs (host TLR2 ligands) will require further experimental approaches, 
and suggest a complex interplay of one or all of these potential sources of TLR2 ligands on Leishmania 
infection and immune response dynamics. The observation that the difference between WT and TLR2-/- 
mice occurs late on in the infection with Leishmania parasites may suggest a role for a commensal bacterial 
or host derived PAMP/s, to which the host is exposed to more in the later stages of infection, and which 
acts to promote a healing response via activation of TLR2, rather than a role for recognition of parasite 
derived ligands during the initial establishment of infection, although further experimental approaches are 
required to test this hypothesis. 
Whilst many questions are raised by our experiments comparing infections of L. major and L. mexicana in 
mice lacking TLR2, 1, 6 and 4 presented in this Chapter and in Chapter 3, a consistent finding is that 
there is a clear role for TLR2 in controlling disease during infection with these two parasite species, and 
that TLR2 activation during infection promotes a protective immune response through the regulation or 
modulation of Th2 immunity. These findings encouraged us to investigate the use of TLR2 ligands as 
potential vaccine adjuvants for use in vaccines for CL.  
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Chapter 5. Development of a vaccine model using 
recombinant kinetoplastid membrane protein 11 (rKMP-11) 
Abstract 
KMP-11 is a small 11 kDa protein that is conserved amongst kinetoplastid parasites and is expressed on 
the surface of amastigotes and promastigotes of Leishmania, making it an attractive vaccine antigen 
candidate and one that has induced protection in several vaccination models. Furthermore, KMP-11 has 
been shown to be associated with the putative TLR2 ligand present on the Leishmania surface, LPG. For 
these reasons, KMP-11 was chosen as the antigen for use in the development of lipopeptide vaccines for 
protection against L. mexicana infection in mice. Recombinant KMP-11 of L. mexicana was successfully 
cloned and expressed in E. coli, and was purified using nickel affinity chromatography. The rKMP-11 
preparation generated was found to react to the sera from C57BL/6 mice infected with L. mexicana, 
indicating that KMP-11 is immunogenic in this infection model. However, when mice were vaccinated 
with rKMP-11 together with CpG as an adjuvant, they developed similar lesion sizes of a challenge 
infection with L. mexicana to those seen in the control group of mice treated with only CpG adjuvant. 
These results suggest that this experimental vaccine model requires further development for the 
assessment of vaccines comprising of KMP-11 and lipopeptides, as no protective immunity was 
generated using this vaccination regimen with gold standard CpG adjuvants.  
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Introduction 
Background 
As demonstrated in Chapters 3 & 4, TLR2 plays a role in chronic infection with L. major and L. mexicana 
suggesting that TLR2 signalling during infection leads to an immune response, which is favourable for 
control of CL. Thus, it is a rational approach to target TLR2 in a vaccine for CL by using TLR2 ligands as 
adjuvants.  
Rationale for the development of a lipopeptide vaccine comprising KMP-11 
epitopes 
Lipopeptides are the archetypal ligands for TLR2 and their ability to stimulate immune responses has 
been widely reported (250, 251). They are produced naturally, particularly by bacteria, but can also be 
synthetically made to incorporate known epitopes into the peptide moiety, which are linked to the acyl 
moiety responsible for activation of TLR2 heterodimers (see Figure 30). Thus, it is possible to create self-
adjuvanting lipopeptide vaccines which are small, cheap to produce and do not require administration 
with other adjuvants (252). 
 
 The basic structure of a lipopeptide vaccine. Figure taken from (253), with permission.  Figure 30.
Lipopeptides are capable of inducing enhanced immune responses to associated antigens, due to the lipid 
moiety activating and recruiting DCs and other APCs, and increasing the uptake of the vaccine into these 
sentinel cells (251, 252). Importantly, lipopeptide vaccines have been shown to be strong inducers of 
cellular mediated immunity, as well as humoral responses (250-252, 254). Whilst TLR ligands have been 
incorporated as adjuvants in a number of new experimental vaccines for CL, few have explored the use of 
lipopeptides. In one report, Cote-Seirra et al successfully linked part of the Leishmania antigen gp63 to a 
lipoprotein from Pseudomonas aeringinosa and showed it could elicit good levels of protection to disease 
caused by L. major (255), suggesting that such an approach can be successful in a model of CL. This study 
also demonstrated that the lipid moiety is crucial for adjuvancy, as vaccine formulations which lacked this 
portion were unable to elicit strong Th1 responses or confer the same level of protection against 
infectious challenge (255). Thus, lipopeptides are a group of new vaccines, which have several advantages 
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over other vaccine approaches in terms of cost, safety and diverse immunogenic properties, which should 
be evaluated in experimental Leishmania vaccines.  The ability of lipopeptides to activate TLR2 mimics the 
stimulatory activities reported for Leishmania LPG, which can activate TLR2 to produce inflammatory 
responses in vitro (26, 27), although our previous results suggest this does not play a major role in vivo. The 
finding that TLR2 adjuvants have been shown to promote greater immunological memory than TLR4 
adjuvants (256),  which have been used to some success in Leishmania vaccine studies, further suggests 
that lipopeptide vaccines are worth evaluating. 
The chosen vaccine antigen to adopt for this approach was kinetoplastid membrane protein 11 (KMP-
11). KMP-11 is a small 11 kDa membrane associated protein which is abundantly expressed on the 
surface of kinetoplastid parasites (257, 258). Leishmania KMP-11 was originally discovered due to its 
tendency to co-purify with LPG, and was first termed ‘LPG-associated protein’ (258-260). LPG was 
found to be highly immunogenic in early studies and was considered a promising vaccine candidate, as 
mice primed with L. major LPG showed elevated numbers of T cells responsive to L. major (261).  
However, the immunogenic activity of LPG was later attributed to the KMP-11 molecules present in the 
LPG preparations (260), and KMP-11 was subsequently shown to be a potent immunogen and stimulator 
of T cell proliferation in infection models of Trypanosoma and Leishmania parasites (258). Thus, KMP-11 is 
a conserved and important membrane molecule of Leishmania parasites, which is antigenic during 
infection, making it a potential vaccine candidate. Epitope mapping of KMP-11 has shown there are 30 
MHC class-I restricted epitopes within the protein that can induce production of IFNγ by human CD8+ 
T cells (262). KMP-11 is expressed in large quantities on the parasite cell surface (259) of both 
promastigotes and amastigotes (263). A DNA vaccine containing the gene for KMP-11 showed strong 
levels of protection against infection of highly susceptible golden hamsters by two strains of L. donovani 
(134). Another KMP-11 vaccine which was generated by making hybrid dendritic cells gave protection in 
a mouse model of L. donovani and induced a strong CTL response (139). KMP-11 has shown strong 
promise as a vaccine antigen in L. donovani models of infection, some promise for use in a vaccine for L. 
major although rIL-12 is required (135), but has yet to be tested in models of new-world CL.  
Aim of the study 
To overall aim of this study was to develop self-adjuvanting lipopeptide vaccines, comprising of an 
antigenic epitope of KMP-11 and acyl moiety capable of activating the immune system via TLR2 
signalling, thus mimicking the natural activation of the immune system by LPG and KMP-11 in 
Leishmania infection.  However, as KMP-11 has not been tested before as a vaccine for a L. mexicana 
model of CL, we first sought to clone and purify recombinant L. mexicana KMP-11 and explore its use as 
a vaccine antigen in this model in recombinant protein form, in combination with TLR ligand adjuvants.  
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Methods 
Cloning, expression and purification of recombinant KMP-11 
The KMP-11 gene was cloned from L. mexicana DNA using a high fidelity enzyme and was then 
incorporated into the TOPO2.1 vector (Invitrogen), as described. After confirmation of correct KMP-11 
gene incorporation using PCR, restriction digest and sequencing analysis, the gene was cleaved from 
TOPO2.1 and sub-cloned into the expression vector pQE-30 (Qiagen). The expression and purification 
of rKMP-11 was then carried out, as described in detail in Chapter 2.  
Immunoreactivity of antibodies to recombinant proteins  
To explore the immunoreactivity of rKMP-11, rDHFR, and L. mexicana lysates to antibodies, western 
blots were performed after protein separation by SDS PAGE (see Chapter 2). The following antibodies 
were used at the indicated concentrations: anti-His antibody (Sigma, 1:3,000 dilution), and pooled plasma 
samples from L. mexicana infected mice (collected as indicated in Chapter 2; 1:150).  
Mice, vaccinations, parasites and infection 
All procedures involving live animals were performed at the BSU in the Duncan Building, University of 
Liverpool. Female C57BL/6 mice (8-10 weeks) were used for the vaccine experiment. For the pilot study, 
3 mice per group were vaccinated subcutaneously with either 10 µg rKMP-11 and 50 µg CpG adjuvant, or 
50 µg CpG adjuvant alone, in a total volume of 20 µl DPBS. Each mouse was given two doses of the 
same vaccine; the first dose was administered s.c. to the upper side of the LHF, and the second dose was 
administered s.c. to the shaven rump two weeks later. L. mexicana M379 promastigotes were grown from 
lesion amastigotes in complete M199 as described, and were sub-passaged twice before use as an 
infectious challenge. Four weeks after the second dose, mice were challenged with 105 L. mexicana 
promastigotes in 20 µl HBSS s.c. to the upper side of the RHF. Lesion development was monitored by 
taking weekly measurements of the thickness of the infected RHF and uninfected contralateral foot 
(LHF) using a dial caliper.  
Results 
Cloning of rKMP-11 
To explore the use of KMP-11 as a vaccine antigen for L. mexicana infection of C57BL/6 mice, we 
generated a recombinant L. mexicana KMP-11 protein. To make recombinant KMP-11, the KMP-11 gene 
was first amplified from L. mexicana DNA by PCR using a high fidelity polymerase and the presence of a 
product of the correct size (c. 300 bp) was determined by visualisation on an agarose gel (Figure 31 A). 
After the addition of poly-A tails and purification of the product, the KMP-11 gene was inserted into the 
TOPO 2.1 vector and the ligated vector was used to transform competent E. coli cells. To screen for 
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uptake of TOPO-KMP-11, colonies were screened by blue-white screening (not shown), PCR for the 
KMP-11 gene, and restriction enzyme analysis (Figure 31 B and C respectively).  
 
 Cloning of Leishmania KMP-11 into TOPO 2.1 vector. The 273 bp KMP-11 gene was Figure 31.
amplified from genomic DNA of L. mexicana (A) before ligation into the TOPO vector. White and blue 
colonies were selected for further analysis after transformation of E. coli cells with ligated TOPO-KMP-11 
vector. Each was tested for presence of the KMP-11 gene by PCR (B) and for the presence of TOPO-KMP-
11 by restriction digest analysis using the SalI and HindII enzymes (C). 
In screening by PCR, all of the white colonies as well as two blue colonies (expected to be negative for 
KMP-11 gene but which have taken up TOPO vector) showed a positive result for the presence of the 
KMP-11 gene. In the restriction digest analysis, two enzymes were used: SalI was chosen as the only 
target site for this enzyme is within the KMP-11 gene, and HindIII as it had two target sites in TOPO-
KMP-11 and only one in TOPO alone. The restriction digest maps for the two plasmids are shown in 
Appendix 3. Despite testing positive for the KMP-11 gene, colonies w4, b1 and b2 did not harbour 
TOPO-KMP-11 as they are uncut by the SalI enzyme and did not give 2 distinct bands when cut with 
120 
 
 
HindIII (Figure 31C). This suggests that the KMP-11 gene was taken up by these colonies but not in the 
complete TOPO-KMP-11 form desired. Therefore, the colonies w1, w2, w3, w5 and w6 were selected for 
sequencing analysis. All of the sequenced TOPO-KMP-11 plasmids showed the presence of a KMP-11 
gene from L. mexicana with 100% homology to one of the published genes of L. mexicana (LmxM.34.2221 
GeneDB) and 98 or 99% homology with the other two L. mexicana genes and 97% homology to L. major 
KMP-11 (LmjF.35.2210, GeneDB) at the nucleotide sequence level. 
Expression and purification of rKMP-11 
For expression of the L. mexicana KMP-11 gene, the BamHI-KMP-11-HindIII construct was cleaved 
from TOPO-KMP-11 by restriction digest and ligated into the pQE30 expression vector. The ligated 
pQE30-KMP-11 vector was used to transform competent E. coli M15 [pREP4] cells. As with TOPO-
KMP-11, colonies which grew on the antibiotic containing plates were selected for further growth and 
analysis to check for transformation with pQE30-KMP-11 by PCR, restriction digest analysis and 
sequencing. The sequencing alignment results for one of the selected plasmids are shown below in Figure 
32. All of the purified pQE-30-KMP-11 plasmids from screened colonies were found to align with 100% 
homology with the KMP-11-3 gene of L. mexicana (Accession number LmxM.34.2221). Furthermore, 
transformed colonies were found to express a protein of approximately 11kDa after induction of rKMP-
11 expression by IPTG, as assessed by SDS PAGE (not shown). 
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 Alignment of pQE30-KMP-11 sequence with Leishmania KMP-11 genes. The plasmids Figure 32.
from three pQE30-KMP-11 positively selected colonies were sequenced by Cardiff DNA Sequencing Core. 
The sequences were aligned against L. mexicana and L. major KMP-11 genes as published on GeneDB. 
All of the pQE30-KMP-11 plasmids shown 100% homology with LmxM.34.2221 (KMP-11 3 gene of L. 
mexicana) – this image shows the alignment of one pQE-30-KMP-11 sample with the KMP-11 genes; the 
matching sequences are highlighted in yellow.  
Large volumes of E. coli [pQE30-KMP-11, pREP4] cells were therefore grown in the presence of IPTG 
to induce production of rKMP-11. The cell lysates of these colonies were passed through Ni-NTA 
columns and purified as indicated, and the purity was assessed by SDS PAGE. Figure 33 shows an SDS 
PAGE of rKMP-11 collected from a Ni-NTA column by eluting with increasing concentrations of 
imidazole. A strong band of rKMP-11 protein is visible at the appropriate size in many of the fractions 
collected after eluting with 100 mM imidazole and above (c 11 kDa), and a faint band at approximately 25 
kDa in size is also visible in the fractions, which is likely to indicate dimers of rKMP-11.  
PQE30-KMP-11      TCTACGACAGTTCTCACTATGAGAGGATCGCATCACCATCACCATCACGGATCCATGGCC 60 
LmxM.34.2220      ------------------------------------------------------ATGGCC 6 
LmxM.34.2221      ------------------------------------------------------ATGGCC 6 
LmxM.34.2210      ------------------------------------------------------ATGGCC 6 
LmjF35.2210       ------------------------------------------------------ATGGCC 6 
LmjF35.2220       ------------------------------------------------------ATGGCC 6 
                                                                        ****** 
 
PQE30-KMP-11      ACCACGTACGAGGAGTTTTCGGCGAAGCTGGACCGCCTGGATGAGGAGTTCAACCGGAAG 120 
LmxM.34.2220      ACCACGTACGAGGAGTTTTCGGCGAAGCTGGACCGCCTGGATGAGGAGTTCAACCGGAAG 66 
LmxM.34.2221      ACCACGTACGAGGAGTTTTCGGCGAAGCTGGACCGCCTGGATGAGGAGTTCAACCGGAAG 66 
LmxM.34.2210      ACCACGTACGAGGAGTTTTCGGCGAAGCTGGACCGCCTGGATGAGGAGTTCAACCGGAAG 66 
LmjF35.2210       ACCACGTACGAGGAGTTCTCGGCGAAGCTGGACCGCCTGGATGAGGAGTTCAACAGGAAG 66 
LmjF35.2220       ACCACGTACGAGGAGTTCTCGGCGAAGCTGGACCGCCTGGATGAGGAGTTCAACAGGAAG 66 
                  ***************** ************************************ ***** 
 
PQE30-KMP-11      ATGCAGGAGCAGAACGCCAAGTTCTTTGCGGACAAGCCGGATGAGTCGACGCTGTCGCCC 180 
LmxM.34.2220      ATGCAGGAGCAGAACGCCAAGTTCTTTGCGGACAAGCCGGATGAGTCGACGCTGTCGCCC 126 
LmxM.34.2221      ATGCAGGAGCAGAACGCCAAGTTCTTTGCGGACAAGCCGGATGAGTCGACGCTGTCGCCC 126 
LmxM.34.2210      ATGCAGGAGCAGAACGCCAAGTTCTTTGCGGACAAGCCGGATGAGTCGACGCTGTCGCCC 126 
LmjF35.2210       ATGCAGGAACAGAACGCCAAGTTCTTTGCGGACAAGCCGGATGAGTCGACGCTGTCGCCC 126 
LmjF35.2220       ATGCAGGAACAGAACGCCAAGTTCTTTGCGGACAAGCCGGATGAGTCGACGCTGTCGCCC 126 
                  ******** *************************************************** 
 
PQE30-KMP-11      GAGATGAAGGAGCACTACGAGAAGTTCGAGCGCATGATCAAGGAGCACACAGACAAGTTC 240 
LmxM.34.2220      GAGATGAAGGAGCACTACGAGAAGTTCGAGCGCATGACCAAGGAGCACACAGACAAGTTC 186 
LmxM.34.2221      GAGATGAAGGAGCACTACGAGAAGTTCGAGCGCATGATCAAGGAGCACACAGACAAGTTC 186 
LmxM.34.2210      GAGATGAAGGAGCACTACGAGAAGTTCGAGCGCATGATCAAGGAGCACACAGACAAGTTC 186 
LmjF35.2210       GAGATGAAGGAGCACTACGAGAAGTTCGAGCGCATGATCAAGGAGCACACAGAGAAGTTC 186 
LmjF35.2220       GAGATGAAGGAGCACTACGAGAAGTTCGAGCGCATGATCAAGGAGCACACAGAGAAGTTC 186 
                  ************************************* *************** ****** 
 
PQE30-KMP-11      AACAAGAAGATGCACGAGCACTCGGAGCACTTCAAGCAGAAGTTCGCCGAGCTGCTTGAG 300 
LmxM.34.2220      AACAAGAAGATGCACGAGCACTCGGAGCACTTCAAGCAGAAGTTCGCCGAGCTGCTTGAG 246 
LmxM.34.2221      AACAAGAAGATGCACGAGCACTCGGAGCACTTCAAGCAGAAGTTCGCCGAGCTGCTTGAG 246 
LmxM.34.2210      AACAAGAAGATGCACGAGCACTCGGAGCACTTCAAGCAGAAGTTCGCCGAGCTGCTTGAG 246 
LmjF35.2210       AACAAGAAGATGCACGAGCACTCGGAGCACTTCAAGCAGAAGTTCGCTGAGCTGCTCGAG 246 
LmjF35.2220       AACAAGAAGATGCACGAGCACTCGGAGCACTTCAAGCAGAAGTTCGCCGAGCTGCTCGAG 246 
                  *********************************************** ******** *** 
 
PQE30-KMP-11      CAGCAGAAGGCTGCGCAGTACCCGTCCAAGTAAAAGCTTAATTAGCTGAGCTTGGACTCC 360 
LmxM.34.2220      CAGCAGAAGGCTGCGCAGTACCCGTCCAAGTAA--------------------------- 279 
LmxM.34.2221      CAGCAGAAGGCTGCGCAGTACCCGTCCAAGTAA--------------------------- 279 
LmxM.34.2210      CAGCAGAAGGCTGCGCAGAACATGTGCAAGTAG--------------------------- 279 
LmjF35.2210       CAGCAGAAGGCTGCGCAGTACCCGTCCAAGTAA--------------------------- 279 
LmjF35.2220       CAGCAGAAGGCTGCGCAGTACCCGTCCAAGTGA--------------------------- 279 
                  ****************** **  ** *****                              
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 Purification of rKMP-11. Fractions were collected after addition of buffer containing Figure 33.
increasing concentrations of imidazole. Codes: M = Marker; Ly = Lysate of culture; Ly+ = Lysate of 
induced culture; FT = flow-through.  
After first purifying rKMP-11 using a gravity column, and then with the AktaPrime system, the purity was 
found to be satisfactory by SDS PAGE analysis. Selected fractions were pooled, dialysed to exchange into 
a DPBS buffer, depleted of endotoxin and filter sterilised. The endotoxin levels of rKMP-11 was found 
to be between 380 -810 EU/mg protein before, and 14.4 EU/mg after removal of endotoxin. According 
to Brito and Singh of Novartis Vaccines, levels of up to 20 EU/mg are acceptable for recombinant 
protein preparations for use in pre-clinical vaccines (264).  
Immunogenicity of rKMP-11 in L. mexicana infection 
To test the immunogenicity of KMP-11 in the L. mexicana model of infection of C57BL/6 mice, the 
reactivity of sera obtained from L. mexicana infected C57BL/6 mice to rKMP-11 was analysed by western 
blot. It was found that the sera from infected C57BL/6 mice reacted to rKMP-11, as shown in Figure 34. 
As controls, samples were also checked for reactivity to the anti-His tag and anti-KMP-11 antibodies. The 
anti-His antibody showed reactivity to rKMP-11 and control rDHFR, but not to the parasite lysates, as 
expected (data not shown).  
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 Plasma from L. mexicana infected mice recognises rKMP-11 in reduced and non-reduced Figure 34.
forms.  Lysates from L. mexicana and rKMP-11 samples in different dilutions were either reduced (R) or 
not (NR) before separating by SDS-PAGE and then transferring onto a PVDF membrane. The membrane 
was incubated with pooled plasma (1:150) collected from L. mexicana infected C57BL/6 mice, prior to 
incubation with secondary anti-mouse–HRP conjugated antibody and developed for 1 minute. 
Representative of two experiments.  
Vaccine efficacy – pilot study 
As KMP-11 has not previously been tested as the vaccine antigen in a model of L. mexicana infection, we 
carried out a small pilot experiment using two groups of 3 mice. The test group was vaccinated with 
rKMP-11 plus the gold standard adjuvant for Leishmania vaccines, TLR9 ligand CpG, whilst the control 
group received CpG adjuvant alone. CpG was chosen as it is a TLR ligand which drives strong Th1 
responses and has been shown to improve the efficacy of Leishmania protein and whole cell vaccines (265, 
266). Mice were vaccinated twice with the same vaccine preparation and then challenged 4 weeks after the 
final dose by s.c. injection of 105 L. mexicana promastigotes to the top of the RHF. As shown in Figure 
35, lesions developed in both groups of mice beginning at approximately 11 weeks post infection. Both 
groups then showed a progressive increase in lesion size until the end of the experiment at 19 weeks p.i.  
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 Lesion development in mice vaccinated with rKMP-11 + CpG adjuvant (green) or CpG Figure 35.
adjuvant alone (pink) after needles challenge with 105 L. mexicana promastigotes. Groups were compared 
using the Mann-Whitney U test.  
Despite the average lesion size of the rKMP-11 + CpG vaccinated mice being consistently smaller than 
those that were vaccinated with CpG alone, the difference was not significant. Whilst this may be due to a 
the small group size (n=3) used in this trial experiment, the lack of a significant level of protection 
suggests that vaccination with rKMP-11 did not replicate the efficacy reported in other vaccination 
models.  
Given the poor efficacy of rKMP-11 vaccination in this pilot experiment, further experimentation was 
suspended due to time constraints.  
Discussion 
KMP-11 has been tested as a vaccine candidate in several different types of experimental vaccines, mostly 
using L. donovani or L. chagasi models of infection in mice. Whilst KMP-11 of L. mexicana has not been 
explored as a vaccine candidate, it has more than 95% homology to other Leishmania spp. KMP-11, and 
studies using the closely related L. amazonensis have shown that KMP-11 is abundantly expressed in the 
amastigote stage as well as the promastigote stage, and is an important membrane component (263), 
suggesting that it is also a potential vaccine candidate for new-world CL. Here, we have shown that L. 
mexicana rKMP-11 can be successfully produced in an E. coli expression system, as has been achieved with 
KMP-11 from other Leishmania species elsewhere (267). Furthermore, KMP-11 appears to be 
immunogenic in L. mexicana infection, as indicated by the binding of antibodies from infected C57BL/6 
mice to the rKMP-11 protein in western blots. However, our pilot study suggested that rKMP-11 did not 
provide significant protection against disease caused by L. mexicana when administered with the gold-
standard CpG adjuvant, although a small reduction in lesion size was observed compared to the control 
vaccinated mice.  
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The CpG adjuvant has proven successful at improving efficacy in protein vaccines for Leishmania 
infection in mice by others (266, 268). However, these studies used either L. donovani or L. major for the 
challenge infection, and therefore the efficacy of CpG as an adjuvant has not been tested in vaccines 
against L. mexicana. In addition to this, KMP-11-containing vaccines, which have had success in inducing 
protection by other groups have typically used DNA vaccination, rather than in a recombinant protein 
form (134), which may be a more robust vaccination strategy.  
It is possible that despite lesion development in all mice in this experiment, the control group used was 
protected to some extent by the CpG adjuvant alone. Others have reported a protective effect of the 
CpG adjuvant when used alone as a vaccine in mice (265, 269).  Furthermore, Verthelyi et al found that in 
Rhesus macaques, CpG ODNs reduced parasite burden and lesion development when used as a 
prophylactic vaccine for protection against L. amazonesis (closely related to L. mexicana) in the absence of 
antigen (270). A study also using L. amazonensis infection (but in BALB/c mice) identified a similar 
protective effect of the TLR4 ligand ONO-4007 when used alone in a vaccine, compared to either a PBS 
or antigen alone vaccination (271). Thus, we may have observed no difference between the rKMP-11 + 
CpG and CpG groups in this study due to both benefitting from a protective prophylactic effect of the 
CpG adjuvant alone. It would be interesting to repeat the experiment using a PBS or antigen alone 
vaccine group, to test this hypothesis.   
The aim of the pilot study was to determine whether a vaccine consisting of rKMP-11 and CpG adjuvant 
could provide sufficient protection in our model to act as a positive control, against which to compare 
other vaccine formulations consisting of lipopeptide adjuvants and rKMP-11. As we did not demonstrate 
efficacy with our rKMP-11 vaccine, we decided to investigate the use of lipopeptide vaccines with whole 
cell antigen vaccines (ALM) that have consistently demonstrated efficacy in several Leishmania vaccine 
models.   
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Chapter 6. Lipopeptides as adjuvants for a Leishmania 
vaccine  
Abstract 
TLR2 plays a role in the control of CL as demonstrated by exacerbated disease in TLR2-/- mice upon 
infection with either L. major or L. mexicana parasites. Studies exploring the immune response in infected 
TLR2-/- mice suggest that TLR2 activation plays a role in promoting a protective immune response to 
Leishmania, which helps clear the infection faster and reduce disease severity. We therefore proposed that 
TLR2 ligands could be beneficial as adjuvants for use in Leishmania vaccines. To test this hypothesis, we 
explored the use of Pam2 and Pam3 lipopeptide adjuvants, which activate TLR2/6 and TLR2/1 
heterodimers respectively, in a vaccine model for CL using the whole cell antigen ALM.  The lipopeptides 
were compared to the gold-standard Th1-inducing TLR ligand adjuvant CpG in their ability to provide 
protection against challenge with L. major in C57BL/6 mice. Surprisingly, we found that the use of 
lipopeptides in ALM containing vaccines did not provide any protection for mice upon infection with L. 
major, and in the case of Pam2, the adjuvant even exacerbated the disease severity in vaccinated mice, in 
contrast to protective immunity induce by vaccination with ALM + CpG. Assessment of the immune 
response in these mice indicated that Pam2, and to a lesser extent Pam3, were able to elevate antigen 
specific immune responses to L. major, but the immune response displayed a skewed Th2 phenotype, 
particularly characterised by elevated IgG1 levels. We observed that vaccines containing CpG and Pam2 
adjuvants resulted in local reactions at the site of vaccination, but that this did not relate to vaccine 
efficacy. When the local response was further explored in mice exposed to lipopeptides alone, we noticed 
a difference in the time course of localised reactions between Pam2 and Pam3. In conclusion, Pam2 and 
Pam3 were not suitable adjuvants in an ALM containing vaccine for protection against L. major, as they 
both elicited a Th2 immune response, and Pam2 resulted in exacerbated disease. 
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Introduction 
Background 
In the previous chapter we attempted to develop a vaccine using rKMP-11 in a model using L. mexicana, 
but we were unable to show significant protection when the gold-standard Th1 adjuvant, CpG was 
included in a vaccine with rKMP-11. We therefore decided to test the use of lipopeptides as vaccine 
adjuvants in the well characterised whole cell antigen vaccine (ALM) model against L. major.  
The use of ALM vaccines in mouse vaccine models for L. major infection 
A widely used vaccine model for CL is where heat-killed autoclaved L. major (ALM) parasites, are given in 
two doses (prime and boost) prior to challenge with L. major promastigotes (53, 265, 268, 272). Killed, 
whole-cell Leishmania preparations have been widely used for several decades in human and mouse 
vaccine studies for protection against infection with Leishmania parasites (226, 268, 273-275). ALM is 
obtained by heat-killing large numbers of cultured parasites, and this is the most widely used approach for 
the preparation of whole cell vaccine antigens (others include freeze-thawing or formalin fixing parasites 
(265, 275)). Whilst the efficacy of ALM vaccines in humans studies was found to be very poor overall, the 
success was greater in trials conducted in South American countries when compared to the middle east or 
Africa (118, 123, 273, 276).  
The BCG vaccine has been explored as an adjuvant for the ALM vaccine in human trials, but ALM + 
BCG was not found to significantly improve upon the efficacy of protection to VL compared to BCG 
alone (118, 273). However, this may be related to a prophylactic effect of BCG alone, due to either cross-
reactivity of antigens in BCG and Leishmania parasite, or to immune-stimulatory (adjuvant) effects of 
BCG on those who were naturally exposed to infection during or around the time of BCG exposure 
(273).  
In mice, the ALM vaccine has shown to provide good efficacy to needle challenge of infection with 
Leishmania parasites, in a number of different studies (268, 277). Whilst the ability of ALM vaccines to 
provide long term protective immunity has been disputed, Okwor et al recently demonstrated that 
repeated inoculation with ALM could result in the expansion of sufficient Th1 memory T cells specific 
for L. major and this strategy was as effective as live parasites at providing protection to challenge up to 13 
weeks after the final dose was given (277). This demonstrates that the use of first generation killed 
parasite vaccines can provide protection to L. major when delivered in the appropriate manner. The use of 
immune responses boosting adjuvants may be an alternative strategy to multiple doses in increasing the 
efficacy of ALM vaccines. Furthermore, this model of vaccination provides a good foundation on which 
to compare the use of TLR2-stimulating lipopeptide adjuvants to the TLR9-stimulating gold-standard 
CpG adjuvant. Walker et al explored the use of CpG as an adjuvant in a vaccine containing killed L. major 
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parasites (in the form of freeze-thawed parasites), which elicited a strong Th1 response to L. major in 
susceptible BALB/c mice, and provided protection in 40% of individuals receiving the vaccine (265). 
Aim of the study 
In this study, we aimed to explore the efficacy of Pam2 and Pam3 as adjuvants in a vaccine against L. 
major. Their efficacy was compared to the gold standard Th1-driving TLR9 ligand CpG. We also explored 
the use of TLR2 ligands Pam2 and Pam3 in combination with CpG, as synergy of TLR responses has 
proved effective in boosting Th1 responses in other studies (278). The C57BL/6 model of infection was 
chosen, as this strain of mouse mounts immune responses which are more comparable to those seen in 
human infections, as opposed to the Th2 responses which occur in the BALB/c model (73).  
Methods 
Mice and parasites 
All procedures involving live animals were performed at the BSU in the Duncan Building, University of 
Liverpool. Female C57BL/6 mice were purchased from Charles River, and were 8-10 weeks at the start of 
each experiment. L. major FV1 promastigote parasites were cultured in complete M199 medium, and were 
sub-passaged no more than two times after culture was established from lesion-derived amastigotes. For 
the infectious challenge, parasites were enriched for metacyclics as described in Chapter 2.  
Vaccinations and challenge infection 
C57BL/6 mice (7-8 per group) were vaccinated twice with the same vaccine dose in a 20 µl volume; the 
first dose was given s.c to the upper side of the LHF, and the second dose was given s.c to the shaven 
rump two weeks later. There were 7 different groups each receiving one of the following vaccines (the 
components of which are given in Table 6): PBS; Pam2 + Pam3 + CpG (Adjuvants only); ALM; ALM + 
CpG; ALM + Pam2; ALM + Pam3; ALM + Adjuvants. Four weeks after the second vaccine dose, mice 
were challenged by s.c. injection of 105 metacyclic-enriched L. major FV1 parasites, in 20 µl HBSS, to the 
upper side of the RHF. The vaccination schedule and groups are indicated in Figure 36.  
To explore the local reactions to lipopeptides adjuvants, C57BL/6 mice (3/group) were given s.c. 
injections of the following in 20 µl HBSS: 50 µg ALM + 16.14 µg Pam2; 16.14 µg Pam2; 16.19 µg Pam3; 
8.07 µg Pam2; 8.10 µg Pam3; 1.61 µg Pam2; 1.62 µg Pam3. 
Measurement of local reactions at the site of immunisation on the foot, and lesion size on the infected 
foot, were measured using the same method, i.e. by measuring the thickness of the two hind feet using a 
dial calliper and subtracting the thickness of the unexposed/uninfected foot from that of the 
exposed/infected foot (mm).  
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Immune responses 
To assess recall responses in the infected vaccinated mice, DLN cells and splenocytes were collected, 
processed and used at a concentration of 8 x 105 cells/ well. Cells were cultured for 72 hours in the 
presence of either 20 µg/ml L. major FTAg, 2.5 µg/ml ConA or media alone in a total volume of 200 
µl/well. Culture supernatants were then removed and stored at -20°C until analysis for IFNγ, IL-10, IL-4 
and IL-13 levels using cytokine ELISA. The levels of antigen specific IgG1 and IgG2c in plasma samples 
from mice were measured using antibody ELISA with L. major FTAg as the capture antigen. 
Results 
Vaccine efficacy – disease severity 
Mice were divided into seven groups and were vaccinated with two doses of the same vaccine, as 
indicated by the vaccine schedule outlined in Figure 36. At four weeks after the second dose of vaccine 
was given, mice were challenged in the RHF with 105 L. major promastigotes. Lesion development was 
monitored by taking weekly measurements of the infected and uninfected hind feet and recording the 
difference. These results are displayed in Figure 37A. “Sham vaccinated” mice received two doses of PBS 
in their vaccination regime, so are effectively naïve controls. In these mice, lesions were evident at 2 
weeks p.i. and peaked at week 7, before beginning to reduce in size. Mice inoculated with the adjuvants 
only were included as a control group to assess for any non-specific protective effect of the adjuvant 
components in absence of antigen. These mice showed lesions that were not significantly different in size 
from naïve controls, suggesting that the combined adjuvants alone did not have a protective effect on 
lesion development when administered prior to infection in the absence of antigen. 
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 The vaccination and challenge schedule. All mice received two doses of the same vaccine, Figure 36.
with a two week interval, and were then challenged with L. major 4 weeks after the last dose, as displayed 
on the schedule (A). There were 7 groups of mice (n = 7-8) in the experiment, and the components in the 
vaccines are indicated in (B) along with the symbol used for each group (as used in Figures in the Chapter 
from hereon). Vaccine doses and infectious challenge were administered s.c. to distinct tissue sites, as 
indicated in (C).  
Those vaccinated with the killed cell vaccine ALM alone, showed a reduced lesion size in the later stages 
of infection, but this was not found to be significant at any time point. Consistent with these results, the 
AUC values for the Adjuvants only and ALM vaccinated groups did not differ from the PBS group 
(Figure 37B). When the gold standard CpG adjuvant was included in the ALM vaccine, however, mice 
developed smaller lesions compared to either PBS or ALM vaccinated mice, and a lower average AUC, 
indicating that this adjuvant acts to increase protection and reduce lesion development. There was no 
difference in lesion development when ALM + Pam3 was used as the vaccine, compared to either the 
naïve control group or the ALM vaccinated group, indicating that this adjuvant had no effect on the 
efficacy of the ALM vaccine. Notably, when Pam2 was used as an adjuvant with ALM, the lesion sizes 
were increased when compared to PBS and ALM vaccinated groups at several time points post 4 weeks 
p.i., and the AUC values were also increased in this group over the course of the experiment. However, 
when both lipopeptide adjuvants were included in the ALM vaccine in addition to the protective CpG 
adjuvant, lesions sizes and AUC values were reduced when compared to the PBS group, but not the ALM 
vaccinated group, demonstrating little or no impact on the addition of lipopeptides to protective CpG 
efficacy. 
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 Development of disease in mice vaccinated with ALM and adjuvants. Lesion Figure 37.
development was monitored by measuring the difference in thickness of the infected and uninfected feet 
(RHF-LHF) in mm (A); mean values + SEM are shown. The overall disease severity is summarised by 
calculating the area under the curve (AUC) from weekly lesion size data sets (B) (mean + SEM is shown), 
and by calculating the parasite burden in infected tissue after 10 weeks, using qPCR (C) (points represent 
individual parasite burdens and horizontal bars represent median values). Groups were compared using 
the Mann-Whitney U test (* p <0.05). 
Vaccine efficacy – parasite burden 
The parasite burdens of infected feet were determined by qPCR at the end of the experiment, after 9 
weeks of infection with L. major, as shown in Figure 37C. The results show a high degree of variation in 
parasite burdens, between and within groups. As a result, few statistically significant differences were 
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found between groups when they were compared using the non-parametric bivariate analysis (Mann-
Whitney U test). Those vaccines which displayed protective effect as determined by a reduction in lesion 
size and AUC (i.e. ALM + CpG and ALM + Adjuvants) did not show a reduction in parasite burden 
compared to either PBS or ALM vaccinated controls. In fact the lowest parasite burdens were seen in the 
ALM vaccinated group. The groups which received vaccines containing lipopeptides displayed the highest 
parasite burdens, with the mice vaccinated with just adjuvants (Adjuvants only) or ALM + Pam3 having 
significantly greater parasite burdens than the ALM vaccinated controls. Surprisingly, the ALM + Pam2 
vaccinated mice did not have significantly greater parasite burdens compared to either control group, 
despite the greatest average parasite burden being in this group as well as the individual with the highest 
burden. The variation in parasite burden within the ALM + Pam2 vaccinated group of mice was notable, 
with almost a 5-log difference between those presenting with the highest and lowest parasite loads.  
As with the parasite burden data from the L. major infection experiments in Chapter 3, the variation in the 
dataset from the vaccinated mice was found to be greater than the mean values for each group, suggesting 
extra-Poisson dispersal. The differences between groups were then also estimated using parametric 
methods, by fitting the data to a negative binomial model using a generalised linear function. The results 
are outlined in Appendix 4. This approach to statistical analysis found significantly elevated parasite 
burdens in the ALM + Pam2, ALM + Pam3 and Adjuvants only vaccinated groups (*** p<0.001 in all 
cases) when compared to ALM and PBS vaccinated controls. Furthermore, the ALM vaccinated mice had 
significantly reduced parasite burdens when compared to the PBS vaccinated group (* p<0.05).  
To summarise, the vaccines which showed efficacy in reducing lesion size and AUC (i.e. those containing 
both ALM and CpG) did not give significant reduction in parasite burden at the lesion site at 9 weeks p.i., 
whilst those vaccines containing lipopeptides (except where ALM and CpG were both present also), 
resulted in elevated average parasite burdens at 9 weeks p.i.   
Spontaneous production of cytokines by splenocytes from vaccinated mice 
infected for 9 weeks with L. major 
After 9 weeks of infection, the splenocytes of infected vaccinated mice were recovered and processed for 
in vitro stimulation with antigen. Spontaneous production of Th1, regulatory and Th2 cytokines in culture 
was detected for individuals across all vaccination groups, as shown in Figure 38A. Surprisingly, the ALM 
vaccinated group, which had the lowest parasite burdens at week 9 p.i., presented with spontaneous 
production of the regulatory cytokine IL-10 which was significantly greater than the PBS control group, 
and those vaccinated with ALM + Pam3 or ALM + Adjuvants. Low levels of IL-4 were spontaneously 
produced by splenocytes of mice from all groups, although these were significantly lower in the ALM 
+Pam3 vaccinated group, compared to others.  
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 Cytokine responses after 9 weeks of infection with L. major in mice vaccinated with ALM Figure 38.
vaccines +/- adjuvants. Mice were vaccinated twice with the indicated vaccines, and were challenged 4 
weeks after the final dose with L. major. After 9 weeks of infection, mice were culled and their splenocytes 
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were processed and cultured in the presence of FTAg and controls. The levels of IFNγ, IL-10, IL-4 and IL-
13 were measured by ELISA; (A) shows the spontaneous production of these cytokines in cultures, (B) 
represents the FTAg specific responses (adjusting for spontaneous production). Individual points 
represent the mean average levels of cytokine from triplicate wells per mouse, and horizontal bars 
represent median averages for each group. Groups were compared using the Mann-Whitney U test: 
differences to the control PBS group are indicated above the group data points, whilst differences between 
vaccinated groups are indicated by connecting bars (p<0.05 *; p<0.005 **; p<0.001***).    
Some mice produced high levels of IL-13 spontaneously in culture, and mice vaccinated with ALM or 
ALM + Pam2 produced significantly more IL-13 compared to the sham vaccinated (PBS) mice. 
Interestingly, the pattern of spontaneous production of IL-4 and IL-13 was not comparable, despite these 
both being Th2 cytokines. 
In vitro recall responses from splenocytes, at 9 weeks post infection 
The antigen specific responses by splenocytes were determined by subtracting the spontaneous 
production of cytokines from the levels of cytokine produced in the presence of L. major FTAg (Figure 
38B). Mice vaccinated with ALM + Pam2 showed elevated production of the protective Th1 cytokine 
IFNγ compared to 5 of the 6 other groups of mice. No differences in antigen specific IL-10 or IL-13 
were detected between groups. However, notably a number of individuals produced lower levels of IL-13 
in response to FTAg than was produced spontaneously in culture, which suggests an antigen-specific 
downregulation of production of IL-13 in response to L. major in these mice. Those mice vaccinated with 
ALM + Adjuvants produced significantly lower levels of antigen specific IL-4 when compared to other 
groups. ALM + CpG vaccinated mice also produced lower levels of IL-4 in response to antigen, although 
this was not found to be significantly lower than other groups. These findings suggest that vaccines 
containing CpG and ALM act to reduce IL-4 responses to antigen after exposure to the infectious L. 
major parasites.  
Given that the overall lesion development in the ALM + CpG and ALM + Adjuvants was lower than 
other groups from 4 weeks post infection with L. major, it is likely that the level of exposure of immune 
cells to parasite antigen was lower compared to other groups where lesions developed to a greater extent 
(and therefore are likely to have had higher parasite burdens), which may help to explain the lower 
antigen specific responses we detected in individuals from these vaccine groups. The ratio of IFNγ to IL-
10, IL-14 and IL-13 produced in response to antigen was also determined for each individual. There were 
no detectable differences in the ratio of protective (i.e. IFNγ) to non-protective (IL-4, IL-13, IL-10) 
cytokines produced by mice from each group, indicating that the overall type of cytokine response to the 
L. major antigen was similar across groups, despite elevated cytokine responses being evident in some 
cases (data not shown). This likely reflects that fact that at this stage of the infection the mice have all 
begun to control the infection and reduce the parasite burden, and have broadly comparable immune 
responses to the parasite.  
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Levels of antigen specific IgG antibody isotypes in the plasma of vaccinated mice 
infected for 9 weeks with L. major 
As the cytokine responses at week 9 p.i. were perhaps sub-optimal (due to timing in relation to the 
infection) for exploring differences between groups in terms of the immune responses, we used antibody 
isotypes (IgG1/IgG2c) from infected mice as markers of the type of Th1 and Th2 immune responses. 
After 9 weeks of infection with L. major, plasma was collected from the blood of vaccinated mice and the 
levels of antigen specific IgG isotypes were determined by ELISA (Figure 39). Whilst concentration levels 
were calculated using standard curves on ELISA plates, not all samples fitted within this range, and 
therefore absorbance values were used for displaying and final group comparison analysis even though 
the patterns observed were found to be the same. When the Kruskall-Wallis test was used to assess for 
differences in populations across the entire datasets for each of the antibody isotypes, the levels of IgG1 
were found to significantly differ across all groups (** p<0.0016) whereas levels of IgG2c were found to 
be the same (p = 0.1484). Therefore, results indicate that the different vaccines differ markedly in their 
ability to drive an antigen specific IgG1 response, compared to the IgG2c response where differences 
between vaccinated groups were not detected (Figure 39A). The IgG1 antibody subclass was significantly 
elevated in the ALM + Pam2 and ALM + Pam3 vaccinated mice, when compared to sham vaccinated 
controls, suggesting that both lipopeptide adjuvants result in elevated Th2 antibody responses. The 
highest IgG1 levels were recorded in the group vaccinated with ALM + Pam2; the levels of IgG1 in this 
group were significantly greater than all other groups, except for those which received ALM alone or 
ALM + Adjuvants, suggesting that the presence of Pam2 in an antigen containing vaccine drives an 
elevated antigen specific IgG1 response compared to CpG and Pam3 adjuvants, but this is reduced to 
some extent by the addition of the other two adjuvants. Given that the lowest levels of IgG1 were 
recorded in the group vaccinated with ALM + CpG, it is likely that this reduction of IgG1 levels in the 
ALM + Adjuvants group compared to the ALM + Pam2 group is a result of the inclusion of CpG. The 
presence of CpG adjuvant alone in a vaccine containing ALM acted to reduce the concentration of 
antigen specific IgG1 levels compared to the ALM vaccine alone, suggesting this adjuvant restricts the 
class switching of antigen specific IgG to an IgG1 isotype, which is consistent with its known Th1 
promoting activity.  
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 Antigen specific IgG antibody responses to FTAg in mice vaccinated mice infected with Figure 39.
L. major for 9 weeks. Plasma samples were collected after 9 weeks of infection with L. major in mice that 
were vaccinated with ALM containing vaccines, with or without adjuvants, or controls. Levels of IgG1 and 
IgG2c antibodies specific for L. major FTAg were determined by ELISA, results are displayed as 
Absorbance (Abs) at 450-570 nm (A); bars represent the mean + SEM values for the average levels of 
antibody (from duplicate samples for each individual) in each group. The ratio of IgG1:IgG2a was 
estimated using the mean absorbance values for each individual (from supplicate values) and is displayed 
in (B); points represent the ratio of mean antibody levels (IgG1:IgG2c) for each individual.  Groups were 
compared using the Mann-Whitney U test: differences to the control PBS group are indicated above the 
group data points, whilst differences between vaccinated groups are indicated by connecting bars (p<0.05 
*; p<0.005 **; p<0.001***).    
The ratio of antigen specific IgG1:IgG2c antibody levels in plasma or serum is often used as a marker of 
the type of antigen specific adaptive immune response, with higher values indicating a Th2-skewed 
response, and lower values indicating a Th1-skewed response (235). The ratios of IgG1:IgG2c antibody 
levels were all below 1 when concentration values were used (data not shown), indicating that in general, 
all mice were producing more of a Th1 than Th2 type of adaptive immune response to L. major antigens. 
This fits with the observation that at this point in the infection (week 9 p.i.), all the mice had begun to 
control the infection and reduce lesion sizes. When either Pam2 or Pam3 was included in an ALM 
vaccine on their own, there was a significant shift towards a Th2 response to L. major antigen when 
compared to sham vaccinated (PBS) mice, or mice vaccinated with ALM + CpG (Figure 39B). Thus, 
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despite the finding that both antibody isotypes were significantly elevated by ALM + Pam2 adjuvant 
when compared to ALM + Pam3, both the lipopeptide adjuvants shifted the immune response towards a 
Th2 type when compared to CpG adjuvant or when mice were unexposed to antigen prior to infection. 
The CpG adjuvant was included in the experiment as a gold standard Th1-driving adjuvant, and in this 
experiment we found that it was able to shift the adaptive immune responses significantly towards a Th1 
response, as indicated by a significant reduction in IgG1:IgG2c values when compared to those found in 
ALM vaccinated mice.  
Local reactions to lipopeptide containing vaccines 
After mice were vaccinated with the first dose, local reactions were observed with some groups 
developing a significant swelling at the site of the first injection (the LHF). In order to monitor this 
reaction, the thickness of both hind feet was measured, as is done for the measurement of Leishmania foot 
lesions. Figure 40 shows the swelling reactions at the injection site of mice from each vaccine group at 
one and three weeks after the first dose was given. No reaction was seen in the PBS vaccinated or ALM 
vaccinated mice. Those mice that received the ALM + Pam3 vaccine showed a marginal increase in the 
average level of swelling after 1 week, compared to PBS or ALM vaccinated mice, but this was not 
significant. Mice which received either the ALM + CpG or ALM + Pam2 vaccine, however, showed 
significantly elevated swelling at 1 and 3 weeks post exposure, when compared to either PBS or ALM 
vaccinated animals. This indicated that addition of either of these adjuvants to ALM was sufficient to 
induce a long-lasting local swelling at the injection site. Furthermore, ALM + CpG resulted in an 
increased swelling when compared to ALM + Pam3. However, the adjuvants alone (i.e. Pam2 + Pam3 + 
CpG) were also sufficient to induce a local reaction, as mice vaccinated with Adjuvants only also showed 
significantly increased swelling at these two time points. The most severe swelling was recorded in mice 
vaccinated with ALM + Adjuvants (i.e. when all vaccine components were present) where an average 
increase of over 1.5 mm in thickness was seen at the vaccinated foot site after one week; the swelling in 
this group of mice was significantly greater than every other group. These findings indicate that the 
addition of either 10 µg Pam2 or 50 µg CpG to the ALM antigen is sufficient to induce an localised 
swelling response, which is present for up to 3 weeks post vaccination. The presence of antigen does not 
appear to be a requirement for induction of the reaction, but addition of antigen to the three adjuvants 
resulted in a further increase in swelling, indicating that there is an additive response after the addition of 
all whole cell antigen vaccine and adjuvant components.  
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 Local reactions at the injection site after s.c. immunisation with experimental vaccines Figure 40.
including ALM and/or TLR ligand adjuvants, at 1 or 3 weeks post exposure. Data points represent 
swelling on the exposed foot of individuals, as determined by subtracting the size of the contralateral foot 
(RHF-LHF, mm), with median values shown as horizontal bars. Groups of vaccinated mice were 
compared against sham inoculated (PBS) controls using the Mann-Whitney U test (*p<0.05; **p<0.005).  
Two weeks after the first vaccine dose, mice received the second dose s.c. to the shaven rump. Some local 
responses were also recorded at this site, in the form of redness but not swelling. As the area of tissue 
exposed at this site is less confined than that of the upper side of the foot, it is possible that a local 
swelling response could dissipate more readily compared to the confined space of the foot. The swelling 
responses in the feet had subsided in all mice by 4 weeks post first vaccination, allowing for the infectious 
challenge to be administered to the contralateral foot and for the lesions on the infected feet to be 
measured by comparing to the contralateral foot (which received the first vaccine dose). 
It is intriguing that the presence of the Pam2 adjuvant induced a significant local reaction at the 
vaccination site, yet the presence of Pam3 did not. To further explore the swelling response to 
lipopeptide adjuvants, a small study was carried out in naive mice where groups of mice (n=3) received 
equimolar (10, 5 or 1 mmole) doses of either Pam2 or Pam3 subcutaneously to the upper side of the 
LHF. The sizes of the exposed and unexposed feet were measured a regular intervals after injection and 
the difference between the two gave a measurement of foot swelling (mm). The results are displayed in 
Figure 41 and they demonstrate that the dynamics of local reactions are different between the two 
lipopeptides.  
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 Local reaction to lipopeptide adjuvants. The swelling response to the s.c administration Figure 41.
of Pam2 (red) and Pam3 (blue) lipopeptides at differing concentrations was measured by comparing the 
thickness of the exposed foot to the contralateral unexposed foot. Data points represent mean values at 
each time point post injection (p.i.) +/- SEM (squares with solid lines = 10 nmole; triangles with dashed 
lines = 5 nmole; open circles with dotted lines = 1 nmole). 
No significant differences were found between groups receiving equimolar doses of Pam2 and Pam3. 
However, clear patterns in the local response to these lipopeptides were observed. Pam3 induced a rapid 
swelling of the exposed foot resulting in a peak increase in foot size after 4 hours which exceeded that 
caused by Pam2 at the corresponding dose. After 24 hours, the levels of swelling caused by Pam3 had 
already reduced, whereas those mice that received Pam2 showed the greatest swelling after 48 hours. The 
swelling caused by 5 or 10 nmole of Pam2 was sustained above 0.5 mm for up to 11 days after the initial 
injection, whereas the swelling caused by the other treatments had subsided by 4-5 days after injection. 
Thus, the local reactions caused by lipopeptides are dose dependent, but the dynamics of the swelling 
responses induced by the triacylated and diacylated lipopeptide molecules differ considerably: Pam3 
induces an immediate swelling which subsides after 4 hours, whilst Pam2 induces a more prolonged 
localised swelling response which peaks after 2 days and is sustained for over a week at higher doses. A 
control group was included which receive the same vaccine as was used in the initial experiment, i.e. ALM 
+ Pam2 (50 and 20 µg respectively), to control for the effect of ALM. This presented with the same 
reaction pattern as the 10 and 5 µg doses of Pam2 alone, but was not shown in Figure 41 in order to 
increase clarity. 
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The lipopeptide exposed animals were sacrificed after 11 days (264 hours) post injection, and the exposed 
foot tissue was preserved in formalin and processed for histology by staining slide sections with H&E. 
However, no noticeable differences in cell composition or tissue structure were detected.  
 
Discussion 
As in other studies using similar vaccine models for CL, we found that CpG was effective at providing 
reduction in disease severity (in terms of lesion size and AUC) when included in a leishmanial whole cell 
vaccine (266, 268, 279).  However, parasites were still present at week 9 p.i., and were not significantly 
reduced when compared to other vaccine groups, indicating this vaccine was not sufficient to provide 
complete protection and did not reduce parasite burden as measured by qPCR at this timepoint. The use 
of Pam2 in the ALM vaccine resulted in exacerbated infection in the form of larger lesions and a higher 
average AUC value. The average parasite burden in the ALM + Pam2 vaccinated group was also elevated 
compared to the other groups, although this was only significant using the parametric statistical approach 
(see Appendix 4). Therefore it cannot be ruled out that the increased lesion sizes observed are a result of 
increased swelling, instead of an indication of higher parasite loads during infection. As the mice in all 
groups had reduced their lesions sizes from the peak point by the time at which parasite burden was 
measured, a lack of significant differences between parasite burden at this stage may not reflect the 
situation at the time of peak parasite burden (likely to be at weeks 3 -5 based on other studies exploring 
parasite burden and lesion development in L. major infection (50)), when differences between the groups 
are likely to have been greatest.  
Raman et al have recently shown that the use of both a TLR4 and TLR9 ligand in a polyprotein vaccine 
for CL can enhance efficacy compared to the use of either ligand adjuvant alone (144), suggesting that 
synergy of TLR activation by vaccine adjuvants can promote enhance protection. When Pam2 and Pam3 
were used in combination with CpG in an ALM vaccine, they did not act to bolster or reverse the vaccine 
induced protection provided by the CpG adjuvant in the vaccine, although the lowest disease severity was 
observed in those mice which were exposed only to antigen and CpG. Nevertheless, this suggests that the 
addition of TLR2 ligands to the Th1 promoting TLR9 ligand CpG does not reduce its ability to promote 
vaccine induced protection to a disease which requires a cell-mediated Th1 immune response. The only 
vaccine available in humans which provides cell-mediated immunity to an infection is BCG, which has 
been shown to act in part by activation of both TLR2 and TLR9 (220, 221). Combined, this suggests that 
the activation of both TLR9 and TLR2 by adjuvants in a vaccine favours an overall Th1 type of immune 
response.  
Surprisingly, those mice which showed the lowest parasite burdens and disease severity did not have the 
greatest IFNγ responses, and instead presented with increased IL-10 and Th2 responses, especially in the 
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case of the ALM vaccinated mice. This may reflect the late stage of the infection, i.e. all of these mice 
have begun to control parasite replication and reduce lesion sizes from their maximum. Whilst Th1 
responses are required for controlling parasite replication, they are also inflammatory and delay wound 
healing, whereas Th2/IL-10 responses can assist wound healing and reduce inflammation/pathology at 
the wound site (68). It would be useful to explore antigen specific responses at the time of challenge, 
instead of several weeks after exposure. The immune responses at the time of challenge may be a better 
measure to explore immune correlates of protection, and may correspond better with studies which have 
explored cytokine responses to Pam2 and Pam3, or related lipopeptides, in other models (such as (254, 
280)). In addition, other studies exploring immune correlates of protection in Leishmania vaccines have 
used the time of challenge at which to explore the immune responses in mice given different vaccines 
combinations (141-143). 
The immune response elicited by Pam2 and Pam3 in this study appears to be one where the Th2 immune 
response was favoured over the Th1 response. This is best demonstrated by the ratio of IgG1:IgG2c 
levels in the vaccinated mice, which are skewed in favour of IgG1 in Pam2 and Pam3 vaccinated mice. 
Pam3 has been shown to drive Th2 responses to antigen in C57BL/6 in a study where the OVA peptide 
was used as the antigen. This Th2 response to Pam3 was found to be mediated by increased 
phosphorylation of ERK1/2 and expression of c-Fos in DCs, acting to promote IL-10 production and 
suppress IL-12 (281). However, we didn’t observe an elevated IL-10 response in the recall responses by 
splenocytes in mice that received the Pam3 containing vaccine.  
Studies of lipopeptide-containing vaccines in mice have yielded conflicting results regarding the adaptive 
immune response elicited. When an antigenic peptide epitope of M. tuberculosis was attached to a Pam2 
diacyl moiety and used as a vaccine in mice, DC activation was enhanced compared to administration of 
antigen alone, and both a protective Th1 response and a long-lasting memory response to M. tuberculosis, 
was elicited in vivo. Thus, the lipopeptide vaccine was able to provide efficacy and this was found to be 
better than the existing vaccine, BCG (254). This study suggests that lipopeptides can be developed to 
provide cell-mediated immunity to an intracellular pathogen, which requires a similar immune response 
for protection than Leishmania. In fitting with we these findings, Pam3 was found to enhance protection 
in a mouse study using a DNA/MVA prime-boost vaccine approach for protection to L. braziliensis (282). 
This enhanced protection was linked with increased protective Th1 (IFNγ and Granzyme B production) 
and memory T cell responses, as well as reduced IL-10 and IL-13 responses (282). BCG acts in part by 
activation of TLR2, and has been used as an adjuvant in immunotherapy for the treatment of cancer for 
years. Yamazaki et al therefore wished to explore the use of Pam2 and related diacyl lipopeptides for their 
ability to promote anti-tumour responses and reduce tumour size in a mouse model of melanoma. As 
with M. tuberculosis and L. major infections, effective immune destruction of melanoma tumour cells 
requires NK cell activation and a Th1 response (especially IFNγ). Upon s.c. administration of Pam2 
142 
 
 
lipopeptides to mice with melanomas on their back, tumour growth was not reduced, but was slightly 
increased compared to PBS injected controls (280). This response was found to be due to an elevated 
production of IL-10 which led to the expansion of tumour specific Tregs, which act to suppress 
protective tumour specific immune responses (280). Despite the similarity between the activity of Pam2 
in driving exacerbated disease in both the model presented here and by Yamazaki et al, we did not observe 
an elevated IL-10 response (or decreased IFNγ) in the Pam2 vaccinated mice and the immunological 
readouts point instead towards a skewed Th2 response to infection. Nevertheless, this disparity in the 
adaptive immune responses may be in part due to the timing at which the immunological parameters were 
assessed, as Yamazakai et al explored the immune response elicited by Pam2 in a period of hours to 3 
days, whilst here we are looking at the responses after 9 weeks of infection after challenge. Thus, an 
elevated IL-10 production may have occurred at the time of vaccination with Pam2 in our study, and the 
reduced expansion of specific phenotypes of T cells may well have followed this and impacted on the lack 
of resistance to L. major upon challenge.  
The differences observed therefore may be related to the attachment of the TLR2 ligand to the vaccine 
antigen of interest. Studies have shown that linking peptides to acyl group moieties can enhance delivery 
of the antigen to immune cells, such as T cells, by providing a mechanism of endocytosis via TLR2 (251, 
283). In our lipopeptide-containing vaccines, the complex antigen mixture was co-administered with the 
lipopeptides but not attached, and therefore the delivery of antigen to immune cells may not result in 
adequate innate immune stimulation, antigen processing and presentation and co-stimulatory molecule 
expression when compared to where the antigen/s and lipopeptide are physically attached. However, 
Kamath et al recently explored the influence of co-administration of antigen and adjuvant (CFA in this 
case) components in the shaping of Th1 and Th17 immune responses to vaccines, and determined that it 
is the timing of DC exposure to antigen and adjuvants which is crucial, as opposed to there being a 
physical interaction between the two components. Exposure of DCs to free antigen prior to their 
exposure to the adjuvant lead to suppression of Th1 T cell expansion in mice, whereas increased numbers 
of DCs that had been activated by adjuvant at the same time as exposure to the antigen led to Th1/Th17 
expansion (284).  
The antibody responses elicited in our experiment by CpG are similar to studies exploring the type of 
immune response elicited by CpG, which found a strong Th1 bias in immune responses to co-injected 
antigen and an absence/suppression of Th2 responses (285). However, whilst others have reported 
significant increases in antigen specific IgG2 antibodies to vaccine antigen when CpG was used as an 
adjuvant (212, 266), we saw no difference to those vaccinated with ALM antigen alone. This may be 
explained by the use of different strains of mice (BALB/c mice were used in (212, 266)). The effect of 
including Pam2 and Pam3 when used in combination with CpG was to increase the levels of antigen 
specific IgG1 in vaccinated mice, when compared to when CpG was used alone. This suggests that 
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lipopeptide adjuvants are able to shift some of the adaptive immune responses to vaccines elicited by the 
strong Th1-promoting CpG adjuvant, and the response that was most significantly altered in this study 
was the level of IgG1. Hutchison et al have also reported elevated IgG1 levels when CpG adjuvant was 
used in combination with the Th2-driving adjuvant Alum (212).  A combination of CpG and Pam2/3 
adjuvants may therefore be useful in a vaccine where a Th1 biased responses is required but elevated 
antibody responses are also favourable.  
The ability of TLR ligands to enhance antibody responses has been linked to the activation of both DCs 
and B cells (173, 286). Other studies exploring the use of TLR ligand adjuvants in promoting antibody 
responses have reported an increase in antigen specific antibody titres when two TLR ligand adjuvants are 
used, in comparison to one. Kasturi et al reported that IgG1 and IgG2 were both significantly enhanced 
by the use of TLR4 and TLR7 ligand adjuvants combined in a vaccine for use against H5N1 influenza in 
mice, when compared to the use of single TLR ligands (286). These findings differ from our observations, 
where the highest levels of IgG1 were elicited when the TLR2/6 ligand Pam2 was used alone, and these 
levels were not altered by the addition of Pam3 and CpG (TLR2/1 and TLR9 ligands). This suggests that 
effect of activation of multiple TLRs does not have a simple synergistic effect in relation to antibody 
production (i.e. that a combination of endocytic and extracellular TLRs being activated leads to enhance 
antibody production).   
Differences between the activation of antigen specific responses by the different TLR ligand adjuvants 
used in this study could be explained in part by the distribution of the TLRs on different subsets of cells. 
TLR9 which recognises the CpG adjuvant is expressed by pDCs and B cells specifically in humans, but is 
also expressed by myeloid lineage cells (including MΦs) in mice (287). TLR2/1 and TLR2/6 heterodimers 
are expressed by many more cell types including neutrophils, T and B cells, NK cells and immature DCs 
(218). The activation of innate immune responses in the different vaccines was therefore likely to target 
different subsets of cells, which may influence the type and magnitude of an immune response to the 
vaccine. By directly activating pDCs and B cells, K-class CpG adjuvants (such as the CpG ODN 1826 
used in this experiment) results in an immune response which is characterised by the production of 
proinflammatory and Th1 cytokines (TNFα and IL-6) as well as the production of polyreactive antibodies 
(287). A study exploring the use of CpG in a vaccine containing the LACK antigen in protection against 
L. major, found that CpG enhanced efficacy and that the protective response elicited by the CpG 
containing vaccine could be transferred to naive recipient mice by CD11c+ DC cells from vaccinated 
mice (288), indicating that activated DCs in CpG vaccinated mice are sufficient to develop a protective 
response. The specific immune responses elicited in vivo by Pam2 and Pam3 have not been as 
comprehensively characterised as they have for CpG ODNs. However, it is known that lipopeptide 
adjuvants are also capable of activating DC populations in vivo, leading to enhanced adaptive immune 
responses to antigen (280, 289). Our experiments add to the published results so far by describing an 
144 
 
 
elevation in antigen specific antibody by lipopeptide adjuvants; specifically, the IgG1 isotype was elevated 
by Pam2, and an overall skewed isotype response towards increased IgG1 over IgG2a by both Pam2 and 
Pam3 was observed, when used in a whole cell vaccine model.  
It is interesting that Alum, an adjuvant which promotes Th2 and antibody responses to vaccines  
(particularly in mice), has shown improved efficacy in Leishmania vaccine studies, including with ALM and 
other whole-cell preparations in BALB/c mice (275). Alum was even able to reduce lesion development 
greater than the use of BCG (275), which is the only licensed vaccine known to stimulate cell mediated 
immunity. This suggests that an archetypal Th2 driving adjuvant can promote protective responses to L. 
major in BALB/c mice, but in C57BL/6 mice, we observed that Pam2 resulted in an elevated Th2 
response, which exacerbated disease.  In conclusion, we found lipopeptides to be ineffective adjuvants for 
use in an ALM vaccine to protect against L. major, and the inefficacy was linked to an enhanced Th2 
adaptive immune response during infection, particularly with respect to elevated IgG1.  
Marked and persistent local swelling reactions to the adjuvants Pam2 and CpG were observed with the 
primary inoculum. Furthermore, we identified a differential swelling reaction to the lipopeptides adjuvants 
Pam2 and Pam3 in the absence of antigen, with the former inducing a more delayed onset and more 
sustained swelling reaction than the latter. The doses used here were comparable to other studies (254, 
280). Wiedemann et al compared the inflammatory infiltrates after s.c. injection of different adjuvants, 
complete Freund’s adjuvant (CFA), incomplete Freund’s adjuvant (IFA), LPS and Pam3 (290). After a 
dose of 50 µg Pam3 the inflammatory response in the tissue site of exposed mice was characterised by the 
accumulation of inflammatory cells including MΦs, neutrophils and epithelial cells, which differed to that 
induced by CFA and IFA where oil accumulation was associated collagen formation and necrosis. LPS 
also induced a local inflammatory response over a sustained period. Despite the obvious induction of an 
inflammatory response by the TLR ligands used in this study, the authors describe that in comparison to 
the potent CFA and IFA adjuvants, which are associated with tissue damage and side effects, Pam3 and 
LPS induced responses which healed over time and were associated with improved efficacy in terms of 
adaptive immune response priming (290).  
Here we identified a different pattern of swelling reaction in exposed mouse tissues after s.c. injection 
with Pam2 and Pam3. Interestingly, a recent phase 2 clinical trial exploring the immunogencitity and 
safety of a (diacylated) lipopeptide vaccine developed for HIV, reported dose dependent local reaction in 
the human participants, following i.m. injection (291), which is fitting with our observations. Our 
comparison of the reactions two Pam2 and Pam3 suggests that the local reaction to the lipopeptide 
differs depending of the acylation pattern.  A comprehensive study by Farhat et al, showed no differences 
in signalling events between activation of TLR2 in combination with either TLR1 or TLR6 (246), and 
others have reported no distinct immune responses to Pam2 and Pam3 (292). Turner et al reported that 
diacylated lipopeptides were more potent stimulators of TNFα production by peritoneal MΦs of 
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C57BL/6 mice, and that the dynamics of TNFα production different between the two types of 
lipopeptide: with diacylated lipopeptides demonstrating a complete dependency on TLR6, whereas 
triacylated lipopeptides were only partially dependent on TLR1 (293). Therefore, differences in the 
binding kinetics and a complete or partial dependency of the ligand-TLR complexes, may account for 
some of our findings. DePaolo et al observed a regulatory immune response after stimulation of the 
TLR2/6 complex, whilst an inflammatory immune responses after stimulation of the TLR2/1 complex in 
bacterial infection, and they speculate that pathogens such as the bacterium Yersinia pestis selectively 
activate the regulatory TLR2/6 complex (294). The crystal structures of The TLR2/6-Pam2 and TLR2/1-
Pam3 complexes have been determined and these findings indicate that the TLR2/6 structure may have a 
stronger interaction than the TLR2/1 structure upon ligand binding (295), which may account in part for 
the prolonged local reaction observed in the mice treated with Pam2 compared to Pam3. It is also 
possible that the observed differences in local reactions is due to a difference in hydrophobicity between 
the two lipopeptides.  
Given that the ability of adjuvants to drive enhanced protective responses has been consistently linked 
with an ability to drive innate immune responses (296), it was initially hypothesised that the localised 
swelling response may correlate with efficacy of the vaccines and could act as an early marker or correlate 
of vaccine efficacy. If this was the case, the most effective antigen-containing vaccine would have been 
ALM + Adjuvants, followed by ALM + CpG and ALM + Pam2, then ALM + Pam3 and ALM. 
However, we did not find this to be the so, showing that the ability to drive a localised response in the 
form of swelling is not a useful indicator of the ability of an adjuvant to improve efficacy. This is not 
surprising as swelling responses can manifest in many different forms (i.e. inflammation, innate immune 
cell recruitment or oedema for example), and distinct innate inflammatory responses promote different 
adaptive responses (210, 296, 297).  
In summary, this study identified that lipopeptides are ineffective adjuvants for use in a whole-cell 
containing vaccine for protection against L. major, and can even exacerbate disease in challenge infections 
through promoting Th2 or regulatory responses that can compromise Th1 dependent protective 
immunity (280). However, the ability of Pam2 in particular to drive elevated antigen specific immune 
responses (especially IgG1 levels), indicates that this adjuvant may be useful in other vaccines where a 
Th2 and antibody response is desired.  
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Chapter 7. Lipopeptides as adjuvants in a Th2 disease model 
Abstract 
A protective immune response to helminth infections comprises mainly of a robust Th2 response. As we 
previously found that the Pam2 adjuvant promoted a strong Th2-type response, which was found to be 
inappropriate for protection against the intracellular protozoa L. major, we tested the use of Pam2 as an 
adjuvant for a helminth vaccine where Th2 responses would be favourable. Thus, a murine Brugia malayi 
infection model was utilized to test the relative efficacy of vaccination with soluble B. malayi extracts in 
the presence or absence of Pam2. The gold standard Th2-driving adjuvant Alum was able to improve the 
efficacy of a vaccine containing Mf antigens (BmMfE), so that it provided enhanced protection against B. 
malayi challenge infection, when compared to sham vaccinated mice or mice vaccinated with BmMfE 
alone. The use of Pam2 as an adjuvant also reduced parasite burdens, achieving similar levels of efficacy 
to vaccination with the Alum adjuvant. Pam2 and Alum were both found to enhance antigen specific 
IgG1 antibody production in vaccinated mice, although unlike Alum, Pam2 also induced IgG2a responses 
and did not alter the ratio of IgG1:IgG2a produced in response to parasite antigens. This suggests that 
Pam2 drives different adaptive immune responses to Alum with a broader range of immuno-potentiating 
activity. In conclusion, this data indicates that adjuvants targeting TLR2 pathways could be considered as 
novel therapeutic options for use in vaccines that require Th2 and enhanced antibody-dependent 
immunity.  
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Introduction 
The previous chapter presented data which identified lipopeptides, and in particular the diacylated 
lipopeptide Pam2, as adjuvants that are able to induce significant antigen specific immune responses to 
parasite antigens when used in vaccines. However, the use of Pam2 resulted in exacerbated disease upon 
challenge with L. major. The use of Pam2 as an adjuvant in a whole-cell vaccine, skewed the immune 
response towards a Th2-type, characterised by high IgG1:IgG2 antibody isotype ratio and enhanced IL-4 
and IL-13 production in response to antigen. Such an immune response to an intracellular parasite such 
as L. major is detrimental to control of infection, and resulted in exacerbated disease in this model. 
However, a strong Th2 response is required for the control of other pathogens, including parasitic 
nematodes. We therefore tested the use of Pam2 as an adjuvant for vaccines that require a strong Th2 
response, by utilising a mouse vaccination model of Brugia malayi, which causes lymphatic filariasis (LF) in 
humans.  
Lymphatic filariasis 
LF is an NTD caused by three species of filarial nematode: Wuchereria bancrofti, B. malayi, and B. timori. It 
affects an estimated 120 million people worldwide (298), and results in severe disability in many of those 
afflicted.  
The parasites which cause LF are transmitted to human hosts by infected female mosquitoes when they 
take a blood-meal, during which time infective L3 larvae exit the mosquito and enter the dermis of the 
host at the wound site. The life cycle of B. malayi is given in Figure 42, which is similar for W. bancrofti and 
B. malayi with the exception that the species of mosquito vectors differs between parasites (299). Within 
the human host, adult parasites reside within the lymphatics and are the life stage responsible for causing 
pathology. However, not all infected individuals present with disease. Pathology ranges from mild 
lymphoedema in affected tissues (usually the leg or scrotum), to severe and prolonged lymphoedema 
associated with skin hardening and infections of the skin and lymph tissues (elephantiasis).    
Immunity to LF and the use of mouse models 
In humans, a range of disease manifestations are observed, and as with leishmaniasis, the host immune 
response to infection has a major impact on disease presentation and progression. Generally, individuals 
living in an endemic area will fall in to one of three main categories: (1) those with clinical pathology (with 
or without signs of active infection in the form of circulating filarial antigen and/or Mf); (2) those with 
infection but no pathology (i.e. asymptomatic infection); and (3) those with no signs of infection and no 
pathology (known as endemic normals, ENs) (298, 300). ENs are often studied to gain information on 
the protective immune responses that provide resistance to infection. Such studies have highlighted that a 
robust mixed Th1/Th2 response in humans, as well as low IgG4/IgE ratios, are associated with an 
apparent resistance to infection and the associated pathology (300). 
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 The life cycle of Brugia malayi. An infected mosquito transmits infective L3 larvae to the Figure 42.
skin of a human and parasites enter at the wound site (1). Once within the human host, the larvae moult 
twice (i.e. from L3 to L4 and finally to the adult stage), over a period of approximately 1 year (2). Adult 
male and females live within the lymphatics and reproduce, producing millions of microfilariae (Mf) which 
then circulate in the bloodstream (3). Mf can be taken up by uninfected mosquitoes when they take a 
blood meal (4). Within the mosquito, Mf migrate through various tissues whilst moulting twice, and 
eventually become infective L3 after approximately 14 days (5-8). Figure taken from (299).  
The cytokines IL-5 and IFNγ appear to be important for resistance in ENs, and are reduced in PBMCs 
responses from other groups (301). However, those with clinical pathology are also capable of mounting 
strong Th1 and Th2 responses to filarial antigens and TLR agonists (302).  
Rodent models of filarial infections have provided further insight into the type of immune responses 
required for resistance to infection. Models have demonstrated the importance of an adaptive immune 
response in the clearance of parasites (303) and both B and T cells have been shown to play crucial roles 
(304). As in many other helminth infections, an important role for Th2 responses in resistance to filarial 
infection has been identified. IL-4 and IL-13 appear to have a role in clearance of larval stages in either 
Litomosoides sigmondontis or Brugia spp. infection models in some cases (300, 305), but these cytokines are 
not always crucial for protection.  For instance, IL-4-/- mice did not differ in their ability to clear 
developing B. malayi worms in the peritoneum when compared to WT mice, but Mf production by adults 
was increased suggesting that IL-4 acts to reduce fecundity during infection (306). The cytokine IL-5 is 
also important to resistance, and its function is to allow for recruitment of eosinophils to the infection 
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site (307). However, a role for Th1 responses is also indicated, as is observed in human infections, as 
C57BL/6 mice which are able to clear parasites quicker than other inbred strains, mount a stronger Th1 
response to infection than BALB/c mice, and IFNγ-/- mice are more permissive to infection compared to 
WT on a C57Bl/6 background (305).   
The effector cells important for parasite killing in LF include eosinophils (308-311). Mice which are 
deficient in eosinophil peroxidase (EPO) or the major basic protein 1 developed significantly greater 
parasite burdens upon infection (310). Whilst eosinophils have been consistently linked with an immune 
response associated with clearance in most studies, a model of adult B. malayi infection in mice has also 
disputed this.  Mice receiving implanted adults have been reported to survive in the peritoneal cavities of 
mice despite a prolonged eosinophilia at the infection site, and an absence of IL-5 (although greatly 
reducing eosinophilia) in C57BL/6 mice did not impact on parasite survival (312). It therefore appears 
that the mechanisms involved in clearance are more complex, and can vary between different parasite life-
cycle stages. The role of MΦs in parasite clearance is unclear. Induction of MΦs with an alternatively 
activated phenotype (aaMΦs) are coincidently elicited as part of the predominant Th2 response to filarial 
experimental infections (313, 314), and monocytes with aaMΦ-like characteristics are observable in 
naturally infected human populations (315). These nematode-elicited aaMΦs have been studied 
extensively for their ability to suppress proliferation of lymphocytes in vitro and in vivo, which is presumed 
to promote parasite survival (313, 314). Recent evidence suggests, however, that in contrast to their role 
in promoting adult worm survival through driving immune tolerance, aaMΦs are essential for 
coordinating eosinophil recruitment and mediating protection against B. malayi infection (Turner et al.  
pers. com.).  
Vaccine studies in mouse models of LF 
A number of different rodent models have been used to explore the use of vaccination to protect against 
filarial infections. Radiation-attenuated larval vaccines have consistently provided the most potent 
protection in these models (300, 316). As with resistance to primary infections, both T and B cell 
responses appear to be crucial for enhanced clearance in vaccinated mice (225, 317). Importantly, recent 
studies have revealed that the key role for B cells in providing vaccine induced immunity is not linked to 
antibody production, but instead to production of cytokines which promote a robust Th2 response, and 
recruitment of cells to the infection site (317). In the L. sigmodontis model, vaccine induced reduction of 
parasite burden has been linked to IL-5 and eosinophilia, as neutralisation of IL-5 in vaccinated mice 
reduced eosinophilia to the infection site and prevented vaccine mediated reduction in parasite burden 
(308).  
150 
 
 
Aim of the study 
As a Th2 response is required for vaccine efficacy for filarial parasites and as our previous work identified 
Pam2 as a potent driver of Th2 immune responses, we tested the use of Pam2 as an adjuvant for 
vaccination against B. malayi. We compared the use of Pam2 with Alum, which is the archetypal adjuvant 
for use in promoting Th2 responses to vaccine antigens (296).  
Methods 
Mice, vaccinations and challenge infection  
Methods used in this study were developed with advice and assistance from Dr Joseph Turner and Miss 
Ana Guimaraes (Filariasis Laboratory, LSTM).  All procedures involving live animals were performed at 
the BSU in the Ronald Ross Building, University of Liverpool. Male BALB/c mice were purchased from 
Harlan, and were aged 8-10 weeks at the start of each experiment. Mice were vaccinated with one of the 
following vaccines, in a 100 µl volume, via s.c. route to the nape of the neck: PBS; Dead L3 (gold-
standard, two doses 2 weeks apart) or BmMfE; BmMfE + Alum; BmMfE + Pam2 as a single dose. Mice 
(4-5/group) were challenged 2 weeks after the last vaccine dose with 50 live B. malayi L3 (Chapter 2). 
After 6 days p.i., mice were humanely culled, and the following were collected and processed accordingly 
as described in Chapter 2: blood via cardiac puncture (for plasma); parasites from the peritoneal cavity, 
peritoneal exudate cells (PEC) cells and splenocytes. The parasite burden was determined by counting the 
number of free, motile parasites collected from the peritoneum of each mouse using a dissecting 
microscope.  
Immune responses in B. malayi infected mice 
To phenotype the inflammatory cells recruited to the site of infection, PEC cells were collected from 
infected mice at necropsy 6 days post challenge infection. After washing, cells were stained for the 
following surface markers as described in Chapter 2: F4/80, Siglec-F and Mannose Receptor. 
Fluorescently labelled PECS were analysed by flow cytometry as described in Chapter 2.  
The splenocytes were washed and resuspended into either complete RPMI extra at a concentration of 8 x 
106 cells/ml and were plated in a total volume of 200 µl in the presence of BmL3E (20 µg/ml), BmMfE 
(20 µg/ml), anti-mouse CD3 antibody (10 µg/ml), or media alone for 72 hours. Culture supernatants 
were then removed and stored at -20°C until analysis for IFNγ, IL-10, IL-4 and IL-13 levels using 
cytokine ELISA.  
The levels of antigen specific IgG1 and IgG2c in plasma samples from mice were measured using 
antibody ELISA with BmMfE used as the capture antigen. 
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Results 
Vaccine efficacy 
The percentage of live parasites recovered was recorded for each individual and the average (median) 
percentage recoveries for each vaccine group are displayed in Figure 42B. The group vaccinated with two 
doses of Dead L3 displayed a 47% reduction in median parasite recovery when compared to challenge 
control mice, but this was not found to be significant, perhaps due to the wide variation in parasite 
recoveries from vaccinated animals. Mice vaccinated with the filarial extract BmMfE alone showed no 
significant reduction in the average parasite recovery. When mice were vaccinated with BmMfE in the 
presence of Alum, a 35% reduction in median parasite recovery compared to challenge controls was 
observed and this was found to be significant, when compared to BmMfE alone (p = 0.018). When the 
Pam2 adjuvant was used, a 47% reduction in parasite recovery was observed compared to challenge 
controls, but this was not significantly different, again perhaps due to a wide variation in parasite 
recoveries. The average parasite recovery in mice vaccinated with BmMfE + Pam2 was reduced to similar 
levels as the gold standard Dead L3 vaccine (20% of challenge dose) and better than mice vaccinated with 
BmMfE + Alum (16%), but this reduction was not significant compared to any other group. Additional 
experiments with larger group sizes to account for the high variability in parasite recoveries observed in 
vaccinated mice and with evaluation of challenge infections at a later time point are warranted to confirm 
these observations.  
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 Efficacy of vaccines containing filarial extracts +/- adjuvants. Groups of mice (5 groups, Figure 43.
n = 5) were given s.c. vaccinations with the indicated vaccines 2 weeks before infection with 50 B. malayi 
L3 i.p. (with the exception of the group vaccinated with Dead L3 which received a prior vaccination 2 
weeks before the final dose), parasites were recovered along with other cells at 6 days p.i. (A). Live 
parasites were recovered and the individual recoveries from mice in each group are given in (B) as a 
percentage recovery of the initial parasite inoculum. Horizontal bars represent the median values. 
Significant differences between the average recovery from groups of vaccinated mice and the control PBS 
group are indicated above the data points for each group, significant differences between recoveries in 
vaccinated groups are indicated by connector bars (Mann Whitney U test, * p<0.05). 
  
Immune responses 
To assess the immune responses in the different vaccinated groups of mice, the PEC infiltrate was 
characterised in the site of infection by determining total cell counts and phenotyping the cells using flow 
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cytometry. Splenocytes and blood were also collected to analyse the cytokine profile and antibody 
responses to parasite antigen respectively.  
Peritoneal cell recruitment 
On average 2.68 x 106 (+/- 1.72 x 105) PECs were recovered from naïve mice, which increased to a mean 
average of 8.62 x 106 (+/- 6.03 x 105) upon infection with B. malayi for 6 days (sham vaccinated mice). 
When comparing vaccinated groups of mice to sham vaccinated (PBS) mice, an elevated number of PECs 
were recovered from vaccinated mice, which was significant for the Dead L3, BmMfE and BmMfE + 
Alum vaccinated mice (Figure 44A). The BmMfE + Pam2 vaccinated group presented with fewer PECs 
than the other vaccinated mice, which was significantly less than the Dead L3 vaccinated group. Thus, 
Pam2 did not act to increase the cellular infiltrate at the site of infection when used in combination with a 
BmMFE antigen vaccine.  
The PECs were stained with fluorescently conjugated antibodies and analysed by flow cytometry to 
determine the proportion of cell types recruited to the infection site (peritoneal cavity) in the different 
groups of mice. As two major effector cells associated with B. malayi infection in mouse models are 
eosinophils and MΦs (225), we focused on these populations of cells. The marker used for eosinophils 
was Siglec F and the marker for MΦs was F4/80, and cells were gated using these markers (Figure 44B). 
Gated MΦs were further assessed for expression of Mannose Receptor (MR, CD206), which is a marker 
of alternative activation (78). The percentages of eosinophils and MΦs in individual PEC samples, and the 
proportion of MR positive (MR+) and highly MR expressing (MRhigh) MΦs within each sample, were 
used to determine the average percentage of each cell type in the cellular infiltrates for each group (Figure 
44C). The cells termed “other” within PEC populations are F4/80- and Siglec-F- and consist mainly of 
small and large lymphocytes as judged by forward and side scatter characteristics (225). 
The proportion of eosinophils in the PEC samples increased in vaccinated mice, particularly in those 
mice vaccinated twice with Dead L3 (Figure 44C). The proportions of MR+ and MRhigh MΦs were also 
elevated in vaccinated groups of mice, and seemed to be related to increased eosinophil 
numbers/proportion of PECs, and were again elevated in particular in mice vaccinated with the Dead L3 
vaccine. These findings suggest that all vaccines, especially the Dead L3 vaccine, were able to result in a 
selected elevated recruitment of effector cells to the site of infection, which are known facets of a 
protective anti-B. malayi response, but did not relate directly with the level of efficacy observed. These 
findings indicate enhanced Th2-associated effector cell responses in all vaccinated mice. 
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 Characterisation of the cellular infiltrate in the peritoneal cavity of vaccinated mice Figure 44.
infected with B. malayi for 6 days. The total number of PECs was counted (A), results show cell counts for 
individual mice in each group, and horizontal bars represent median values. Significant differences 
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between naïve controls and PBS vaccinated mice are indicated by arrow bars; where levels of cytokines 
produced by mice vaccinated with antigen-containing vaccines differed to PBS vaccinated mice, this is 
indicated above the data points for that group, whilst other difference between vaccine groups are 
indicated by connector bars (Mann-Whitney U test, P<0.05 *; p<0.005 **). The proportion of cellular 
phenotypes analysed by flow cytometry. The gating strategy of MΦs (F4/80 positive) and Eosinophils 
(Siglec-F positive) is shown, as well as the gating for Mannose Receptor positive and high populations of 
MΦs (red dashed lines indicate sample incubated with isotype control) (B). The resulting percentages 
were used to determine the mean average percentages of each cell type within the PEC and MΦ 
populations for each group of (n=5) mice (D).  
 
The percentages of gated cells was used to determine the total numbers of each cell type in the PEC 
samples recovered, thereby allowing for a quantitative measure of recruitment of these cells in each 
individual (Figure 45). The greatest numbers of eosinophils were recruited to the peritoneal cavity of 
Dead L3 vaccinated mice, although BmMfE and BmMfE + Alum vaccinated mice also recruited 
significantly greater numbers of eosinophils compared to sham vaccinated mice (Figure 45A). The 
BmMfE + Pam2 vaccinated mice did not show elevated numbers of eosinophils, indicating that this 
vaccine was not effective at bolstering recruitment of eosinophils to the infection site. Overall, numbers 
of eosinophils recruited to the site of challenge infections did not relate with levels of efficacy. The 
BmMfE and BmMfE + Alum vaccinated mice recruited elevated numbers of MΦs, but this was reduced 
significantly by the addition of the Pam2 adjuvant (Figure 45B). The expression levels of MR, a marker of 
alternative activation, were measured on MΦ populations. MR positive and MRhigh MΦs were generally 
elevated in vaccinated mice, with the exception of mice vaccinated with BmMfE + Pam2. Overall 
numbers of MΦs or MR+ or MRhigh phenotypes did not correlate precisely with vaccine efficacy. 
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 Recruitment of effector cells to the infection site. The total number of eosinophils (A) Figure 45.
macrophages (B), MR+ macrophages (C), and MRhigh macrophages (D) recruited to the peritoneal cavity 
of vaccinated mice 6 days after challenge infections with B. malayi L3. Individual counts are shown for 
mice in each group, horizontal bars represent the median values; significant increases in mean number of 
cells produced by vaccinated mice compared to PBS sham-vaccinated mice is indicated above the data 
points for that group, whilst other differences between vaccine groups are indicated by connector bars 
(Mann-Whitney U test, P<0.05 *; p<0.005 **). 
Splenocyte cytokine production  
In order to assess the adaptive immune responses to the infective B. malayi L3 parasite, splenocytes were 
cultured in vitro for 72 hours in the presence of soluble antigen from B. malayi L3, BmL3E. The levels of 
cytokines produced by unstimulated cells were subtracted from the levels produced when cells were 
stimulated with BmL3E, in order to quantify the levels of antigen specific cytokine production to L3 
antigens (Figure 46). The results indicate a general elevation of Th2 response to L3 antigen upon 
infection with B. malayi in sham vaccinated mice, and this is boosted by vaccination with B. malayi antigen-
containing vaccines. In the case of IL-4, IL-13 and IL-5, all groups challenged with L3 infection showed 
elevated responses to BmL3E when compared to naïve mice (N.B. these comparisons are not indicated 
on the figures). In the case of IFNγ, however, none of the groups produced IFNγ in response to BmL3E 
compared to naïve mice. Interestingly, in some cases the levels of IFNγ produced to BmL3E was lower 
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than that produced by unstimulated splenocytes, thereby resulting in negative values, and indicating the 
background levels of IFNγ produced by splenocytes from these mice were reduced upon exposure to 
BmL3E, i.e. the Th1 response was down-regulated in these individuals. This could indicate the presence 
of a regulatory population of cells, but may also be a result of regulation of Th1 response by the 
dominant Th2 response.  
 
 L3 specific immune responses from splenocytes of vaccinated mice and controls. Levels Figure 46.
of cytokine (IL-4, IL-13, IFNγ and IL-5) produced by unstimulated cells were subtracted from those 
produced in the presence of BmL3E. Control groups of naïve mice and those vaccinated with PBS but 
challenged with L3 are included (white and black points respectively). Individual points represent the 
mean average levels of cytokine calculated from triplicate splenocyte cultures per mouse, and horizontal 
bars represent median averages for each group. Where levels of cytokines produced by mice vaccinated 
with antigen-containing vaccines differed to PBS vaccinated mice, this is indicated above the data points 
for that group whilst other differences between vaccinated groups, or between naïve mice and PBS 
vaccinated mice are indicated by connector bars (Mann-Whitney U test, P<0.05 *; p<0.005 **). Note that 
differences between vaccinated groups and naïve controls are not indicated, to allow for greater clarity in 
the figure.  
The Dead L3 vaccine significantly increased the IL-13 and IL-5 responses to L3 antigen when compared 
to sham vaccinated controls, and the IL-4 response was also elevated. The BmMfE vaccines did not 
perform as well overall as the Dead L3 vaccine in terms of boosting Th2 cytokine responses to L3 
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antigen, with the notable exception of the BmMfE + Pam2 vaccine where a significantly greater 
production of IL-4 was observed in this group compared to all other vaccinated groups (Figure 46).  
Antigen specific IgG isotype responses 
There were no detectable levels of antigen specific IgG antibody isotypes specific for BmMfE from naïve 
or sham vaccinated mice, whilst those vaccinated with the Dead L3 vaccine did have delectable levels of 
both isotypes specific for BmMfE (data not shown). The highest levels of BmMfE specific antibodies 
recorded were from mice vaccinated with BmMfE, and in the case of both isotype subclasses, the greatest 
responses were recorded in individuals vaccinated with BmMfE + Pam2 (mean absorbance of 0.83 +/- 
0.26, compared to a mean of 0.071 +/- 0.019 in the BmMfE vaccinated group and 0.413 +/- 0.129 for 
the group vaccinated with BmMfE + Alum), indicating that Pam2 is a strong driver of IgG responses 
generally.  
Both Pam2 and Alum adjuvants significantly elevated the levels of IgG1 antibody specific for the antigen 
compared to the groups vaccinated with BmMfE antigen alone (p=0.008 in both cases). Thus Pam2 is 
able to induce a comparable antigen specific IgG1 response when compared to Alum. The levels of 
antigen specific IgG2a antibody were elevated in the BmMfE + Pam2 group, but not the BmMfE + 
Alum group, indicating that Pam2 is able to drive an elevated IgG2a response to antigen, whereas Alum 
does not. When the ratio of IgG1:IgG2a levels were determined for each group, it appears that Alum 
drives a specific elevated IgG1 (i.e. Th2) responses as displayed by an elevated IgG1:IgG2a ratio of 
antigen specific isotypes (although not significant), whereas the average IgG1:IgG2a levels induced by 
Pam2 were no different to the mice vaccinated with antigen alone. Thus, Pam2 is a strong driver of both 
IgG1 and IgG2a responses, and does not skew the antigen specific humoral response towards a Th2 
subtype when compared to the Alum antigen, where only IgG1 levels are elevated.  
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 Levels of Mf antigen specific IgG antibody isotypes in mice vaccinated with BmMfE in Figure 47.
the presence or absence of adjuvants. The levels of IgG1 and IgG2a isotypes specific to BmMfE were 
determined for individuals in each group and from naïve mice by ELISA: Absorbance values (Abs) at 450-
570 nm are shown. Just those mice vaccinated with BmMfE vaccines (i.e. with no adjuvant, with Pam or 
with Alum) were compared for the levels of antigen specific IgG1 and IgG2a in their plasma (A). 
Individual points represent the mean average levels of antibody in duplicate wells per mouse, and 
horizontal bars represent median averages for each group. In addition, the ratio of IgG1:IgG2a was 
calculated using the Abs values (B). Groups were compared using the Mann-Whitney U test (*p<0.05; 
**p<0.005).  
 
Discussion 
This study aimed to test the use of Pam2 as an adjuvant in a vaccine where Th2 responses are required 
for vaccine efficacy. We observed a significant reduction in parasite burden when BmMfE + Alum was 
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used as a vaccine. However, even though vaccines using Pam2 as an adjuvant showed greater a reduction 
in parasite recoveries compared to the Alum adjuvant, and to the same level as the Dead L3 ‘positive 
control’ vaccine, a high variability in parasite recoveries from these vaccination groups failed to produce 
statistically significant differences. High variability in parasite recovery has been reported from B. malayi 
models in mouse peritoneal cavities, and the variability reported by others was often greater than what we 
have found (e.g. from 0 to 60% recovery within the same group of mice (225)), suggesting that it was not 
a variability unique to our experimental set up. Nevertheless, the levels of vaccine efficacy were 
encouraging as they indicated that the use of Pam2 as an adjuvant in this model was able to improve upon 
an antigen only vaccination (BmMfE) and produce comparable reductions in parasite burdens to Alum, 
which should be confirmed with further experiments including larger group sizes.  
Although correlates of protection in vaccine models for LF have yet to be comprehensively defined, the 
role of effectors which are important for clearance of primary infection appear to differ to some extent 
compared to those for clearance in vaccinated mice or upon secondary infection (307, 318). Nevertheless, 
recruitment of eosinophils and other effector cells (e.g macrophages) appears to be a common factor 
linked to resistance (225, 308, 316). By counting and phenotyping the cellular infiltrate at the site of the 
challenge infection we were able to assess the effect of vaccination on the local immune response to B. 
malayi challenge infection. Challenge infection resulted in a recruitment of large numbers of cells to the 
peritoneal cavity as previously reported (225). Vaccination acted to increase the recruitment of cells to the 
peritoneal cavity in all cases, with the notable exception of mice vaccinated with BmMfE + Pam2, which 
showed reduced cellular recruitment compared to all other vaccine groups. The finding that the Dead L3 
vaccine consistently recruited the greatest numbers of Th2-associated effector cells (i.e. eosinophils and 
aaMΦs) upon challenge indicates that intact parasites drive local Th2/eosinophilic responses to a greater 
extent than soluble protein preparations when used in vaccines.  
The role of aaMΦs in LF infection remains unclear. Loke et al identified a population of adherent PEC 
cells recruited to the peritoneal cavity by adult B. malayi which were able to suppress proliferation of 
antigen specific T cells and reduce antigen specific IFNγ, via an IL-4 independent and TGFβ dependent 
mechanism; and these cells were identified as aaMΦs (314). Therefore recruited aaMΦs play an important 
role in the suppression of an early Th1 response and promotion of a dominant Th2 response to B. malayi 
adult parasites. However, in our laboratory, aaMΦs in the PEC population has been linked to increased 
resistance to B. malayi (Turner et al, unpublished), and they appear to have an important and essential role 
in the recruitment of eosinophils (319, 320) (Turner et al, unpublished).  
No apparent effect on the magnitude or composition of the inflammatory infiltrate was observed by 
using Alum adjuvants with a BmMfE vaccine, in contrast to other vaccine models, where Alum is 
associated with increasing the recruitment of eosinophils, monocytes, neutrophils and other cells (297, 
321, 322). When Pam2 was used as an adjuvant, a reduction in most cell numbers recruited was observed 
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in comparison to the use of BmMfE antigen alone. In general, neither the total amount, or relative 
proportions, of different cellular types or activation phenotypes recruited to the site of challenge infection 
were consistently related with the level of efficacy and suggest that under the conditions used in this 
vaccination model, they do not serve as useful correlates of vaccine efficacy. Further studies determining 
the dynamics of effector cell recruitment during challenge infection over longer time frames may help to 
more precisely define correlates of immune protection. 
Our results indicate a polarised Th2 response to L3 is present in the spleen cells of mice after a six day 
exposure to B. malayi challenge infections, as indicated by the elevated production of IL-4, IL-13 and IL-5 
cytokines by sham vaccinated mice in response to B. malayi antigens, when compared to naïve controls. It 
is known that B. malayi L3 are strong drivers of systemic Th2 responses, and this is a characteristic feature 
of helminth infections in general (301). The splenocyte immune responses to filarial antigens indicate 
boosted cytokine responses in all vaccinated mice, and a generally skewed Th2 response to L3 antigen in 
all exposed mice. The observation that restimulation of splenocytes with parasite antigen was unable to 
drive the production of an IFNγ response from vaccinated mice confirmed the restriction of B. malayi 
vaccines to driving Th2 immunity. When comparing vaccinated groups of mice, the IL-4 response to 
BmL3E was boosted by the use of Pam2 compared to all other vaccine groups, providing further 
evidence of the potent Th2-driving capacity of this lipopeptide as an adjuvant.  
Alum adjuvants are clinically approved adjuvants which have been used for in vaccines for decades to 
boost immune responses, and typically drive strong antibody and Th2 responses (296). They consist of 
aluminium salts (aluminium phosphate and aluminium hydroxide), which adsorb to the antigen 
components of the vaccine. Despite being used in many different human and animal vaccines, the cellular 
and molecular mechanisms by which Alum is able to boost immune responses has only recently been 
studied in detail (210, 296). Alum adjuvants are able to stimulate enhanced innate immune responses at 
the site of exposure, in a mechanism independent of TLR and signalling (via MyD88 and/or Trif) (323). 
Thus, while Alum and Pam2 both act to enhance innate and adaptive immune responses, the mechanism 
of action by which they do this is strikingly different, as the effects of Pam2 on immune responses are 
elicited via TLR2/6 and MyD88 signalling (163). Mechanisms which have been attributed to the activity 
of Alum to activate immune responses include activation of the NOD-like receptor family, pyrin-domain-
containing 3 (NLRP3) inflammasome (322), and induction of cell death followed by subsequent release of 
endogenous danger signals (296). However, the importance of each of these in the ability of Alum to 
drive adaptive immune responses is still a subject of debate, as some groups have yet to find evidence of 
the involvement of the NLRP3 inflammasome upon exposure to Alum (296, 297, 324). Flach et al 
propose that by binding to plasma membrane lipids, Alum results in alterations in lipid structures on 
DCs, which leads to increased antigen uptake and presentation (324). Thus, the initial mechanism/s of 
action of the most widely used adjuvant in human vaccines is still unclear. What is clear, however, is that 
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Alum results in elevated production of cytokines and chemokines at the injection site, which leads to the 
recruitment of various different cell subsets, including APCs, and an increased presentation of antigen 
(210, 215, 216, 324, 325).   
We found the Alum adjuvant was able to drive an elevated IgG1 response to the vaccine antigen, as was 
expected given its use in vaccines to enhance antigen specific antibody levels (296), and a reported ability 
to promote IgG1 responses in mice (212). We also showed that Pam2 was found to elevate antigen 
specific IgG1 in vaccinated mice, which is consistent with the results of the previous chapter where Pam2 
elevated antigen specific IgG1 to Leishmania antigens when used as an adjuvant in an ALM vaccine. In 
this study, however, an elevated level of antigen specific IgG2a was also detected in mice vaccinated with 
a BmMfE + Pam2 vaccine, which was not observed in the previous study (for IgG2c). Importantly, the 
ratio of IgG1:IgG2a was reduced compared to Alum, indicating that Alum is a more selective driver of 
Th2 rather than Th1 responses (reported before in mice (212)), whilst Pam2 appears to drive both 
antibody isotypes. Humoral responses have been reported to have important roles in parasite clearance in 
LF. Antibodies are required for adequate clearance of Mf, as mice lacking B cells (µMT) or the FcγR 
(FcγR-/-) showed a dramatically reduced ability to clear B. malayi Mf from blood (326), and B cell deficient 
mice were unable to reduce L. sigmodontis parasite burden after pre exposure to irradiate L3 vaccine (327). 
However, it has also been reported that antibodies have no effect on parasite clearance, as in a C57BL/6 
model of B. pahangi infection mice deficient in FcγRs were not impaired in their ability to clear parasites 
(317), perhaps suggesting different requirements for antibodies in different models. It would be 
interesting to determine the levels of antigen specific IgE in these mice, as this has been linked with 
vaccine induced clearance of filarial parasites in mouse models (300, 327). IgE-/- mice were more 
permissive to primary infection with B. malayi L3 than BALB/c mice, and parasites were able to develop 
to adulthood in the absence of IgE, although they could not produce Mf (318). Unlike in humans, where 
eosinophil degranulation can be mediated by antibody-dependent cell-mediated cytotoxicity (ADCC) via 
the Fc receptors for IgE (FcεR), mice do no express FcεRs on eosinophils, and so their function in 
response to filarial infection is not directly linked to antigen specific IgE production (328). Interestingly, 
IgE-/- mice were deficient in IgG1 and IgG2 levels in serum upon primary infection, whilst the PEC 
infiltrate was unaltered compared to WT. Upon secondary infection with B. malayi L3 however, IgE-/- 
mice were as resistant as WT and the serum levels of IgG1 were also comparable (318). This perhaps 
suggests a role for IgG1 in clearance of parasites in secondary infection (or prior to previous exposure). 
IgG is recognised by mouse eosinophils and has been shown an ADCC upon binding to FcγRs (328), but 
this mechanism has not been linked with the effector function of eosinophils in filarial infection. The 
roles of complement, ADCC and degranulation in eosinophil-mediated killing of B. malayi L3 is currently 
being researched in our laboratory.  
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In summary, this study strongly indicates that Pam2 is able to drive improved efficacy in a vaccine model 
where a Th2 response is favourable for enhanced immunity to the pathogen of interest, and that levels of 
efficacy were comparable to that of the archetypal Th2-driving adjuvant Alum. However, the immune 
response readouts suggest that the two adjuvants differ in the type of immune responses they elicit; whilst 
both are capable of driving elevated antigen specific IgG1 responses, Pam2 also resulted in increased 
antigen specific IgG2a levels and an elevated systemic IL-4 antigen recall response by splenocytes.  
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Chapter 8. Discussion 
The role of TLR2 in CL 
This study has identified a role for the receptor TLR2 in controlling disease severity in CL infection in 
mice, and this role was linked to driving a favourable protective Th1 response to infection (Chapters 
3&4). The dynamics of the role of TLR2 on Leishmania infection are such that the effect of TLR2 
activation on disease severity manifests several weeks after initial infection, and appears to function to 
promote an effective healing response. However, a lack of TLR2 does not prevent the eventual resolution 
of the infection. This finding improves our understanding of how Leishmania parasites interact with TLRs 
during infection in vivo, and how this interaction impacts on immune responses and disease outcome. A 
picture emerges whereby TLR2, TLR4 and TLR9 are all involved in the recognition of Leishmania 
parasites in vitro and in vivo, in addition to TLR3 in recognition of the dsRNA of the LRV. Whilst the 
studies by others using TLR deficient mice indicated TLR9 as having the more dominant role in driving 
protective immune responses to Leishmania infections (207), our findings suggest that TLR2 activation 
may act to bolster this protective immune response during infection. Although the protective influence of 
TLR2 was consistently observed in our experiments for both L. major and L. mexicana, other studies using 
the mucocutaneous species L. braziliensis and L. amazonenesis, have demonstrated an exacerbatory role for 
TLR2 during infection (40, 200), illustrating the influence of TLR2 is complex and can exert profoundly 
different species-dependent outcomes. Our findings further suggest that the ligand for the TLR2-
mediated effects in vivo is not, at least exclusively, LPG, and that if the ligand in question is parasite 
derived, it is expressed by amastigotes in L. mexicana infection. Whilst others have shown activation of 
TLR2 by LPG preparations in vitro resulting in inflammatory responses (26, 27, 234), it is important to 
note that this is in contrast that many of the known functions of LPG in vivo, which are related to the 
down regulation of inflammatory responses (15, 19, 32, 329), so it would be paradoxical for LPG to also 
promote protective immune responses in the context of an in vivo infection. Further research is needed to 
understand which host cells are involved in the TLR2 interaction with Leishmania, and to determine 
whether that activator of TLR2 is in fact derived from the parasite, or an alternative source, such as other 
microbes present at the infection site, or host DAMPs.  An interesting area of research is the impact of 
resident skin microflora at the lesion site (249), which play an important role in lesion development and 
immunity to L. major.  It would be interesting to further explore the role of the skin microbiota in relation 
to TLR2 activation during CL infection in mice.  
In addition, whilst the role of the sandfly bite was not explored in this thesis, it is an extremely important 
aspect of Leishmania transmission, and many aspects of this natural mode of transmission have 
implications on disease outcome. As it is likely that salivary components, including sandfly gut microbiota 
and their products, also possess multiple PAMPs and thus potentially ligands for TLR2 and its co-
receptors, it would be very interesting to explore the outcome of infection in TLR2-/- mice (and indeed 
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those lacking other TLRs) infected by the Leishmania-infected sandfly bites. In addition, 
immunomodulatory components of the saliva may impact on and/or modify any parasite-derived 
activation of TLR2 on host cells at the infection site.  
This study also suggests that TLR2 may have a function independent of its known requirement for a co-
receptor (TLR1 or TLR6), as neither of these were found to have a protective role in Leishmania infection, 
which matched that observed for TLR2. In addition, TLR6-/- mice were found to be more resistant to L. 
major, but not L. mexicana, infection, suggesting an opposing role to TLR2 during infection. These 
findings are intriguing, and may have implications for the current dogma accepted for TLR2 activation by 
bacterial PAMPs for TLR2. Although TLR10 has been shown to act as an additional co-receptor for 
TLR2 in humans, it is not present in mice. However, the presence of an unknown additional co-receptor 
is possible, and the ability of TLR2 to act as a homodimer in some settings cannot be ruled out. TLR12, 
which is part of the same family of surface TLRs as TLR2, has recently been shown to function as a 
homodimer in some settings, or as a heterodimer with TLR11 in others, and this differential receptor 
formation has implications for its role in T. gondii infection in vivo (158).  
When comparing the findings from the first two results Chapters (3&4), which focused on the roles of 
TLR2 and co-receptors during Leishmania infection, to Chapter 6, where TLR2 driving adjuvants were 
explored for use in vaccines for parasitic infection, two contrasting roles for TLR2 in terms Leishmania 
specific responses emerge. During chronic infection, TLR2 appears to have a role in driving protective 
Th1 responses, which act to control parasite replication and reduce lesion size. When activated in a 
prophylactic vaccine setting however, TLR2 activation resulted in a predominantly Th2 response to L. 
major infection upon challenge, which acted to increase disease severity. Thus, stimulation of TLR2 prior 
to infection appears to drive detrimental immune responses whereas TLR2 activation during chronic 
infection acts to promote protective immune responses and assist in controlling infection. This thesis 
therefore demonstrates the divergent complexity of TLR2 functions, and is an example of how TLR2 
activation can have differing consequences in relation to infection, even with the same pathogen. The 
ability for TLR2 to form heterodimers with TLR1, TLR6 and TLR10, as well as interact with other TLRs, 
may help to account for this complexity to some extent (178). It is also likely that different cell types, 
concurrent activation of other TLRs and PRRs, and cytokine/chemokine environment in the tissues, all 
have roles to play in influencing the outcome of TLR2 activation in different settings. For example, fungal 
β-1,3-glucan is known to signal via interacting with both TLR2 and the CLR Dectin-1 (175), and it could 
be that Leishmania PAMP/s can signal via TLR2 in combination with other PRRs (with CLRs being a 
likely candidate group of PRRs, given the abundance of glycoproteins on the surface of Leishmania).  
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Development of a vaccine for CL containing lipopeptides 
The second aim of this project was to develop a vaccine for CL, which included the use of TLR2 ligands 
as adjuvants. Given that both TLR4 and TLR9 have also been shown to play a role in disease outcome in 
vivo (97, 202, 203, 206, 207), and have proven effective adjuvant targets in experimental and clinical 
studies for leishmaniasis vaccines (122, 125, 127, 143, 146, 265, 268, 270, 279, 288, 330), our findings for 
a protective role for TLR2 during infection suggested TLR2 could be a valid target for vaccine adjuvants. 
Our results, however, suggest that the use of TLR2 ligand lipopeptide adjuvants in Leishmania vaccines are 
ineffective (Chapter 6), and in the case of Pam2, acted to exacerbate disease upon challenge infection with 
L. major. However, whether a self-adjuvanting lipopeptide vaccine would give similar vaccine induced 
responses to that observed in our study using ALM and lipopeptide adjuvants cannot be predicted from 
these findings. The formulation, composition and delivery site of the vaccine, which contains a TLR2 
ligand appears to have an impact on TLR2 activation and the extent of the immune response elicited. In 
our hands and in others, the TLR9 ligand CpG promotes enhanced vaccine efficacy in vaccine models of 
leishmaniasis, and has been shown to promote strong Th1 and memory responses. CpG is likely to be a 
highly favourable adjuvant in future vaccine development studies for leishmaniasis, and may also be 
useful in a therapeutic vaccine setting. The topical adjuvant, imiquimod, which activates TLR7 and has 
been approved for use as topical treatment of cervical warts, for example, is also a potent stimulator of 
Th1 responses and has shown promising results when used for prophylactic vaccines and as a therapeutic 
treatment for leishmaniasis (218, 279). The TLR4 ligand MPL, and other LPS/Lipid A derivatives, have 
also shown promising results in other studies on leishmaniasis vaccines, and MPL has the advantage in 
that it has already been already approved for use in humans vaccines (in the AS04 adjuvant) (125, 127, 
271, 279, 330). Indeed, Reed et al are currently exploring using an alternative TLR4 ligand structure, GLA-
SE, with the hope that this will be likely to also be approved for human use given its similarity to MPL 
(218, 279). With the hope that increasing numbers of novel adjuvants which stimulate TLRs are approved 
for use in humans, activation of multiple TLRs (TLR synergy) may also be a favourable approach to take 
in future studies (144).  
A potential caveat of the Leishmania studies conducted for this thesis is the lack of use of the sandfly bite 
in the infection studies, and in particular for the challenge infections in the vaccine studies. Rogers et al 
demonstrated the importance of using a more natural sandfly bite model for challenge in mice vaccine 
studies, by showing that a vaccine which is protective against a needle challenge was effective at reducing 
disease upon sandfly challenge, and vice, versa (331). Indeed, the vaccine used in this study which 
provided the best protection against needle challenge, ALM + CpG, was found to provide no protection 
against sandfly bite challenge in another study (146).  
There are a number of groups exploring different types of vaccine design in the development of a 
protective vaccine for Leishmania.  Many consider that an effective vaccine requires continual stimulation 
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of the immune system, which is most likely to be achieved by using attenuated parasites (123), but the 
finding that even a vaccine using LPG2-/- parasites was only able to provide protection when a CpG 
adjuvant was co-administered (140), highlights the important role in adjuvants in a future Leishmania 
vaccine development. Indeed, some have taken the approach of using adjuvants such a CpG to improve 
on the safety of live parasites (Leishmanisation) as a vaccine approach, as this still remains by far the most 
effective method of vaccination to date (41, 269). Blander and Sander recently speculated that the 
immune responses to PAMPs and other innate signals may differ in terms of magnitude and quality, due 
to a system whereby the ‘microbial’ threat is measured according to whether certain criteria have been 
met. They propose that immune responses to pattern recognition are scaled according to the following 
five checkpoints: 1) whether PAMPs are soluble or particulate; 2) whether PAMPs are associated with a 
dead or alive microbe; 3) whether the microbe is a pathogen or non-pathogen (i.e. does it possess active 
virulence factors?); 4) whether the microbe has invaded or colonised the tissue site; and 5) whether to 
have regulation of inflammatory responses (this decision is dependent on tissue location) (171). Thus, 
recognition of soluble immune PAMPs by cells at the epithelial surface results in relatively weak innate 
immune response, compared to the recognition of multiple PAMPs in a tissue site which is normally 
sterile, and by cells which also detect viability of a living microbe (via recognition of ‘vita-PAMPs’ such as 
microbial mRNA) (171). If this hierachical approach to innate immune activation leads to differing 
responses, it will have major implications for the design of vaccines, which seek to balance these 
outcomes in favour of the host. It suggests that the use of living and/or attenuated microbes, containing 
multiple intact PAMPs, which are targeted to the appropriate cell type and tissue, will be the best strategy 
for ensuring the highest levels of immune activation, if inflammatory responses are required. This would 
support the suggestion by Okwor et al that the development of attenuated parasites is a worthwhile 
approach for the development of a Leishmania vaccine (123).  
The lack of a consensus about the appropriate immune correlates of protection to monitor the efficacy of 
vaccines in CL models is another are of research that requires further study. Although Leishmania 
immunology is among the most intensively studied areas of research and a paradigm system for our 
fundamental understanding of host-parasite immunity, even well-established mouse models have 
identified a range of different factors that are associated with enhanced protection to CL after 
vaccination, and these vary considerably between studies (131, 142, 143, 145, 146) . This suggests that 
factors depending on the nature of the vaccine, as well as the model system, can impact on immune 
correlates, which maybe complex, dynamic, diverse and multifactorial. A priority should therefore be to 
define which of these immune correlates best predicts protective immunity in humans, and to identify 
consistent markers of protective immunity in the most suitable vaccine models.  
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 TLR ligands and adjuvant development 
Adjuvants act in various different mechanisms to directly or indirectly activate DCs and promote 
enhanced immune responses to antigens (210). Compared to many of the TLR ligand adjuvants, such as 
CpG, which is known to drive strong Th1 responses, there is no consensus in the literature on the type of 
immune responses driven by lipopeptides adjuvants, or TLR2 ligands in general. From the findings of this 
study and others, it appears that the immune response elicited by lipopeptides depends largely on the 
vaccine approach that is adopted. For Th1 responses, peptide/protein epitopes which are physically 
attached to the TLR ligand (the acyl moiety) appear to be favourable (251, 254, 332), as is the addition of 
basic lipopeptides to DNA vaccine formulations (282, 333). In contrast, the addition of basic lipopeptide 
structures to protein or whole cell antigen preparations, or the use of lipopeptides structures alone (i.e. 
without antigen) appears to drive a Th2 and/or regulatory response (280, 334). Furthermore, the route of 
administration is likely to have an effect on the type of immune response elicited. The above observations 
were all made in models where s.c. injection with a needle was used, but TLR2 ligands administered by an 
i.p or i.v route have also been shown to induce Th2 and regulatory responses (176, 281). However, when 
administered via i.d. route with a DNA vaccine in a prime boost DNA/MVA approach, Pam3 enhanced 
Th1 and memory responses and improved efficacy of a vaccine for L. braziliensis (282). These combined 
observations suggest that the activation of TLR2 in a vaccination setting is more complex than activation 
of other TLRs, such as TLR9, and that the use of TLR2 ligands as adjuvants may need to be understood 
in the context of the formulation and site of exposure.  
A trend that exists between the two main sections of this study (i.e. the infection experiments in TLR-/- 
mice and the lipopeptide adjuvant studies) is that the immune responses elicited by TLR2, TLR1 and 
TLR6 appear to be different. This conclusion is based on three major observations: Firstly, TLR2 appears 
to have a role in controlling parasite replication and pathogenesis during CL infection, whereas neither 
TLR1 or TLR6 played a similar role; Secondly, a lack of TLR6-/- during L. major infection led to increased 
healing and a stronger protective immune response, whilst a lack of TLR1 had no effect; Finally, we 
observed differences in magnitude of swelling reactions to the TLR2/6 and TLR2/1 ligands, Pam2 and 
Pam3 (respectively) upon exposure to mice, and enhanced antigen specific Th1/Th2 immune responses 
elicited by Pam2.  The field would benefit from more in depth analysis of the immune responses that are 
elicited by activation of TLR2/1 and TLR2/6. For example, it would be interesting to compare the 
phenotypes of cells recruited in response to exposure to Pam2 and Pam3 upon s.c. injection, important 
cell subsets to look at would be neutrophils, MΦs, DCs and eosinophils. In addition, whether there are 
qualitative differences in the type of innate immune responses elicited by Pam2 and Pam3 remains to be 
determined in vivo. Whilst they have both been shown to result in the release of inflammatory cytokines by 
APCs (246, 253, 293), whether there are any differences in the upregulation of costimulatory molecules, 
ability to present antigen or promote memory responses remains to be elucidated in vivo. Studies 
comparing the Th1-driving TLR9 ligand CpG to the Th2-driving TLR-independent Alum adjuvant in vivo, 
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showed no differences in the magnitude and kinetics of the T cell responses induced by these two 
adjuvants, and there were no differences in the uptake and presentation of antigen to CD4 T cells by 
various different APC subsets (212). Instead, differences in the initial mechanism of innate immune 
triggering, the pathways exploited, and resulting genes modulated (e.g. “adjuvant core response genes”) 
are likely to be important to influencing the quality of the immune response (210). A study comparing 
various TLR ligand adjuvants (MPL, R-848 and CpG, which activate TLR4, TLR7/8 and TLR9 
respectively) in primates identified differences in the transcription of genes involved in various innate 
immune pathways in PBMCs recovered from exposed individuals. In addition, whilst rapid expansion of 
DCs and other APCs by ligands of TLR when injected in vivo, differences in the dynamics of activation 
and phenotypes of these APCs were observed (335). It would be useful to have studies comparing 
lipopeptide adjuvants to other TLR ligand adjuvants, in a similar style of study.  
It is now widely accepted that multiple TLRs ligands/innate stimuli are preferable to single components 
when used as vaccine adjuvants (296). Understanding adjuvant specific responses, when used singularly or 
in combination, is important in choosing the appropriate adjuvants, and already we are seeing vaccines 
licensed which use more than one adjuvant in order to enhance and shape the immune response (e.g. 
using alum and MPL) (218). Our findings with Pam2 and Pam3 adjuvants, has improved our knowledge 
in relation to the use of these adjuvants in vaccines, as more suitable for vaccines requiring Th1/Th2 and 
antibody responses.  
Conclusion 
Vaccines remain the most effective, economical and efficient tools for combatting infectious diseases, and 
the effort to develop vaccines for important human parasitic diseases should remain a research priority. 
We are moving towards an era of rational vaccine design, whereby immune correlates of protection will 
be identified for the disease of interest, which can inform vaccine design and adjuvant choice (211, 336, 
337). Current gaps in our understanding of the biology of parasitic infections hamper our efforts in taking 
the right approach to vaccine development. The challenge for vaccine development for CL and other 
parasitic infections is to better understand how to promote the immune responses that provides long 
lasting and if possible, sterile protection, outcomes which challenge even the best experimental vaccines 
to date. The complexities of the role of TLR2 and its co-receptors that have been uncovered in this 
thesis, in CL infection and in a vaccination setting, provide further insight into the prospect of TLR2 
ligands as a target for vaccine adjuvants. The findings also uncovered many new questions, and indicate 
that there remain gaps in our understanding of the role of distinct PRRs in infectious disease 
immunology, and in vaccinology. A greater understanding of how innate immunity drives protective 
adaptive immunity and how this can be exploited in adjuvant and vaccine design is required to achieve the 
ambition of rational vaccine design leading to effective vaccines for future generations.  
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Appendix 1 – Genotyping 
 
 
 Genotyping of WT and TLR-/- mice using PCR.  Figure 48.
Example of results of genotyping of DNA from tissue of naive mice from TLR-/- colonies to ensure for 
correct genotype. DNA from mice were used in PCR reactions for the amplification of the control target 
(ß actin) and WT and KO targets of TLR1, TLR2, TLR4 and TLR6 genes. The different targets are 
highlighted in yellow, and the expected genotype of each sample is indicated above each lane in orange 
(i.e. TLR1-/- samples are identified by ‘1’). A no template control (‘B’) was included for each reaction. 
Products from PCR reactions were ran on an agarose gel and results are displayed above. TLR1-/-, TLR6-
/-, TLR2-/- and TLR4-/- samples all gave positive results for the ß-actin PCR and all gave the expected 
presence/absence of WT and KO products (i.e. TLR1-/- sample was negative for TLR1 WT product, 
positive for TLR1 KO product, positive for all other TLR WT products and negative for all other KO 
products).  
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 Genotyping of WT and TLR2-/- mice by PCR.  Figure 49.
Example of results from genotyping of DNA from lesion tissue of mice used in an infection experiment. 
Lesion DNA from mice infected with L. mexicana lpg1-/- promastigotes was used to check for the 
genotype of the mice used. Lesion DNA was used to check for presence of ß-actin gene (control gene, 
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shown in A), and WT and KO targets of the TLR2 gene (shown in B). It was expected that 5 WT 
(C57BL/6) mice and 5 TLR2-/- mice were used in the experiment. The results indicated that the expected 
products were found in each sample. Thus the mice used were the correct genotype.  
  
191 
 
 
Appendix 2 – Cytokine response, L. major infected mice 
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 Cytokine responses in DLN and splenocyte restimulation experiments from L. major Figure 50.
infected WT and TLR-/- mice, including FTAg stimulated cultures and negative (Media) and positive 
(ConA) controls. Results are given for immune cells harvested at week 10 (A-D) and week 18 (E-H) from 
DLN (A, C, E, G) and splenocyte (B, D, F, H) cell cultures. Groups were compared using the Mann-
Whitney U test (*p<0.05).  
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Appendix 3 – Restriction Digest Maps 
 
 
 Restriction digest maps of TOPO and TOPO-KMP-11 showing the digest sites of Figure 51.
different restriction enzymes.  
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Appendix 4 – Parametric analysis of parasite burden in ALM 
vaccinated mice infected with L. major 
 
The mean, median and standard deviations of the parasite burdens from the different vaccinated groups 
are given in Table 14 below. The distributions are not all Gaussian, as there are greater than 10% 
differences between the mean and median averages in the majority of cases. The overall dataset 
population, and most of the individual populations (the ALM group being the exception), follow a 
negative binomial distribution, as the SD values exceed the mean averages.  
 
Vaccine group 
Parasite number 
n Mean Median SD 
PBS 8 6160.38  3189.00 7929.102 
Adjuvants 7 187316.43  14730.00 234687.270 
ALM 7 1099.71 718.00 1007.230 
ALM +CpG 7 1530.29 1039.00 1788.918 
ALM +Pam2 7 1044241.14 26880.524 2660286.524 
ALM +Pam3 7 125337.29  5666.00  318337.450 
ALM +Adjuvants 7 2820.14 1041.00 3212.658 
Total 50 191713.96  2357.00  1005628.059 
Parasite burdens of different groups could be compared by fitting a negative binomial distribution and 
using a generalised linear model approach, and by calculated the IRRs and CIs for each. A p value of < 
0.05 was considered significant. Results are presented in Table 15 and Figure 52 below.  
Comparison IRR 95% CI P value 
Adjuvants / PBS 30.40782571 5.703 - 162.121 <0.001 *** 
PBS / ALM 5.601867364 1.050 - 29.873 0.0436 * 
PBS / ALM +CpG 4.025704795 0.755 - 21.468 0.103 
ALM +Pam2 / PBS 169.5079791 31.793 - 903.742 <0.001 *** 
ALM +Pam3 / PBS 20.34631878 3.816 - 108.478 <0.001 *** 
PBS / ALM +Adjuvants 2.184528466 0.410 - 11.647 0.36 
Adjuvants / ALM 170.3235733 30.234 - 959.507 <0.001 *** 
Adjuvants / ALM +CpG 122.4006891 21.732 - 689.402 <0.001 *** 
ALM +Pam2 /Adjuvants 5.574485355 0.990 - 31.397 0.0514 
Adjuvants / ALM +Pam3 1.4945124 0.265 - 8.418 0.649 
Adjuvants / ALM +Adjuvants 66.4201185 11.793 - 374.100 <0.001 *** 
ALM +CpG / ALM 1.391524627 0.247 - 7.839 0.708 
ALM +Pam2 /ALM 949.561216 168.558 - 5349.29 <0.001 *** 
ALM +Pam3 /ALM 113.9773791 20.232 - 642.085 <0.001 *** 
ALM +Adjuvants /ALM 2.564337088 0.455 - 14.446 0.2856 
ALM +Pam2 / ALM +CpG  682.3890843 121.156 - 3843.44 <0.001 *** 
ALM +Pam3 / ALM +CpG  81.90827307 14.543 - 461.335 <0.001 *** 
ALM +Adjuvants / ALM +CpG 1.842825515 0.327 - 10.381 0.488 
ALM +Pam2 / ALM +Pam3 8.331137488 1.479 - 46.924 0.0162 * 
ALM +Pam2 / ALM +Adjuvants 370.2950055 65.745 - 2085.630 <0.001 *** 
ALM +Pam3 / ALM +Adjuvants 44.44266805 7.891 - 250.316 <0.001 *** 
Table 14. Average parasite burdens at 9 weeks p.i. in groups groups of vaccinated mice infected 
with L. major.  
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 Parasite burdens in mice vaccinated with ALM and adjuvants, compared using Figure 52.
parametric methods. Individual parasite burdens for mice in each are shown, as well as mean values 
+SEM. Where means were found to be significantly different between groups, this is indicated by 
connector bars and asterisks (* p<0.05; **p<0.005; p<0.001). 
Using parametric analysis on this dataset, significant differences between most of the vaccinated groups 
were found. ALM vaccinated mice had the lowest burden, and this was significantly lower than the PBS, 
Adjuvants alone, ALM + Pam2 and ALM + Pam3 groups. The group with the next lowest burden was 
the ALM + CpG vaccinated group, which was not significantly reduced compared to the PBS group, but 
was compared to the Adjuvants alone, ALM + Pam2 and ALM + Pam3 groups. The group which receive 
only Adjuvants had significantly greater parasite burdens than the naïve mice, and higher than when ALM 
was also included in the vaccine. This was surprisingly and suggests this adjuvant cocktails acts to 
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Table 15. Comparisons of parasite burdens in groups of vaccinated mice infected with L. major 
promastigotes using parametric methods. These values were fitted to a generalised linear model using a 
negative binomial function, to allow for comparison of means between groups. Incidence rate ratios 
(IRRs) are presented (IRR = mean1/mean2) with their confidence intervals. The average values of groups 
are considered significantly different when the CI values of IRRs do not encompass 1; instances where this 
is the case are highlighted in bold and italics in the P column.  
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exacerbate infection, but only when used in the absence of antigen. The parasite burdens in the group 
vaccinated with ALM + Pam2 were highest, and were greater than all other groups, except for those 
which received just the adjuvants. The parasite burdens in the group that receive the ALM + Pam3 
vaccine were significantly greater that received the ALM, ALM + CpG, PBS and ALM + Adjuvants 
vaccines. It therefore appears that the Adjuavnts only vaccine, as well as the ALM + Pam2 and ALM + 
Pam3 vaccines, all exacerbate parasite burdens compared to the control and other groups. The ALM is 
efficacious at significantly reducing burden, and ALM + CpG and ALM + Adjuvants reduced burdens to 
comparable levels to this vaccine.  
 
 
